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This research aims to utilise ligand-based target prediction to (i) understand the mechanism 
of action of African natural products (ANPs), (ii) help identify patterns of phylogenetic use in 
African traditional medicine and (iii) elucidate the mechanism of action of phenotypically 
active small molecules and natural products with anti-trypanosomal activity.  
 
In Chapter 2 the objective was to utilise ligand-based target prediction to understand the 
mechanism of action of natural products (NPs) from African medicinal plants used against 
cancer. The Random Forest classifier used in this work compares the similarity of the input 
compounds from the natural product dataset with compound-target combinations in the 
training set. The more similar they are in structure, the more likely they are to modulate the 
same target. Natural products from plants used against cancer in Africa were predicted to 
modulate targets and pathways directly associated with the disease, thus understanding their 
mechanism of action e.g. “flap endonuclease 1” and “Mcl-1”. The “Keap1-Nrf2 Pathway” 
and “apoptosis modulation by HSP70”, two pathways previously linked to cancer (which are 
not currently targeted by marketed drugs, but have been of increasing interest in recent years) 
were predicted to be modulated by ANPs.  
 
In Chapter 3, we aimed to identify phylogenetic patterns in medicinal plant use and the role 
this plays in predicting medicinal activity. We combined chemical, predicted target and 
phylogenetic information of the natural products to identify patterns of use for plant families 
containing plant species used against cancer in African, Malay and Indian (Ayurveda) 
traditional medicine. Plant families that are close phylogenetically were found to produce 
similar natural products that act on similar targets regardless of their origin. Additionally, 
phylogenetic patterns were identified for African traditional plant families with medicinal 
species used against cancer, malaria and human African trypanosomiasis (HAT). We 
identified plant families that have more medicinal species than would statistically be expected 
by chance and rationalised this by linking their activity to their unique phyto-chemistry e.g. 
the napthyl-isoquinoline alkaloids, uniquely produced by Acistrocladaceae and 
Dioncophyllaceae, are responsible for anti-malarial and anti-trypanosome activity.  
 
In Chapter 4, information from target prediction and experimentally validated targets was 
combined with orthologue data to predict targets of phenotypically active small molecules 
and natural products screened against Trypanosoma brucei. The predicted targets were 
prioritised based on their essentiality for the survival of the T. brucei parasite. We predicted 
orthologues of targets that are essential for the survival of the trypanosome e.g. glycogen 
synthase kinase 3 (GSK3) and rhodesain. We also identified the biological processes 
predicted to be perturbed by the compounds e.g. “glycolysis”, “cell cycle”, “regulation of 
symbiosis, encompassing mutualism through parasitism” and “modulation of development of 
symbiont involved in interaction with host”.  
 
In conclusion, in silico target prediction can be used to predict protein targets of natural 
products to understand their molecular mechanism of action. Phylogenetic information and 
phytochemical information of medicinal plants can be integrated to identify plant families 
with more medicinal species than would be expected by chance.  
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CHAPTER 1: INTRODUCTION  
1.1 TRADITIONAL AFRICAN MEDICINES 
Humans have used traditional medicines since before written history began, ranging 
from the Neanderthals in the Palaeolithic era1, the Sumerians in Mesopotamia2, Ancient 
Egyptians2, to India since 4000 BC3 and China since 2000 BC. Traditional medicines 
consist of: (a) entire organisms e.g. plant or animal, (b) part of an organism e.g. leaf or 
gland, (c) extracts, (d) exudates, (e) pure compounds or (f) venoms and toxins4. The 
early use of traditional medicines drives our aim to investigate the underlying 
mechanism of action of the NPs they contain. 
 
The WHO5 estimates that more than 30% of the population in developed countries and 
more than 80% of the population in developing countries use herbal medicines either 
to promote and maintain health or as treatments for diseases such as malaria, dysentery, 
and cancer. The significant use of traditional medicine by the population of developing 
countries may be attributed to the inadequate availability of pharmaceuticals in those 
areas, the low purchasing power of these communities, and that these natural products 
seem to work.  
 
Of particular interest to our work are Traditional African Medicines (TAMs). The 
knowledge of African Traditional medicine is passed on from one generation of healers 
to the next by word of mouth, most often in the form of stories6. Prior to gaining access 
to this knowledge, apprentices are initiated into secret societies where they are educated 
in the aspects of TAM7. Traditional healers are known by different names in Africa e.g. 
sangoma, n’anga, and inyanga. 
 
The main difference between TAM and western medicine is that TAM takes a holistic 
approach to treating illness6, much like TCM8 and Ayurveda9. In Africa a person is 
considered to exist in a balance of different aspects. These are shown in Figure 1:1 
below: 
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Figure 1:1 The different aspects that are in harmony in a healthy individual. 
 
In TAM a person is considered to be in good health when the different aspects are in 
harmony. Alternatively, when one or more of these aspects is out of balance, a person 
becomes ill in health and “spirituality”. In such cases, illness is considered to be caused 
by “supernatural ancestor spirit anger”10. During the healing procedure, all aspects 
(“spiritual”, “moral”, “social” or “physical disorders”) are addressed. Thus, the holistic 
regimen taken in TAM includes not only the pharmacology of the medicine, but also 
physical characteristics of the medicine, e.g. aroma, taste, shape and colour, as well as 
attendant rituals, e.g. “incantation and song”11. The work in this thesis focuses on the 
pharmacological aspect of TAMs in the treatment of “physical disorders”. 
 
Plants that are the source of drugs (e.g. atropine, strychnine, the ergot alkaloids, 
physostigmine, d-tubocurarine), used in western medicine to selectively target the cause 
of the disease, are rarely used in TAM. This is due to a lack of precision technology in 
administering controlled doses of the plants6. Nevertheless, drugs have been discovered 
from African medicinal plants (see Table 1:1). This table shows the African medicinal 
plant and the natural products isolated from it that are responsible for medicinal activity. 
There are very few marketed drugs from these medicinal plants; these include 
Vincristine, Vinblastine and Reserpine, used as anti-cancer, anti-hypertensive and anti-
psychotic respectively. The very small number of medicines isolated from the ~45,000 
plants in the African flora11 (5,000 of which have documented medicinal use11) allows 
a great deal of scope for further exploration and exploitation. 
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Table 1:1 Drugs from African medicinal plants 
Plant Activity Natural Product 
Catharanthus roseus L. Anti-cancer 
Vincristine 
Vinblastine 
Combretum caffrum 
(Eckl. & Zeyh.) Kuntze 
Anti-cancer Combretastatins 
Pausinystalia johimbe (K. 
Schum.) Pierre ex Beille 
α-adrenergic agonist Yohimbine 
Physostigma venunosum 
Balf. 
Cholinesterase inhibitor Physostigmine 
Rawolfia vomitoria Afzel. 
Anti-hypertensive 
Anti-psychotic 
Reserpine 
Strophanthus gratus 
(Wall. &Hook.) Baill. 
Cardiotonic Ouabain 
Tabernanthe iboga Baill. Hallucigenic Ibogaine 
 
1.1.1 AFRICAN NATURAL PRODUCTS AND CANCER 
As can be seen from the table above, natural products (which in the context of this work 
are “isolated and purified compounds from plant extracts” and their derivatives) 
isolated from medicinal plants from Africa play a role in the treatment of cancer. Cancer 
is a group of diseases characterised by an abnormal growth of cells. A cancerous growth 
is a malignant tumour whose cells continue to grow and divide uncontrollably and 
without coordination with normal tissues, and can then invade surrounding organs and 
other parts of the body12. According to the WHO, it is the second leading cause of 
death13 after cardiovascular diseases, accounting for 8.8 million deaths in 2015. The 
most prevalent cancers in Africa are cervical cancer, breast cancer, liver cancer and 
prostate cancer, as well as Kaposi’s sarcoma and non-Hodgkin’s lymphoma13. 
 
The biological steps involved in the different stages of human cancer development, 
defined by Hanahan and Weinberg in 200012, are sustaining proliferative signalling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis. These were updated in 
201114 to include deregulating cellular energetics and evading immune destruction. 
Modulation of targets involved in the pathways of these hallmarks forms the basis of 
targeted anti-cancer therapy. One of the main aspects to consider when studying NPs 
isolated from traditional medicines used against cancer is the definition of cancer as 
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used by traditional healers. “Cancer” in this case can include tumours, warts, excessive 
growths, excrescences, polyps, pustules and corns 15, 16. These presentations may or 
may not be malignant and may present anywhere in the body. In the context of this 
work, the Western definition of cancer is used when considering plants to be studied. 
 
Eighty-five of the 175 drugs (i.e. 49%) approved by the FDA for cancer treatment 
between 1940-2014 have either been NPs or derived from them17. The alkaloids 5-
methoxymaculine, flindersiamine and 7-hydroxy-8-methoxydictamine from the plant 
Oricia suaveolens (Rutaceae) have shown significant cytotoxicity against lung 
adenocarcinoma cell lines, with IC50 values of 9.5, 7.9 and 8.9 μM respectively18. The 
vinca alkaloids from Catharnathus rosaeus are a prime example of African plants that 
are currently in the market as anti-cancer agents and are used for their antimicrotubule 
activity19. Terpenoids have been shown to supress NF-κB signalling20, which is 
important in the pathogenesis of inflammatory diseases and cancer. These studies and 
others provided in the review by Simoben et al21 and Nwodo et al22 provide a promising 
start to the chance of finding novel NPs from TAMs with anti-cancer activity, as well 
as identifying the mechanism of action of those with activity. 
   
1.1.2 HUMAN AFRICAN TRYPANOSOMIASIS  
TAMs are also used to ameliorate or treat human African trypanosomiasis23. Human 
African trypanosomiasis (HAT) is a parasitic disease transmitted by the tsetse fly 
(Glossina sp) in 36 sub-Saharan African countries. It is caused by two kinetoplastids, 
namely, Trypanosoma brucei gambiense (west Africa) and Trypanosoma brucei 
rhodesiense (central and east Africa).  A summary of the lifecycle of Trypanosoma 
brucei is shown in Figure 1:2. 
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Figure 1:2 Life cycle of Trypanosoms brucei. Human stage: The tsetse fly bites a mammalian host delivering 
growth-arrested metacyclic trypomastigotes into the lymphatic system and eventually the blood stream. The 
metacyclic trypomastigotes differentiate into bloodstream trypomastigotes (long slender forms of the parasite), 
causing a bloodstream infection. They then penetrate the CNS by crossing the BB where they continue to replicate 
by binary fission. Tsetse fly stage: This is initiated when a tsetse fly takes short stumpy forms of the parasite in a 
blood meal from a mammalian host. They are transported to the midgut where they replicate by binary fission into 
procyclic trypomsatigotes and infect the midgut. The midgut procyclic trypomastigotes migrate within the fly to 
reach the proventiculus where they undergo differentiation and assymetric division to produce 1 long epimastigote 
and 1 short epimastigote. They then migrate onwards towards the salivary gland where the short epimastigote 
attaches to the salivary gland epithelium and undergoes assymetric division to metacyclic trypomastigotes, hence 
completing the cycle. (This image is a work of the Centers for Disease Control and Prevention, part of the United 
States Department of Health and Human Services, taken or made as part of an employee's official duties. As a work 
of the U.S. federal government, the image is in the public domain.) 
 
Good control efforts have decreased the number of cases from 50,000 deaths in 2001 
to fewer than 10,000 in 2009 and 2,804 reported cases in 2015. It is estimated that 
11,000 people are currently affected.24 The disease can be characterised by two stages: 
the symptoms of the first stage are fevers, headaches, itchiness and joint pains; and 
symptoms of the second stage (which occur when the parasite crosses the blood brain 
barrier (BBB) by expressing a parasite version of cysteine proteases causing an increase 
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in the oscillatory pattern of calcium ions in the cell) include confusion and trouble 
sleeping.  
 
Treatment for the first stage is by Pentamidine and Suramin, whereas for the second 
stage, Melarospol, Elfornithine or a combination of Elfornithine and Nifutimox are 
used. Current drugs (i) have toxic side effects, e.g. encephalopathy (Melarospol)25, (ii) 
require skilled workers for administration (all drugs)26, (iii) have complex 
administration regimens (Elfonithine)26 or (iv) are developing resistance 
(Melarospol)26. Potential new drugs for HAT in the drug discovery pipeline include 
Oxaboroles27 (Preclinical), and Fexinidazole28 which is currently in Phase III trials. 
Insufficient market forces could explain the lack of drive for more drugs entering the 
pipeline. 
 
Current approaches to antitrypanosoid drug discovery include target-based screening29 
and phenotypic screening30. Both have advantages and drawbacks, discussed by Field 
et al31 and Pink et al32. The recently published genome sequence of Trypanosoma 
brucei revealed approximately 1,500 genes coding for immunogenic Variant Surface 
Glycoproteins (VSG), which are the targets of vaccines33. For each individual 
organism, only one VSG is expressed at a time34. The VSG changes semi-randomly in 
1 in every 100 cell divisions, meaning the antibodies generated by the body against the 
VSG no longer recognise the surface antigen of the parasite or its progeny as they have 
a new VSG coat35, making it extremely difficult to develop a vaccine against HAT. It 
is thus important to identify new targets for anti-trypanosomals and to understand their 
MoA. The only validated target in HAT is ornithine decarboxylase36, but others are 
suspected to be drug targets e.g. cysteine proteases, responsible for haemoglobin 
degradation, turnover of VSG and crossing of the BBB37; type II enoyl-acyl carrier 
protein reductase, responsible for fatty-acid biosynthesis38; and trypanothone reductase 
,which is responsible for defence against oxidant and chemical stress39. Table 1:2 shows 
the important points as set out by the DDNDi40 for selecting parasite molecular targets 
and ligands.  In order to be considered a viable target, those targets identified to be 
modulated by compounds must be essential for the survival of the parasite. In this work, 
we consider this factor when predicting targets of phenotypically active anti-
trypanosomal compounds. For the ligand, it is important to consider passage across the 
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blood brain barrier (important for stage 2 of the disease when the parasite crosses into 
the brain tissue). This is also a factor that we consider in this thesis when discussing the 
mode of action of phenotypically active anti-tryapanosomal compounds.  
 
Table 1:2 Important points to consider in selecting parasite molecular targets and ligands 
Target Ligand 
Target must be essential to the viability 
of the parasite (essential targets tend to be 
highly conserved among different 
species which causes a problem of 
selectivity) 
Selectively active on parasite target – in 
some cases the host may have a survival 
mechanism e.g. the turnover rate of 
ornithine decarboxylase in humans is 
faster, thus allowing the ligand to be cidal 
to the parasite which is unable to 
regenerate the enzyme at a sufficient 
speed to overcome blockade 
Must be amenable to modulation by 
drug-like ligands 
Permeable in order to be able to access 
the target 
Open to selective inhibition Cross BBB 
Structurally and chemically 
characterised 
Orally active 
Resistance potential e.g. single point 
mutations, over-expression of the target, 
efflux pumps gene amplification of target 
and inactivation of the drug 
 
 
1.1.2.1 NPS FROM AROUND THE WORLD WITH ANTI-TRYPANOSOME ACTIVITY 
Promising results have been achieved by screening NPs from around the world against 
HAT. This is an important starting point to identify lead compounds for drugs against 
this disease. A review41 outlines a range of natural product classes with activity against 
HAT and covers a period from the mid-1980s to 2003. Recently, eight plant extracts 
from North America were shown to have anti-trypanosomal activity with IC50 values < 
1μg/ml and 125 plant extracts had activity with IC50 values < 10μg/ml, with none of the 
extracts showing toxicity towards THP1 cells. In 2017, Afrotryp, a public dataset of 
African compounds active against HAT, was released. The pharmacokinetic properties 
of NPs in this dataset were predicted and they were docked against six trypanosome 
targets, identifying nine compounds suitable for the treatment of stage two HAT, due 
to their low polar surface area. Taken together these results provide a promising start 
for investigating the target space in HAT from NP space, which is what we do in this 
thesis. 
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1.2 AFRICAN NATURAL PRODUCT DATABASES 
Despite containing a plethora of unique phytochemicals with therapeutic value, 
knowledge of the mechanism of action of African phytochemicals remains largely 
unexploited; a point we wanted to address in this work. Recently several electronic 
databases have been created, which group the compounds according to their ethno-
botanical uses and which can now be used together with novel computational tools to 
better understand the mechanism of action of African medicines (Table 1:3). These 
databases comprise in particular NANPDB, ConMedNP, AfroCancer and AfroMalaria 
and they form the basis of the current study. The North African Natural Products 
Database (NANAPDB) was published in 2017 and contains natural products from 4 
Kingdoms (endophytes, animals, fungi, and bacteria) and 146 families with 98 reported 
activities. The North African region consists of Algeria, Egypt, Libya, Morocco, Sudan, 
South Sudan, Tunisia, Western Sahara, and parts of Northern Mali. The biggest classes 
of NP in this dataset are terpenoids (38%), flavonoids (22%) and alkaloids (10%). The 
compounds were collected from literature (links to literature are included in the 
database) as well as PhD theses from 1962-2016. Where available, information about 
the uses of the source species, experimentally verified activities and modes of action is 
also included. Compounds can be accessed via query searches and can be downloaded 
directly from the website. ConMedNP was published in 2014 and contains compounds 
from plants mainly from countries in the Congo Basin (Burundi, Central African 
Republic, Chad, Congo, Equatorial Guinea, Gabon, the Democratic Republic of Congo, 
Rwanda and the Republic of São Tomé and Príncipe). The NPs were collected from a 
literature search and PhD theses published between 1971-2013. These compounds 
come from 376 plant species and 79 plant families. AfroMalaria was also published in 
2014 and contains 265 compounds from 131 species and 44 families from plants across 
Africa. The compounds were collected from literature sources and PhD theses 
published between 1971-2013. The major compound class in this dataset is the 
terpenoids (30.7%), followed by alkaloids (27.7%), flavonoids (12.9%), quinones 
(4.5%) and xanthones (4.5%). Twenty compounds in the datasets showed in vivo anti-
malarial activities, while 278 compounds showed in vitro activities from moderate 
(0.06 μM ≤ IC50 ≤ 5 μM) to very high activities (IC50 < 0.06 μM). AfroCancer, 
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published in 2014, contains compounds collected from literature sources and PhD 
theses between 1971-2014. The compound information, which is available on request 
from the authors, includes plant sources (species, genus and family), traditional uses of 
plant, region of collection of plant material, isolated metabolites, phytochemical class 
(e.g., flavonoid, alkaloid, etc.), and, where available, the measured biological activities 
of isolated compounds. The compounds are stored in SDF format. 
 
It is important to note that these datasets are not complete. For example, not all 
compounds from all medicinal plants used against cancer, malaria or HAT have been 
characterized. Information about which NP is responsible for the activity of the 
medicinal plant is also not fully available. Furthermore, we don’t have quantitative 
information or full bioactivity profiles of all the NPs in these datasets. While there is 
still much information missing, these datasets provide a starting point to understanding 
the mechanism of action of African medicinal plants. 
 
Table 1:3 Datasets of African NPs analysed in the current study 
 
 
 
 
 
 
 
 
 
 
1.3 ADVANTAGES AND LIMITATIONS OF NATURAL PRODUCTS IN DRUG 
DISCOVERY 
The advantages of using natural products isolated from traditional medicines as a 
starting point for drug discovery have been extensively reviewed46. One of the main 
advantages is that, since medicinal plants have been used for many generations to 
alleviate or treat symptoms, their tolerance levels and toxicities are relatively well 
Database Number of 
Compounds 
Notes 
NANPDB42 4469 Natural products from 4 Kingdoms, available 
to download as SMILES, SDF-2D and SDF-
3D 
ConMedNP43 3,177 Compounds available in sdf format 
Annotated bioactivity can be obtained directly 
from the authors 
AfroCancer44 364 Compounds available in .sdf format. 
Annotated bioactivity can be obtained directly 
from the authors. 
Some ligand-target information. 
AfroMalaria45 265 Compounds available in .sdf format. 
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known47. This cannot be said for the NPs isolated from these plants, which is one of the 
reasons why it is important to elucidate their mechanism of action. Another advantage 
of natural products is that they are more likely than synthetic compounds to resemble 
endogenous metabolites and hence are more likely to enter the cells via active 
transport47.  
 
The limitations of natural products in the field of drug discovery were reviewed 48 and 
include (i) difficulty isolating and identifying the active compounds, (ii) synthesis of 
active constituents (too many chiral centres, rings, etc.) and (iii) elucidating and 
validating the mechanism of action.  Another difficulty in the study of traditional 
medicines is that most are used in the form of an extract49. It is not yet understood 
whether the compounds act individually or in synergy with compounds that have little 
or no activity. A prime example of this is the case of the peroxysesquiterpene lactone, 
Artemesinin from the anti-malarial Artemesia annua, which has been found to be 30-
60 times more active in leaf tea than when it is used alone50. The crude extract of the 
triterpenoid acids glycyrrhizin and glycyrrhetinic acid from Glycyrrhiza glabra root has 
been found to inhibit angiogenesis, whereas the isolated compounds promote 
angiogenesis51. Synergy may also play a role in the reduction of the toxicity of the 
isolated active compound as observed with the extract of Rauwolfia serpentina52. 
Another role that synergy may have is the enhancement of absorption of the active 
constituent when it is in the form of an extract. Phospholipids and polysaccharides 
found in the plant extracts may help in the absorption and hence increase in blood levels 
of the compounds compared to when they are administered individually (e.g. in the case 
of flavonoids)53, 54. This may be explained by the NMR studies which reveal that 
interaction occurs between the polar heads of the phospholipids and the phenolic groups 
of the flavonoids50. But most of the phospholipids and polysaccharides are removed 
during the early phases of extraction. Secondary metabolites also have the risk of being 
recognised as xenobiotics and being exported out of the cell. Despite these drawbacks, 
NPs are still an important source for drugs. The limitations need to be considered when 
making choices about which compounds are to be chosen as HIT/lead compounds. 
 
Limitations for natural product drug discovery of particular relevance to Africa are as 
follows: low levels in investment in science and technology, lack of collaboration and 
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coordination between different research groups for various reasons including 
diplomatic and political issues, and limited drug discovery expertise, are among the 
problems faced in the continent55.  Other issues highlighted by Ntie-Kang56 include: 
results obtained in labs not being extrapolated to an industrial setting due to funding 
shortages, results obtained by various research groups in the same field not made public 
and curated in a single repository, and labs not equipped to carry out high throughput 
screens of the isolated and purified active components. The most that can be done in 
terms of research is the collection of information from the local healers, collection of 
the plants from their area of origin, taxonomic identification and extraction of fractions, 
which then need be sent away to European labs for isolation, purification and HTS. 
 
To benefit from the advantages of natural products (NPs) and begin to address some of 
the limitations, it is important to understand their underlying mechanism of action. One 
of the ways of achieving this is to identify the targets and pathways modulated by these 
NPs. This will contribute towards understanding their medicinal activity, metabolic 
profiles as well as their toxicities. In this work we address their medicinal activity.  
 
1.4 MODE OF ACTION ANALYSIS 
Mode of action analysis comprises the study of biochemical and physiological 
mechanisms by which compounds or drugs elicit a response. This step is important for 
elucidating the mechanism of action (MoA) of a drug candidate. The importance of 
elucidating the mechanism of action of NP is two-fold. First, knowing the target, and 
hence the pathway that these NPs modulate, validates the use of the natural products by 
the herbalists and will inform authorities in the regulation of their use. MoA information 
allows medicinal chemists to understand the side effects and toxicity of the NPs. Here 
we will briefly mention the three main approaches to target identification, namely 
biochemical methods, genetic interaction methods and computational inference. 
Computational inference methods will then be discussed in greater detail, as this is the 
area on which the thesis mainly focuses. 
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Biochemical Methods: this involves labelling either the compound or target of interest 
and incubating them together for some time, followed by direct measurement of 
binding57. 
Genetic Interaction: this method involves altering the functions of putative targets by, 
for example, gene knockout, RNAi or small molecules58, 59. This allows for a target 
hypothesis to be generated. 
Computational Inference: In these methods, pattern recognition is used to compare 
the effects of the tested compounds to those with known and validated activities. Here 
hypotheses are made about targets/pathways, but the results remain to be 
experimentally validated. Thus combining computational inference methods with direct 
measurements is a good approach for target convolution for mode of action analysis57. 
 
These methods detect interactions between ligands and targets, and not the actual 
mechanism of action of the ligands. Once a ligand is bound to a target/receptor it can 
act in a number of different ways to elicit a biological response, including but not 
limited to activating the receptor (agonist), blocking or reducing the biological response 
of the receptor (antagonist), or binding to the same receptor as an agonist but producing 
a pharmacological response opposite to that agonist (inverse agonist). 
 
1.5 COMPUTATIONAL METHODS OF TARGET PREDICTION 
1.5.1 LIGAND-BASED TARGET PREDICTION 
There are several chemo-informatic approaches to investigating the potential targets of 
a natural product. These can be broadly divided into three categories, based on 
information used, into single ligand based, multiple ligand based and ligand-target 
based. Single-ligand mechanism of action studies include molecular similarity 
modelling and pharmacophore modelling. Multiple-ligand approaches include machine 
learning and quantitative structure activity relationship (QSAR) modelling. Target-
ligand approaches to mechanism of action studies include proteochemometrics and 
docking studies. These methods are explored further in Table 1:4. 
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1.5.2 MACHINE LEARNING IN LIGAND-BASED TARGET PREDICTION 
Machine learning approaches are currently one of the most important in computer-aided 
drug discovery70. Machine learning techniques use pattern recognition algorithms to 
detect mathematical relationships between empirical observations of small molecules71. 
The relationships are extrapolated to predict chemical, biological and physical 
properties of new compounds. Machine learning is also used to understand and exploit 
the relationship between chemical structures and their bioactivities72, which is what we 
aim to do in this thesis. 
 
Machine learning techniques can broadly be classified into two categories: supervised 
techniques, in which labels are assigned to training data and, after training, the model 
predicts labels for the input data; and unsupervised techniques, which involve learning 
patterns of molecular features directly from unlabelled data73.  
 
The main types of supervised machine-learning techniques used in target identification 
along with their advantages and disadvantages are shown in Table 1:5. In this work, a 
supervised machine-learning model (Random Forest) is used. 
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Numerous target prediction approaches have been published, e.g. SEA (Similarity 
Ensemble Approach)80 and PASS (Prediction of Activity Spectra for Substances)81, that 
predict biological targets of a query ligand,  including natural products. These methods 
rely on training models on bioactivity information of the ligands obtained from 
databases. Some of the open source databases include PubChem82, ChEMBL83 and 
WOMBAT84.  
 
SEA is a molecular similarity method that quantitatively relates proteins to one another 
based on the chemical similarity of their bound ligands85. This method was used to 
predict the anti-malarial activity of the physalins B, D, F and G (isolated from Physalis 
angulata), with B, F and G subsequently showing IC50 values of 2.8μm, 2.2μm and 
6.7μm (respectively) against Plasmodium falciparum86. 
 
Another tool that allows targets to be predicted based on the Tanimoto similarity of 
ligands to ligands associated with the target is TargetHunter87. TargetHunter uses the 
Targets Associated with its MOst Similar Counterparts (TAMOSIC) algorithm to 
predict the biological targets of query ligands. When a query compound is input into 
TargetHunter, the TAMOSIC algorithm generates the fingerprints of the compound 
(chosen by the user, any of ECFP6, ECFP4 and ECFP2) and compares the Tanimoto 
similarity of this compound to compounds in a chemogenomics database, ChEMBL-
11. Targets with the most similar compounds to the query compound are output as the 
predicted targets and ranked according to the similarity scores of the ligands to the input 
compound. TAMOSIC was trained on 117,535 unique compounds from ChEMBL and 
794 targets. TargetHunter obtained 91.1% prediction accuracy of the top 3 targets, i.e. 
91.1% of the compounds are assigned to their known targets in the top 3 predictions. 
TargetHunter was used to identify the mechanism of action of compound CID46907796 
from the PubChem database. This compound was reported in PubChem to display 
cellular apoptosis with AC50 values of 0.4136 and 4.908 μM, but the mechanism of 
action of this compound was not known. TargetHunter predicted the nuclear factor 
erythroid 2-related factor 2 (Nrf2), which is known to have anti-apoptotic activity88 as 
a likely target due to the Tanimoto similarity score of 0.78 and 0.63 to compounds in 
the dataset. 
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A machine learning method, PASS, predicts the biological activity of a compound 
based on its structure81. The principle underlying this method is that biological activity 
equates to structure. This method has been used to predict the anti-oxidant and anti-
microbial activity of the acetogenin alkaloid, neoannonin, from an extract of Annona 
reticulata89. It has also been used by Goel et al90 to predict the mechanism of action of 
natural products  in five plants. The authors generated a prediction coefficient, P, which 
calculates the number of activities predicted by PASS over the number of reported 
activities for the compound. An average prediction co-efficient of 0.66 for the five 
compounds led to the conclusion by the authors that PASS can be applied to predicting 
the MOAs of natural products. 
 
Another machine learning target prediction method, used by Nidhi et al91, uses a 
Laplacian-modified Bayes model to predict biological targets of compounds in the 
MDDR Database.  For every target class in the database, the authors built a Laplacian-
modified Naïve Bayesian model. A query ligand is passed through each Laplacian-
modified Naïve Bayesian model of each target class. The relative estimator score for 
each of the target classes is calculated. The most probable predicted target for that query 
compound is the target with the highest score. The model was trained on 103,735 
compounds annotated to 964 target classes from World of Molecular BioAcTivity 
(WOMBAT)84. It was used to predict the top 3 most likely targets for compounds from 
the MDL Drug Database Report (MDDR) dataset92. The model predicted 77% correct 
targets for compounds from 10 target classes in MDDR. 
 
Self-organising maps (SOMs) have been used to predict ligands of targets as well as 
selective ligands of targets.  Self-organising maps are a type of artificial neural network 
developed by Kohonen in 198293. SOMs learn through unsupervised learning. They are 
essentially a clustering technique used to visualise similarity in the data where 
geometric similarity between nodes indicates similarity. This method of SOM was used 
by Schneider et al94 to correctly predict prosanoid E receptor 3 as a target for the anti-
cancer natural product Doliculide. The authors trained the SOM model, on COBRA 
data, which contains 4,236 drugs and drug candidates95. They computed the p-values 
based on the background distribution of known ligands and drugs to rank the predicted 
targets96. 
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In 2017, Huang et al97 proposed the MOst-Similar ligand Target (MOST) based 
approach to predict targets. This method incorporates the explicit bioactivity of the most 
similar ligand. The method is also able to remove false positive predictions due to 
incorporating p-values associated with explicit bioactivity information as an index. The 
method involved training a combination of different machine learning algorithms 
including Naïve Bayes, Logistic Regression and Random Forest using compounds 
characterised by ECFP-4 Morgan-like fingerprints and FP-2 fingerprints. The model 
was trained on 61,937 compounds annotated with 173 targets from ChEMBL-19 and 
validated used 7-fold cross-validation. The dataset comprised 91.3% active compounds 
and 8.7% inactive compounds. The algorithm worked by calculating the Tanimoto 
similarity between the input compounds and annotated ligands of the targets. The 
Tanimoto similarities were then ranked and the most similar ligand was chosen. The 
Tanimoto similarity and pKi (-log dissociation constant) of the most similar ligand were 
fed into the training model to generate the probability of how likely the input compound 
is to be inactive. If the probability of being active is greater than the probability of being 
inactive, then the query compound is classified as active and vice-versa. MOST was 
able to identify the mechanism of action of aloe-emodin by predicting 
acetylincholinesterase as the target, which was validated in vitro. MOST was also able 
to predict novel targets for the drug Fluanisone (not in ChEMBL), where MOST 
correctly predicted adrenoreceptor alpha 1B and adrenoreceptor alpha 1D as the second 
and third most likely targets. These targets were validated by literature to be human 
targets of Fluanisone. 
 
Deep Learning (DL) is a class of machine learning that uses artificial neural networks 
(ANN) with a hierarchy of multiple layers whereby each layer transforms input data 
into more abstract representations98. They contain more layers and more nodes per layer 
than an ANN. The architecture of a DNN consists of many layers, each layer formed of 
a row of neurons. Neurons (or nodes) in each of the layers can either be fully connected 
or partially connected. Each successive layer of the DNN uses the output from the 
previous layer as input. A basic layer of a DNN consists of an:  
(i) input layer, which receives large volumes of data (features) as input in 
different formats, e.g. target descriptors or drug descriptors. 
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(ii) hidden layer(s), which uses several activation functions e.g. rectified linear 
unit (ReLU), Sigmoid, Step function etc. to calculate weighted sums of input 
and add a bias to each layer. The output of the computation determines 
which nodes to fire. The predicted output is compared with the actual output 
and the difference in the output i.e. the error is back-propagated through the 
network and weights are adjusted accordingly. Error in the network is 
calculated using a cost function  
(iii) output layer which generates the desired output i.e. predictions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Each input arrow is associated with a weight wi. The neuron is also associated with a 
function f(z) called the activation function and a default bias b. When a vector of 
features X=[x1, x2….xN]T is fed into a neuron, the output can be represented as shown 
in Equation 1: 
 
O = 𝑓(∑ 𝑤𝑖𝑥𝑖 + 𝑏)
𝑁
𝑖=1  
Equation 1 – Neuron Output 
xi refers to the input features, wi, is the weight of input neuron and f is the cost 
function.  
Output 
x1 
x2 
x3 
x4 
xn 
1 
b 
w4 
w3 
w2 
w1 
wn 
f(z) 
Figure 1:3 Architecture of a single neuron 
 
 
 
 
37 
 
The number of layers, number of neurons in each layer and activation function in each 
neuron need to be pre-specified when training. 
There are two main issues faced when training a DNN. The first involves vanishing 
gradients99, exploding gradients and oscillating gradients100. Vanishing gradients occur 
when small weights are updated during training with repeated multiplication of values 
less than 1 leading to cost functions in lower layers approaching zero. This issue is 
mitigated by either (i) layer-by-layer unsupervised pre-training of the DNN 101, or (ii) 
using benchmark guidelines for choosing hyper parameters102.  
 
The second issue that occurs in DNN is “over-fitting” of the model. This can be 
overcome by “early termination”103. This process involves separating the dataset into a 
training set and a test set, followed by further separating the training set into a training 
set and an external validation set. The DNN is optimised on the training set while 
simultaneously tested on the validation set. As soon as the accuracy drops on the 
validation set, the training is terminated. “ Dropout”104 is another method that is used 
to mitigate “over-fitting” used. In “Dropout” randomly selected neurons in each layer 
vanish (by setting the activation function output=0) at each training round. This leads 
to the nodes competing to learn a general feature independently as they cannot rely on 
the presence of other neurons.  
 
DNNs have been successfully used to predict compound target interaction and activity 
prediction105, 106. A study by Dahl et al102 which applied DNN on the Merck Kaggle 
challenge dataset showed that DNNs can handle thousands of descriptors without prior 
feature selection. They were also able to optimise the performance of the DNN by 
optimising the hyper-parameters of the model (number of layers, number of nodes per 
layer and activation function used). In the study DNNs outperformed RFs in 13 out of 
15 datasets. Other studies have also shown that DNNs outperform commonly used 
machine learning methods like RF, SVM and naïve Bayes regression models107, 108. 
Several studies have shown that multi-task DNN outperform single-task DNN in 
activity and toxicity predictions109, 110. Despite the successes of DNN in activity 
predictions, it will not be the method of choice in this work. This is because DNN 
require a large amount of data for training111 and ANP databases in this study only have 
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between 364-3177 compounds, This is in addition to model training and validation 
being computationally expensive and hyper-parameter optimisation is subjective111. 
 
ECFP4 fingerprints used in the previously mentioned studies do not capture many of 
the important features required for NP activity, including stereochemistry, repeat units, 
etc. This is important because stereoisomers can have very different activities as 
exemplified by the stereomer alkaloids quinidine (antiarrhythmic) and quinine (anti-
malarial). Another case of difference in enantiomer activity can be exemplified by 
cocaine. The naturally occurring (1R,2R,3S,5S)-(-)-cocaine is psychoactive whereas its 
enantiomer is inactive112. This is also the case with the atropine enantiomers: R-(+)-
hyoscyamine is a fairly potent analgesic whereas S-(-)-hyoscyamine is completely 
devoid of such activity113. Nevertheless, it can be seen from the above-mentioned 
implementations that in silico target prediction has been successful in identifying the 
protein targets of ligands including natural products, without need for information about 
the target. 
 
In this work ECFP4 fingerprints were used as the molecular descriptors to transform 
the chemical information of the compounds. ECFP4 fingerprints capture molecular 
features relative to their activity, which is useful for gaining information about activity 
114. The steps to generate ECFP4 fingerprints are: 
1. Each atom in the molecule is assigned an integer identifier these might be e.g. 
atomic numbers of the atoms. These identifiers are collected into an initial 
fingerprint set. 
2. Each atom identifier is iteratively updated to reflect the neighbouring atom 
identifiers. This includes updates identifying structural duplicates of existing 
features. Identifiers of the initial atom and its neighbours are collected into an 
array and a hash function is applied to this array to get a new single integer 
identifier. (ECFP4 hashing generates identifiers that are comparable across 
molecules). This occurs for all the atoms in the molecule. All the old identifiers 
are replaced by the new identifiers, which are subsequently added to the 
fingerprint set. In our case, this iteration is repeated four times (hence ECFP4) 
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3. Upon completion of the four iterations, any duplicate identifiers (multiple 
occurrences of the same feature) are removed. The final ECFP-4 fingerprint is 
comprised of the remaining integer identifiers in the fingerprint set. 
ECFPs have been used for virtual screening 115, SAR modelling 116 and compound 
library analysis 117, 118. 
 
1.5.3 DATABASES USED TO TRAIN LIGAND-BASED TARGET PREDICTION 
ALGORITHMS 
Several databases are available to train ligand-based target prediction models. These 
include PubChem119, ChEMBL83, DrugBank120 and WOMBAT84. These databases 
contain bioactivity data including phenotypic readouts and toxicity readouts as well 
structure information of compounds and drugs. PubChem contains 2,570,179 tested 
compounds, with information on 10,857 protein targets and 22,106 gene targets. 
ChEMBL-23 contains 1,735,442 unique compounds annotated to 11,538 targets and 
14,675,320 bioactivities. DrugBank 5.0 contains information from 11,037 drug entries, 
2,524 approved small molecule drugs with 4,913 proteins annotated to them. 
WOMBAT 2006.1 contains 136,091 unique SMILES and 1,320 unique targets 
annotated to 307,700 activites. 
 
 It is important to note however that the accuracy of predictions of a model is only as 
good as the training set, i.e. the accuracy of the model beyond the training set (outside 
the applicability domain) cannot be guaranteed. Several limitations have been 
highlighted by Kalliokoski et al121 and these are:  
1. Chemical structure related errors;  
2. Transcription errors;  
3. Inaccurate and insufficient target annotations;  
4. Ineffective and incomplete archiving of original data;  
5. Redundancy 
6. Different lab conditions with different protocols for measurement. 
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1.5.4 APPLICABILITY DOMAIN OF TARGET PREDICTION MODELS TO NP 
CHEMISTRY 
When extrapolating the predictions of a QSAR model to compounds outside of the 
training set, it is possible to get good predictions for compounds that are relatively 
similar to the training set122. Predictions may fail for those compounds that are very 
different to those in the training set122. This concept is known as the applicability 
domain of a model and is usually defined using the similarity of molecular structures 
or a similarity measure based on descriptors of the compounds123. Several 
chemoinformatic analyses comparing the properties of different sets of natural products 
and synthetic compounds124-126 found that natural products differ considerably from 
synthetic compounds in several molecular properties. They found that natural products 
on average tend to have: more oxygen atoms, fewer nitrogen atoms, more stereogenic 
centres, more fused rings, but fewer aromatic rings and fewer rotatable bonds. These 
models also use fingerprint similarity to compare training sets to the test compounds. 
This is not the best representation since fingerprints lead to a loss of atom order as well 
as the fact that they do not capture many aspects important for NP activity, e.g. repeat 
units, stereochemistry etc as mentioned above. This leads to one of the limitations of 
utilising ligand-based target prediction trained on ChEMBL, WOMBAT etc. e.g. 
PIDGINv2. Natural products generally do not share the same chemical space as the 
training space of the algorithm. In PIDGIN (the model used in this thesis), the models 
perform better overall, with up to 96% probability scores achieving 0.98 (maximum of 
1) true positive prediction when the similarity between the test and training sets are 
higher than 0.3127. To address this, in this work prediction results for natural products 
were filtered for compounds that fall below a specified (Tc = 0.3) similarity threshold 
to their nearest neighbour in the training set.  
 
1.6 PATHWAY ANNOTATIONS 
When attempting to understand mechanism of action of compounds, studying 
individual target/gene information does not give insight into the underlying mechanistic 
action. In this work we look at biological pathways. These consist of genes, proteins 
and small molecules interacting with each other in a cellular setting to elicit cellular 
change or creating products. The most well-known types of biological pathways are 
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signalling pathways, which move a signal from outside a cell to its interior; metabolic 
pathways, responsible for chemical reactions within the body; and gene-regulatory 
pathways which control the activation and deactivation of genes. We use pathway 
annotations to put the isolated targets into biological context128. This is carried out by 
combining information from databases with statistical testing128. This facilitates both 
the interpretation of isolated target information and generation of a hypothesis of mode 
of action. Pathway annotation can be used to identify the biological roles of candidate 
genes129 (in this work: predicted targets). It has been applied to predicted targets of NPs 
and it improved the mechanistic understanding of the mechanism of action of the 
studied NPs130. Pathway annotation has also been used to identify important targets to 
be modulated in order to elicit a required response, e.g. stop a particular function or 
inhibit a particular mechanism131. 
 
Several databases are available that provide signalling, metabolic and gene-regulatory 
pathway annotations when provided with gene lists, e.g. Reactome132, KEGG133, 134, 
Gene Ontology (GO)135, 136, PANTHER137 and Comparative Toxicogenomics Database 
(CTD)138. In this work we use Gene Ontology (GO) and WikiPathways139. 
 
The Gene Ontology (GO)135, 136 is a large resource that provides a standardised, 
structured and controlled vocabulary of terms for both gene and gene product functions 
across all species. It operates based on the observation that similar genes will often 
display conserved functions in different organisms140. The vocabulary of terms is 
divided into three non-overlapping ontologies, namely, Molecular Function (MF), 
Biological Process (BP) and Cellular Component (CC). It associates each gene with the 
most specific set of terms that describes its functionality140. In this work we use the 
Biological Process ontology in an attempt to understand the mechanism of action of 
phenotypically active anti-trypanosome compounds by analysing the biological 
processes they are predicted to modulate. 
 
WikiPathways is a database of biological pathways, which is maintained by the 
scientific community141. In this work we use WikiPathways due to its clear 
interpretability142. In this work it was accessed by PIDGIN143, via the NCBI 
BioSystems Database144. 
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1.7 PHYLOGENETIC AND ETHNOBOTANICAL BIO-PROSPECTING 
One method of predicting the activity of medicinal plants used in traditional medicine 
is by incorporating a priori information of the phylogenetics of the medicinal plant. 
The rationale behind this is that evolutionarily similar plants will produce NPs with 
similar structure (as measured by the Tanimoto similarity of their ECFP4 fingerprints) 
and therefore (based on the similarity hypothesis) they will have similar activity 
profiles. In previous studies relating phylogeny of plants to their ethnobotanical use, 
Hawkins, J. A. et al145 found that in the genus Pterocarpus (Leguminosease) related 
species were used for similar ethnobotanical uses in different geographical areas. This 
was demonstrated by studying plants from the genus Pterocarpus across Indomalaya, 
Tropical Africa and the Neotropics. Plants with medicinal activity were concentrated 
on specific clades, i.e. they were not randomly distributed. This provided a link between 
biogeography and phylogeny of the plant. 
 
Some studies146, 147 have also looked at the possibility of predicting medicinal potential 
of a plant using its phylogeny. The study by Hawkins et al147 found that phylogenetic 
patterns were shared among the medicinal plant species of the flora of Nepal, New 
Zealand and Cape of South Africa. It was observed that for the geographic areas under 
study, traditional medicine use is not randomly distributed on the phylogenetic tree, but 
rather concentrated on specific nodes. Hot nodes comprised on average 133% more 
medicinal plants than a random sample of the studied floras. They found that on average 
“hot nodes” from one region contain 17% more medicinal plants from another region 
than would be expected by chance. Furthermore, on average, the “hot nodes” from one 
region contain 38% more disease specific medicinal plants from another region. 
 
In a study by Duez et al148 an ethnobotanical study of plants used by Burundian 
traditional healers to treat microbial disease was carried out. They attempted to compare 
the plants used to the plant distribution in the area of interest (Burundi). They found 
that 155 plant species, distributed in 51 families and 139 genera, were used, with the 
most common families being Asteraceae, Fabaceae, Lamiaceae, Rubiaceae, Solanaceae 
and Euphorbiaceae. 
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To our knowledge, none of the phylogenetic studies to date have incorporated or 
integrated the chemical information of the NPs produced in a plant to aid prediction of 
activity, which is what we are aiming to do in this thesis. 
 
1.7.1 PHYLOGENETIC TREES 
To study the evolutionary relationship between the medicinal plants in our datasets, and 
relate this to their activity, we used phylogenetic trees. Phylogenetics is defined as the 
study of the evolutionary history and relationships among individuals or a group of 
organisms149. These relationships are not observed but inferred through two steps: (i) 
identifying homologous characters, e.g. amino acid sequences, nucleotide sequences, 
biochemical pathways or any other homologous character and (ii) reconstructing the 
evolutionary history of the individuals using either distance-based or character-based 
methods.  
 
In distance-based methods, the distance between every pair of sequences is calculated 
to produce a matrix and a cluster algorithm, e.g. neighbour joining (NJ)150, minimum 
evolution (ME)151, 152, or least squares method153 is applied to this matrix to produce the 
resolved phylogeny: see Table 1:6. This relies on the assumption that all sequences are 
homologous. 
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Table 1:6 Cluster algorithms used to produce resolved phylogenies in disatance-based methods. 
Cluster algorithm Notes 
Neighbour joining (NJ) This algorithm starts with a star tree. Pairs of taxa are chosen based on 
their distances and successively joined together. This is repeated until 
a fully resolved tree is obtained. The pairs of taxa to be joined are 
chosen in order to minimise an estimate of tree length. The distance 
matrix is updated with the new joined taxa (represented by their 
ancestor) replacing the two original taxa. 
Least squares (LS) This method involves minimising the measure of differences between 
the calculated distances in the distance matrix and the expected 
distances in the tree. A score Q is given to the optimised branch lengths 
liking two species for a given tree. The least square estimate for the 
true tree is the tree with the smallest Q score. 
Minimum evolution (ME) This is similar to LS but uses the sum of branch lengths for tree 
selection. Shorter trees are more likely to be correct in ME than longer 
ones. 
 
In character-based methods all sequences in the alignment are compared 
simultaneously, and one site of the alignment is considered at a time to calculate a score 
for the tree. Maximum parsimony154, 155 assigns character states to nodes on the tree to 
minimise the number of changes on a phylogenetic tree. The maximum parsimony tree 
is the tree that minimises the tree score, which is the sum of character lengths (the 
minimum number of changes required for a particular site) over all sites. In brief, the 
maximum likelihood method156 determines the topology of a tree, its branch lengths 
and the parameters of the evolutionary model that maximise the probability of 
observing the given homologous characters, e.g. nucleoside sequences. Bayesian 
inference157-160 involves combining the prior probability of a phylogeny with the tree 
likelihood of the data to produce a posterior probability distribution on trees. The tree 
that best represents the true phylogenetic tree is the one with the highest posterior 
probability. The tree score for maximum parsimony154, 155, maximum likelihood156 and 
Bayesian inference157-160 are “minimum number of changes”, “likelihood value” and 
“posterior probability” respectively161. The advantages and limitations of these methods 
are shown in Table 1:7. 
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Table 1:7 Methods used for phylogenetic inference with their advantages and limitations. (Adapted from 161) 
Method Advantages Limitations 
Distance-based 
methods 
Fast computational speed 
Can be applied to all data types 
Possible to choose models for distance 
calculation to fit available data 
Variance of distance estimates not 
considered 
Divergent sequences and those with 
many alignment gaps are 
problematic 
Negative branch lengths hold no 
information 
Maximum parsimony Simple and intuitive Poorly understood and implicit 
assumptions 
Knowledge of sequence evolution 
cannot be incorporated 
High substitution rates lead to 
underestimated branch lengths 
May suffer from long-branch 
attraction 
Maximum likelihood Biological reality can be represented 
using complete substitution models 
Iteration is computationally 
expensive 
Bayesian inference Biological reality can be represented 
using complete substitution models 
Expert knowledge can be incorporated 
into model via prior probability 
Easy to interpret posterior probabilities 
of trees and clades 
Computationally expensive 
Difficult to identify and rectify 
Markov Chain Monte Carlo 
convergence 
 
In this work, we use a tree generated by Zanne et al162, constructed using the maximum-
likelihood method, to calculate the patristic distance between medicinal plant families 
and relate this information to their traditional use as well as the predicted activity and 
structural similarity of the NPs they contain. 
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1.8 AIMS OF THE THESIS 
 
In this thesis several aims are explored. The first aim, explored in Chapter 2, is to 
explore the chemical space and biological space of African NPs used against cancer, 
and how this differs from the chemical space and biological space of other NPs used 
against cancer as well as cancer drugs in the market.  In this chapter we utilise machine 
learning to understand the mechanism of action of NPs in an attempt to rationalise their 
ethno-botanical use. 
 
In Chapter 3, methods borrowed from the ecology community are used to determine 
phylogenetic patterns of medicinal plant use in the African continent. We will examine 
whether plants closer together on the phylogenetic tree produce similar compounds that 
are predicted to act on similar targets and vice versa; i.e. where plants that are further 
away phylogenetically synthesize chemically diverse NPs with different predicted 
targets. Ultimately, this information is important to determine whether phylogeny, 
along with ligand-based target prediction and knowledge of ethno-botanic use, can be 
integrated to predict the activity of African NPs. 
 
In Chapter 4 we attempt to understand the molecular mode of action of small molecules 
and NPs active against Trypanosoma brucei, the causative parasite of Human African 
Trypanosomiasis (HAT). We also identify which compounds are predicted to cross the 
BBB. Compounds with the ability to traverse the BBB are important because they are 
essential for the treatment of Stage 2 HAT, for which there are currently only 2 drugs, 
used in combination, in the market. Thirdly we explore the biological processes 
enriched in the predicted gene sets to better understand how these compounds exert 
their phenotypic activity. 
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CHAPTER 2: UTILISING TARGET AND PATHWAY 
PREDICTIONS TO SUGGEST MECHANISMS OF 
ACTION OF AFRICAN NATURAL PRODUCTS 
 
2.1 INTRODUCTION 
The WHO encourages African member states to incorporate traditional medicines into 
their health care systems163. In order to implement this, it is important to understand the 
efficacy, safety and mechanism of action of the natural products (NPs) in these 
traditional medicines. 
 
In this work we will use computational approaches to attempt to understand the 
mechanism of action of African natural products that have recently been curated into 
databases, in particular, ConMedNP and AfroCancer. In our approach to understanding 
the mechanism of action we use ligand based machine learning, taking advantage of the 
“similarity principle”, which says that similar molecules having similar 
physicochemical properties 164 will have similar biological activity”61, 164-166. 
 
Traditional medicines provide us with new starting points for drug discovery in both 
chemical and target space17, 167, and the chemistry of African traditional medicines has 
not yet been explored in much detail. Scaffold diversity analysis of NP datasets has 
been carried out168,whilst the diversity of the most frequent scaffolds of African NPs 
have not been previously analysed. To investigate the chemical space covered by 
traditional African medicines, we studied the scaffold diversity of the African 
compounds in both the datasets and related this to approved drugs in the market. We 
carried this analysis out to see if African NPs contain unique scaffolds and chemistry 
that are not found in drugs in the market, which may be exploited for further drug 
discovery experiments. We also compared the scaffold diversity of African NPs used 
against cancer to Malay and Ayurveda NPs used against cancer. 
 
Secondly, we investigated the target space, and hence the mechanism of action of 
African NPs, compared to approved anti-cancer drugs in the market. In this part of the 
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study, ligand-based target prediction was used to investigate the possible mechanism of 
action of compounds from the AfroCancer dataset. Ligand-based target prediction 
involves comparing a novel ligand to a group of ligands that are known to bind to a 
target, either via similarity or machine learning methods127. Several approaches have 
been published, e.g. SEA (Similarity Ensemble Approach)80 and PASS (Prediction of 
Activity Spectra for Substances)81, and they have been used to rationalise the 
mechanism-of-action of NPs from Chinese, Malaysian and Indian traditional medicines 
169-171 169, but not yet to African medicines. These approaches and their limitations have 
been reviewed in170-173. It is important to note that predicting targets for natural products 
is difficult. This is because the training sets are often small synthetic molecules, 
whereas NPs are generally larger, more complex compounds. One way to overcome 
this problem is to fragment the natural products into smaller entities and predict their 
targets by comparing the smaller entities to synthetic drugs with known targets174. 
Another way to do this is to include natural products with experimentally validated 
results in the training set175. In this study, we use a target prediction algorithm that 
contains natural products in the training dataset. Since the fraction of natural products 
trained in PIDGIN is small, predictions were only kept for NPs with Tanimoto 
coefficient (Tc) ≥ 0.3 to compounds in the training set. Jasial et al176 carried out Tc 
similarity value distributions to determine activity-relevant similarity value ranges. 
They found that there is a much higher probability that a comparison of active 
compounds to active compounds yielded a Tc value of at least 0.3 than a comparison 
of active vs. random or random vs. random compounds i.e. 38.2 % of ECFP-4 Tc values 
for a comparison of active compounds reached or exceeded 0.3 but only 0.3% of 
random vs. active reached or exceeded 0.3. This small percentage of 0.3% translates to 
a large number of false negatives since in reality, when searching a large database there 
are more random vs. active than active vs. active compounds. For example, when 
searching through the 1,828,820 compounds in ChEMBL, where for example only 500 
compounds are active against a particular target, a cutoff of 0.3 will result in 191 true 
positive compounds and 549 false positive compounds. A cut-off Tc value of 0.3 is 
used in our work, as this is the smallest value where the maximum number of true 
positives and minimum number of false negatives can be obtained for active vs. random 
compounds.  
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Lastly, we annotate predicted targets with pathways, with the aim of understanding their 
effects of modulating particular proteins in the human body. Previous studies have 
utilised pathway annotations to understand the mechanism of action of TCM and Indian 
traditional medicines130, 170 as target predictions alone do not provide information on 
downstream biological effects. The idea here is that if a NP from medicinal plant “m” 
is predicted to bind targets “x, y and z”, which are involved in pathway “a”, then we 
can infer that medicinal plant “m” mechanistically works by modulating pathway “a”. 
It is important to mention that not all predicted targets will be linked to the mechanism 
of action of the NP. This method of pathway annotation will enable us to infer the 
pharmacological action of the natural products (at a pathway level), explain the 
molecular basis for their ethno-botanical use, and predict new mechanisms of action if 
they exist. 
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2.2 MATERIALS AND METHODS 
2.2.1 DATASETS 
2.2.1.1 DATASETS USED FOR COMPOUNDS IN AFRICAN NPS 
The compounds analysed in this study were obtained from ConMedNP43, which 
contains 3,177 compounds from 79 plant families comprising 376 species, and 
AfroCancer44, which contains 390 compounds from 48 families comprising 102 
species. All compounds in the datasets were used. Compounds from ConMedNP are 
annotated for a wide variety of diseases collected from traditional healers, while the 
compounds from AfroCancer are focused on cancer indications. Only compound 
structures were used from each of the datasets in subsequent analyses. 
 
2.2.1.2 DATASETS USED AS BACKGROUND FOR AND COMPARISON TO AFRICAN 
COMPOUNDS 
We next identified databases to be used as a background in order to assess the properties 
of African compounds with respect to them. 
  
APPROVED DRUG DATASETS 
As the first dataset to compare compounds used traditionally in African medicine (from 
the ConMedNP dataset) all 1,510 approved drugs from DrugBank 4.0120 were retrieved. 
These compounds will be, hereafter, referred to as ‘Approved DrugBank’.  Secondly, a 
list of approved drugs used for cancer treatment was used as a comparison set (reference 
dataset) to AfroCancer. This list was obtained by request from the National Cancer 
Institute (NCI)177. The ChEMBL-19178 database was queried to identify Simple 
Molecular Input-line Entries  (SMILES) strings for each drug from the NCI, and this 
list of 185 compounds (shown in Supplementary Table 1) will from here onwards be 
referred to as ‘NCI Cancer’. The experimentally validated targets of these drugs were 
also extracted from ChEMBL. An IC50 of 10µm was used for activity against any of 
the targets annotated in the database to assign whether a drug is active against a 
particular protein or not. 
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TRADITIONAL MEDICINES DATASETS 
In addition, two traditional medicine datasets were used as background comparisons for 
the AfroCancer dataset, to determine the similarity of African natural products used 
against cancer to others used in different regions of the world. Firstly, 1,091 compounds 
from Malay traditional medicine with reported anti-cancer activity, using the query 
“cancer” and “tumour”, were derived from the commercial database Natural Product 
Discovery System (NADI179), hereafter referred to as ‘Malay Cancer’ dataset. 
Furthermore, 1,043 compounds with reported anti-cancer properties from Ayurveda 
were obtained from Dr. Duke’s Phytochemical and Ethnobotanical Databases180 which 
will from here onwards be referred to as the ‘Ayurveda Cancer’ dataset.  
 
2.2.2 STRUCTURAL PREPROCESSING 
ChemAxon Standardizer181 was used for structure canonicalization, transformation, and 
conversion of compounds from SD format to SMILES. To standardise the compounds 
in ChemAxon Standardizer, the following options were used: Clean 2D, Mesomerize, 
Neutralize, Remove Explicit Hydrogen and Remove Fragment. Duplicate structures in 
each dataset were removed, using ChemAxon JChem Software181, using the command 
“remove duplicates”. In total, this left us with 185 compounds in NCI Cancer, 1,510 
compounds in Approved DrugBank, 1,015 compounds in Malay Cancer and 1,037 
compounds in Ayurveda Cancer. 
 
2.2.3 CHEMICAL SPACE ANALYSIS 
2.2.3.1 MULTI-DIMENSIONAL SCALING 
Multi-Dimensional Scaling (MDS), was used in R182 using library(rgl) based on 
modified Tanimoto similarity matrices comprised of MOLPRINT2D fingerprints of the 
compounds. MOLPRINT_2D183 fingerprints were generated using Canvas184-186. The 
modified Tanimoto coefficient187 was used since both the ON and OFF bits are 
assessed. The Tanimoto coefficient considers only the ON bits and is sensitive to 
unwanted size dependent effects, i.e. the modified Tanimoto reduces size dependence 
of the similarity coefficient187. It was calculated as follows using Canvas184: 
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Modified Tanimoto = ∝ Tanimoto + (1 − ∝))𝑇0 
 
Equation 2 – Modified Tanimoto coefficient 
    
where: 
∝≡  2/3 – (𝑎 +  𝑏)/[6. min (𝑑, 10000)  and, 
𝑇0 ≡  𝑑/ (𝑎 +  𝑏 –  2𝑐 +  𝑑) )  =  Tanimoto of “off” bit 
Let:  
 a  Count of “on” bits in bitset1. 
 b  Count of “on” bits in bitset2. 
 c  Count of bits that are “on” in both bitset1 and bitset2. 
 d  Count of bits that are “off” in both bitset1 and bitset2. 
2.2.3.2 SCAFFOLD DIVERSITY ANALYSIS 
Next, the scaffold diversity was analysed for the three NP datasets related to cancer, 
namely AfroCancer, Malay Cancer and Ayurveda Cancer, and compared to NCI 
Cancer. The purpose of this part was to assess the diversity of the AfroCancer dataset 
in relation to other NPs from plants with anti-cancer activity. In this study the Bermis-
Murcko188 (BM) scaffolds were used to represent the scaffolds of the molecules. These 
frameworks are defined as “the union of rings plus the linker atoms”, as shown in Figure 
2:1 Bemis-Murcko scaffolds. ChemAxon JKlustor181 command-line was used to 
generate the BM frameworks using the function “bm”, then the compounds were sorted 
into clusters according to their scaffolds and written out in SD format, using the 
function “cluster_*.sdf”.  None of the compounds were sorted into more than one 
cluster.  
 
 
a.                           b.   
 
Figure 2:1 Bemis-Murcko scaffolds The cyclic systems in this study were obtained by removing the side chains 
from the entire molecule (a), and leaving the linkers between the rings to get the Bermis-Murcko scaffold (b). 
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The next step involved analysing the diversity of the most frequent scaffolds. The 
Shannon Entropy measure (SE) was used to quantify the distribution of compounds in 
the n most populated scaffolds189, 190. The SE is defined in Equation 3 as: 
 
 
𝑆𝐸 =  − ∑ 𝑝𝑖𝑙𝑜𝑔2𝑝𝑖:               𝑝𝑖 =  𝑐𝑖 𝑃⁄
𝑛
𝑖=1
 
Equation 3 – Shannon Entropy 
Where:   
pi is the relative frequency of the cyclic systems i in a dataset of P compounds 
that contain n distinct cyclic systems 
ci is the absolute number of compounds containing a cyclic system i 
 
To normalise the results for varying values of n, a Scaled Shannon Entropy 
(SSE)190 was used, which is defined as in Equation 4: 
𝑆𝑆𝐸 =  
𝑆𝐸
𝑙𝑜𝑔2𝑛
 
Equation 4 – Scaled Shannon Entropy 
 
For more diverse indications, the scaffold diversity of the African compounds from 
ConMedNP was also compared to the diversity of the Approved DrugBank database. 
For this purpose, Murcko scaffolds188 were used as generated using DataWarrior, 
version 4.3191. The compounds were then sorted into clusters; according to their 
scaffolds, i.e. all compounds having the same scaffold were placed in the same cluster. 
The diversity of the entire datasets was studied by analysing the diversity of the most 
frequent scaffolds by using the Shannon Entropy (SE) measure, in order to quantify the 
distribution of compounds in the n most populated scaffolds189, 190. This measure 
indicates the global diversity of the datasets. 
 
2.2.4 TARGET PREDICTION – PIDGINV2 
In this work we make use of a Random Forest algorithm (PIDGINv2) trained by Mervin 
et al143 using  ECFP-4 for SAR modelling. Active compounds were extracted from 
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ChEMBL2183 and are those with activity values (IC50/EC50/Ki/Kd) of 10 μM or lower, 
with a confidence score of 5 or greater for ‘binding’ or ‘functional’ human protein 
assays. The active dataset contains 2,089,404 bioactivities across 3,394 proteins. The 
inactive dataset contains 11,829,475 inactives derived from PubChem. PIDGIN v2 is 
therefore capable of predicting both the probability of activity and inactivity for orphan 
compounds against a range of biological targets. The parameters used were: Random 
Forest with 100 trees, class weight = “balanced”, sample weight = ratio inactive:active.  
 
The steps involved in a Random Forest algorithm are192: 
 
Ensemble of Trees: A Random Forest is represented by [T1(X), ..., TB(X)], with B being 
the number of trees and X = [x1, ..., xv] is a v-dimensional vector of molecular 
descriptors or properties associated with a molecule. The ensemble produces B outputs 
[Yˆ1 = T1(X), ..., YˆB ) TB(X)] where Yˆ b, b = 1, ..., B, is the prediction for a molecule 
by the bth tree. Yˆ is the final predicted class as predicted by the majority of the trees.  
 
Training Procedure: For a dataset of n molecules, D = [(X1, Y1), ..., (Xn, Yn)], where 
Xi, i = 1, ..., n, is a vector of descriptors and Yi is the class label (e.g., active:inactive) 
The algorithm functions as follows:  
(1) From the training data of n molecules, draw a bootstrap sample (n samples chosen 
at random, with replacement).  
(2) For each bootstrap sample, grow a tree and at each node, select m random variables 
out of all possible M variables. Select the best split on the selected m variables. 
(3) Grow the trees until no further splits are possible or until a maximum depth specified 
at the start (in this case 100). 
Repeat the steps until a specified number of B trees are grown. A simplified schematic 
of this process is shown in Figure 2:2. 
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Figure 2:2 Schematic showing a simplified Random Forest model. In the Random Forest algorithm, each new 
data point goes from the root node to the bottom until it is classified in a leaf node. It visits all the different trees in 
the ensemble, which are grown using random samples of variables. In this classification model, the function used 
for aggregation is the mode or most frequent class predicted by the individual trees (also known as a majority vote).  
 
The models were scaled using Platt Scaling193. Platt Scaling assigns true positive rate 
(TPR) values to the predictions by splitting the training set into a calibration and 
training set, thereby converting the Random Forest predictions into the corresponding 
TPR for a given threshold. In this work targets were predicted for the input compounds 
with a cut off of 0.9 (meaning that a 10% false positive rate is accepted, which is a 
rather stringent value).  
 
To obtain the enriched targets, the list of predicted targets was compared by Mervin et 
al143 to the predicted targets of a random sample of over 2,000,000 compounds obtained 
from PubChem. The Fisher’s exact test and odds ratio194, 195 were calculated using the 
contingency table for both sets143. A low odds ratio and p-value indicate a higher 
enrichment for a target when compared to targets from a random set. In this work the 
resulting list was filtered for an odd ratio of less than 0.1 and ranked by p-value.  
 
INSTANCE 
Tree 1 Tree 2 Tree n 
Active Inactive Inactive 
Majority Voting 
Prediction 
Random Forest 
 
 
 
 
56 
 
2.2.5 PATHWAY ANNOTATION 
The output from the PIDGIN v2143 pathway prediction results contains pathways 
predicted from NCBI BioSystems pathways. The WikiPathways annotations in 
PIDGIN2 were used for pathway annotation due to their interpretability141, 142. 
 
Figure 2:3 shows a workflow of the work carried out in this chapter. 
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NP Databases – all compounds in recorded 
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- Scaffold diversity 
- Most common scaffolds 
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MOLPRINT_2D  
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Tanimoto similarity 
Figure 2:3 Workflow illustrating the work carried out in this study. (i) Chemical space of ANPs in 
ConMedNP was studied and compared of the chemical space coverage of approved drugs in DrugBank. 
(ii) Scaffold diversity of ANPs in the AfroCancer and ConMedNP datasets was studied and compared to 
the scaffold diversity of the approved drugs in DrugBank and approved drugs for cancer (NCI). (iii) 
Target and pathway prediction of ANPs was carried out to understand their mechanism of action. These 
predicted targets were compared to the experimentally validated targets of the NCI dataset. Enriched 
targets were only calculated for the ANPs and these were compared to experimentally validated targets 
of the NCI dataset. Enriched pathways were calculated for both the AfroCancer and NCI dataset 
compounds. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 COMPARATIVE CHEMICAL SPACE ANALYSIS 
The distribution of the ConMedNP database in chemical space, in comparison with the 
approved DrugBank compounds, were first compared, using MOLPRINT2D 
fingerprints and multi-dimensional scaling (MDS, Figure 2:4). It can be seen that 
ConMedNP compounds dominate two areas, (shown in red), not populated by many 
compounds from the Approved DrugBank set. The approved drugs that did populate 
this area were also natural products such as Colchicine. The overlap in space may be 
due to the fact that marketed drugs (those in Approved DrugBank) might be influenced 
by natural products. This has been shown by Newman and Cragg17  in their study of the 
sources of drugs between 1981-2014. They found that 26% of new drugs are either 
botanical drugs, unaltered natural product drugs or synthetic drugs derived from natural 
products. Our results indicate that the African compounds occupy a different chemical 
space. The space of Approved DrugBank is not as diverse in chemical space due to the 
fact that compounds are screened for Lipinski’s rule violations early on in the drug 
discovery process. Lipinski’s rule does not apply to natural products because they 
mostly enter the cells via transmembrane transporters and not passive diffusion.196 In 
conclusion we have shown that African NPs and drugs occupy a different chemical 
space. 
 
 
. 
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Figure 2:4 MDS of molprint2d fingerprints of compounds of the CONMEDNP (red) and Approved DrugBank 
(blue). Compounds with unique scaffolds from ConMedNP occupy a different chemical space to those occupied by 
Approved DrugBank compounds. The modified Tanimoto coefficients shown between the pairs of compounds range 
from 0.80 to 0.83 for similar compounds and about 0.35 for structurally dissimilar compounds. Examples of 
bioactive compounds from the ConMedNP dataset are shown in the red and green circles. 
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The range of molecular weights covered by the compounds in both datasets is also 
shown in Figure 2:5. It can be seen that there are more compounds in the ConMedNP 
dataset, with molecular weights raging from 84.16 to 1439.59 with a mean molecular 
weight of 241.75 Daltons. On the other hand, the compounds in the Approved 
DrugBank dataset have molecular weights which range from 17.00 to 1449.27 with a 
mean molecular weight of 354.73 Daltons. 
 
Figure 2:5 Range of molecular weights of compounds in the Approved DrugBank and ConMedNP datasets. 
Molecular weights for the ConMedNP dataset range from 84.16 to 1439.59 with a mean molecular weight of 241.75 
Daltons. Molecular weights for the Approved DrugBank dataset range from 17.00 to 1449.27 with a mean molecular 
weight of 354.73 Daltons. 
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To understand the difference in chemical space covered in the different datasets further 
a scaffold analysis was carried out next. 
 
2.3.2 SCAFFOLD DIVERSITY OF AFRICAN NATURAL COMPOUND DATASETS 
Next, the scaffold diversity of African compounds isolated from traditional medicines 
was quantified. Scaled Shannon Entropy (SSE) was used to analyse the distribution of 
compounds in the scaffolds of the datasets, with a value of 0 indicating that all 
compounds are contained in one cyclic system (representing the lowest possible 
diversity) to 1, indicating that each cyclic system contains an equal number of 
compounds (representing highest possible diversity). Looking at Table 2:1 the SSE 
values for the AfroCancer and NCI Cancer dataset (of 0.94 and 0.89 respectively) 
demonstrate their higher diversity when compared to the other datasets (of 0.73 and 
0.69 for Malaya Cancer and Ayurveda Cancer respectively). ConMedNP and Approved 
DrugBank showed relatively lower (but still high) diversity values of 0.87 and 0.85, 
respectively. These results are in line with results obtained by Schneider et al197 who 
found a greater diversity of ring systems in natural product libraries compared to 
synthetic and combinatorial libraries. Yet this was not the same as results obtained in a 
previous study168, where it was found that the diversity of a combinatorial library was 
higher than that of the natural products they studied. It is surprising that the more 
focused libraries (on cancer) have a larger diversity on this measure than the more 
diverse ones with respect to indications, i.e. ConMedP and Approved Drug Bank. This 
may be because the compounds in the smaller datasets, e.g. AfroCancer and NCI 
Cancer were synthesised through very different routes, e.g. from plants or via organic 
synthesis to specifically inhibit different targets with different roles in cancer. 
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Table 2:1 Scaled Shannon Entropy table for the 6 studied datasets NC: number of compounds in the database; 
NS: number of scaffolds; NS1: number of singletons; NS/NC and NS1/NC: number of scaffolds and number of 
singletons normalised by the number of compounds, respectively; NS1/NS: number of singletons in relation to the 
number of scaffolds; SSE5, SSE10, SSE20: scaled Shannon Entropy at 5, 10 and 20 most populated scaffolds, 
respectively; n5, n10, n20: fraction of compounds contained in the 5, 10 and 20 most populated scaffolds, 
respectively. It can be seen that the AfroCancer and NCI Cancer dataset are more diverse than the other datasets. 
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AfroCancer 364 226 0.62 164 0.73 0.45 0.94 0.97 0.96 0.96 0.13 0.19 0.28 
Malay Cancer 1,043 425 0.41 322 0.76 0.31 0.73 0.80 0.81 0.82 0.18 0.22 0.28 
Ayurveda Cancer 1,091 387 0.35 284 0.73 0.26 0.69 0.71 0.77 0.80 0.17 0.22 0.28 
NCI Cancer 187 124 0.66 100 0.81 0.53 0.89 0.97 0.97 0.99 0.14 0.21 0.31 
ConMedNP 2,647 1,128 0.43 758 0.67 0.29 0.87 0.97 0.92 0.92 0.13 0.17 0.23 
Approved Drugs in 
DrugBank 
1,510 892 0.59 740 0.83 0.49 0.85 0.61 0.69 0.77 0.12 0.15 0.19 
 
We next analysed the Murcko scaffolds of our datasets in order to be able to interpret 
scaffold diversity on the chemical level.  
 
Table 2:2 shows the most frequent Murcko scaffolds in the AfroCancer, NCI Cancer, 
ConMedNP and Approved DrugBank datasets, along with the percentage of the dataset 
covered by that scaffold. The percentage of compounds not containing ring systems 
were 2.19%, 10%, 3.9% and 10% for the AfroCancer, NCI Cancer, ConMedNP and 
Approved DrugBank datasets, respectively. The benzene scaffold is the most populated 
scaffold in both the NCI Cancer and Approved DrugBank datasets, whereas it is less 
populated in both the African datasets (at second place for AfroCancer, and at rank 5 
for ConMedNP, respectively). This was also observed in a recent study198 of all drugs 
in DrugBank (we used only the approved drugs). Eight of the scaffolds in our top ten 
most populated scaffold were present in the top 12 scaffolds of this study. A further 
study identified the top five populated scaffolds of drug and drug-like compounds199. 
Of these, three are present in the top 10 most populated scaffolds of the Approved 
DrugBank dataset. The flavone (rank 1 in the AfroCancer dataset) and isoflavone (rank 
5 in the ConMedNP dataset) scaffolds are also more populated in the African datasets, 
but absent in both drug datasets in total. This is expected because flavonoids fulfil many 
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important functions in plants including anti-oxidant activity and cell signalling200. The 
observation of the presence of flavone and isoflavone scaffolds in the top populated 
scaffolds of the natural product datasets is similar to the observation by Yongye et al168, 
201, 202 that flavones, coumarins and flavanones are the most frequent scaffolds in NP 
datasets. Our analysis shows that the frequent ring systems in African NP datasets are 
consistent with those found in NP datasets in the literature. 
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Table 2:2 Top 10 most common scaffolds in the AfroCancer, NCI Cancer, ConMedNP and Approved 
DrugBank datasets. It can be seen that the benzene scaffold appears in the top 10 most populated scaffolds in all 
datasets. The compounds in the AfroCancer and ChEMBL dataset are more evenly distributed across their scaffolds. 
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Figure 2:6 Overlap of scaffolds between the different datasets and scaffolds representing them. AfroCancer 
and NCI Cancer share six Murcko scaffolds, while the ConMedNP and Approved DrugBank datasets share 33 
Murcko scaffolds. The table shows the five scaffolds shared by all four datasets and the number of compounds in 
each dataset having that scaffold. 
 
We next analysed the scaffolds that were present in all 4 datasets. From Figure 2:6 we 
can see that there are five structures shared between all four datasets. The AfroCancer 
dataset shares six scaffolds with the NCI Cancer dataset, and ConMedNP shares 33 
scaffolds with the Approved DrugBank dataset. For the five-shared scaffolds, structures 
ii, iii and v are simple and we would expect to see them as scaffolds for small molecule 
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drugs198. The anthraquinone (i) and stilbene (iv) scaffolds are more common in the NP 
datasets due to the important role these secondary metabolites play in plants, e.g. 
colouring pigments (anthraquinone) and antimicrobial, cell signalling and antifungal 
roles (stilbenes)203. This finding shows that there is more structural variation and hence 
different chemical space being covered by the different datasets. This can be 
extrapolated to see how many unique scaffolds there are in the AfroCancer and NCI 
Cancer datasets. 99 out of 226 scaffolds (43.8%) were unique to the AfroCancer dataset 
(when compared to the 45 out of 124 scaffolds (36.3%) in the NCI Cancer dataset). 
 
The totality of bioactive medicinal chemical space from African and approved drug 
origins were hence rather distinct on the scaffold level: out of the 1,128 scaffolds in 
ConMedNP, there were 1,095 scaffolds (97%) not present in the Approved DrugBank 
dataset. In turn, for the Approved DrugBank dataset 98% of the scaffolds were not 
present in ConMedNP. These percentages are similar to those obtained previously199 
where it was found that 85-92% of scaffolds are unique to a dataset and not found in 
other datasets. This was also similar to results obtained by Lee and Schneider197. They 
compared scaffolds of natural product libraries and drug libraries, but they cleaved the 
single bonds (we kept single bonds between rings). They found that 17% of NP 
scaffolds were present in the drug dataset, and 35% of the drug scaffolds were present 
in the NP datasets. 
 
As an illustration we investigated one of the scaffolds which is only present in the 
African datasets, and describe its pharmacological activity in the following. This 
scaffold, the flavone scaffold, was the fifth most populated scaffold in the ConMedNP 
dataset (which was not present in Approved DrugBank). Two of the compounds 
possessing this scaffold (whose structures are shown in the green circle in Figure 2:4) 
come from the plant Milletia griffonia, which is used traditionally to relieve menopausal 
symptoms and limit bone resorption, i.e. treat osteoporosis43, 204. Another compound in 
this area is Buesgeniine (structure shown in the red circle in Figure 2:4), which was 
isolated from the stem bark of Zanthoxylem buesegenii, a plant used traditionally to 
treat convulsions43. This illustrates the novelty, as well as diversity, of the bioactivities 
that structures from the plant origins analysed here possess. Previous work had been 
carried out to identify small hetero-cycles (by enumerating all possible hetero-cycles) 
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due to their usefulness in the development of drugs205, and our examples now provide 
a list of hetero-cycles with ethnobotanical evidence of bioactivity. 
 
In general, these results show that the AfroCancer and ConMedNP databases exhibit 
more scaffold diversity than traditional compound databases and comparable scaffold 
diversity to approved drugs. The results also show that the African datasets contain 
unique scaffolds that are not represented in approved drug datasets, which are able in 
turn to convey very diverse bioactivities. 
 
2.3.3 PREDICTING THE MECHANISM-OF-ACTION OF TRADITIONAL AFRICAN 
MEDICINES 
2.3.3.1 TARGET PREDICTION FOR COMPOUNDS IN THE AFROCANCER DATASET 
In order to understand the mechanism of action of NPs used against cancer, we 
implemented a target prediction algorithm (PIDGINv2) on the AfroCancer dataset. We 
compared this to the experimentally validated targets of the NCI dataset to see if the 
two datasets shared any predicted target space or if the African NPs have a different 
mechanism of action. 
 
Target prediction (with the software set to a 0.9 true positive rate, corresponding to a 
90% confidence that positive predictions are true positives127) was carried out on the 
AfroCancer dataset and compared with the experimental targets of the NCI Cancer 
dataset. We found that there are 14 shared targets between the two datasets, with 134 
targets uniquely predicted in the AfroCancer dataset, and 82 unique targets in the NCI 
Cancer dataset (see Supplementary Table 2 for details). We will first analyse trends in 
predicted targets on a higher level, before subsequently moving on to individual targets 
and pathways. 
 
We first analysed targets predicted on the protein family level. Figure 2:7 shows the 
target classes that make up the predicted (AfroCancer) and experimental (NCI Cancer) 
targets in each dataset. All targets were counted with their classes and normalised with 
respect to the total number of predictions. In the NCI Cancer dataset kinases are the 
largest predicted target class (36% of all individual target predictions), in contrast to 
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only 7% of the targets targeted by the AfroCancer set. In turn, 20% of the target classes 
were oxidoreductases in the AfroCancer dataset, while only 6% of the NCI Cancer 
dataset were oxidoreductases. There is similarity in some smaller target classes, e.g. 
Lipases, which comprise 1% in both data sets. On the other hand, there is a distinct 
difference in the distributions between both datasets for the GPCRs and Other target 
classes.  
 
 
 
Figure 2:7 Target classes interacting with compounds in the AfroCancer and NCI Cancer datasets. 34% of 
the targets that bind compounds in the NCI Cancer (dark grey) dataset are kinases and 24% are GPCRs. 20% of the 
targets predicted to bind to the AfroCancer (light grey) compounds are oxidoreductases while only 7% are kinases 
and 3% are GPCRs. 
 
We next analysed the number of times a target was predicted. This was carried out to 
identify and compare the popular targets in each dataset. Whereas Figure 2:7 shows the 
distribution between unique targets predicted, Figure 2:8 (a and b) takes the number of 
times a target was predicted into account.  
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(a) NCI Cancer 
(b) AfroCancer 
Figure 2:8 Number of targets per target class in the NCI Cancer and AfroCancer dataset. Each circle represents 
a target from the target class shown on the x-axis. (a) Shows the percentage of the dataset predicted to bind to the 
different target classes in the NCI Cancer dataset. Less than 10% of the dataset is predicted to bind to kinases, even 
though they make up 36% of the target classes in that dataset. (b) Transferases only make up 5% of the targets 
predicted to bind the AfroCancer compounds, yet we see that many compounds in the dataset were predicted to bind 
to them. More than 30% of the dataset is predicted to bind to isomerases, but they represent only 2% of the target 
classes for this dataset. (The binding frequency is higher in the AfroCancer dataset because these are predicted targets 
whereas in the NCI Cancer set, they are experimentally validated targets). 
 
 
 
 
71 
 
In Figure 2:8 (a) we see that even though kinases make up the majority of the target 
classes in the NCI Cancer dataset, only around 9% of the compounds in the dataset are 
predicted to actually target kinases, with the most targeted kinase being Tyrosine 
protein kinase JAK1. Only 26 small-molecule kinase inhibitors are currently approved 
by the FDA for cancer indications 206. In contrast, almost 15% of the AfroCancer dataset 
are predicted to bind at least one of the kinases in the dataset, with the most targeted 
kinase being galactokinase. On the other hand, 21 FDA approved drugs with anti-
neoplastic activity elicit their effect by modulating 14 GPCRs207 as primary targets. 
From Figure 2:7 and Figure 2:8 it can be seen that just over 3% of the compounds in 
the NCI Cancer dataset modulate 24 GPCRs. Meanwhile, just under 10% of the 
compounds in the AfroCancer dataset are predicted to modulate not more than 3 GPCRs 
in total. There are 48 FDA approved Nuclear receptor agonists and antagonists208. In 
the NCI Cancer dataset, 10 Nuclear Hormone Receptors (NHRs) are targeted by over 
5% of the compounds in the dataset. By comparison, ~25% of the compounds in the 
AfroCancer dataset are predicted to modulate only 7 NHRs. These results show that, 
despite the fact that some target classes known to be involved in cancerogenesis only 
represent a small percentage of the overall classes, e.g. kinases (7%) and isomerases 
(2%), the compounds in the AfroCancer dataset are predicted to bind a wide range of 
target classes.  
 
In our next analysis, we attempt to understand the mechanism of action of NPs in plants 
used against cancer at the target level. To do this, the predicted targets for the 
AfroCancer dataset were arranged in order of decreasing enrichment, and the top 10 
enriched targets were analysed, the results of which are shown in Table 2:3. The top 
100 most enriched targets for the AfroCancer dataset are shown in Supplementary 
Table 3.  
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Table 2:3 Top 10 most enriched targets in the AfroCancer dataset and the roles they play in cancer 
Target AfroCanc
er Hits 
PubChem 
Hits 
P Value Odds 
Ratio  
Role of Target in Cancer 
Heat shock protein 
beta-1 
5 18 6.51E-15 6.46E-04 Overexpressed in range of cancers. Plays role 
in tumor cell proliferation, differentiation, 
invasion, metastasis, death, and recognition 
by the immune system209. 
NADPH oxidase 4 38 350 6.76E-91 1.50E-03 Expression is increased in pre-malignant 
states of lung and liver cancer, and plays a 
role in the production of reactive oxygen 
species by cancer cells210. 
Carbonyl reductase 
[NADPH] 1 
32 473 2.12E-70 2.45E-03 CBR1 reduces apoptosis and promotes cell 
survival in pancreatic b cells by reducing the 
generation of reductive oxygen species211. 
Cytochrome P450 1B1 1 21 1.38E-43 3.57E-03 Role in cancer and effect of inhibition by NPs 
are reviewed in212 
Aldehyde 
dehydrogenase 
21 437 4.00E-03 3.81E-03 May play a role in differentiation and 
progression of cancer cells. Roles reviewed 
in213 
Interleukin-2 1 26 4.90E-03 4.72E-03 Used as an immunotherapy agent to treat 
cancer214 
Thioredoxin reductase 
2 
1 33 6.17E-03 5.99E-03 Involved in tumour oxygenation, roles 
reviewed in215 
Multidrug resistance-
associated protein 1 
37 1790 1.15E-62 7.92E-03 Plays a role in reducing resistance to drugs216. 
Steroid hormone 
receptor 
8 419 2.67E-14 9.32E-03 Overexpression is used as a prognostic 
marker in breast cancer. Roles reviewed in217 
Potassium voltage-
gated channel 
subfamily A member 3 
6 18 5.09E-11 9.49E-03 Controls the cell resting membrane potential, 
cell proliferation and apoptosis. Potential 
new target in lymph node cancer, reviewed 
in218 
 
For all the 10 most enriched targets, links to cancer were identified. The most enriched 
target in the AfroCancer dataset is Heat shock protein beta-1. Hsp27 is a chaperone of 
the small heat shock protein and provides cyto-protection and inhibition of apoptosis 
under stress conditions219. Hsp27 is induced by heat shock, hypoxia and DNA damage 
and is overexpressed in a wide range of cancers209. The NP Quercetin is an effective 
inhibitor of Hsp27220 and sensitizes glioblastoma cells to temozolomide by increasing 
caspase-3 activity and inducing cell apoptosis221. The scaffold of Quercetin, which is a 
flavonoid, is the most abundant scaffold in the AfroCancer database (see Table 2:2). 
This indicates that several other African NPs may share this bioactivity with Quercetin 
as well as sharing the same scaffold. 
 
Another target involved in cancer in the top 10 is Cytochrome P450 1B1, a mono-
oxygenase of endogenous compounds and xenobiotics. It is the most efficient 17β-
estradiol hydroxylase (4-hydroxylation of estrogens is considered to be an important 
step in hormonal carcinogenesis)222. Furthermore, Cyp450 1B1 is involved in the 
metabolism of some cancer drugs, e.g Docetaxel, which leads to drug resistance that is 
associated with the overexpression of CYP1B1223, 224. CYP1B1-null mice show no 
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obvious change in phenotype, which indicates CYP1B1 is not necessary for mammalian 
development225. It is highly expressed in cancers of the breast, colon, esophagus, skin, 
lymph nodes, brain and testicles compared to healthy tissues222. These observations 
indicate that CYP1B1 is a potential target of interest in cancer226.  However, it is 
important to specifically inhibit CYP1B1 because CYP1A1, which displays 41% amino 
acid sequence similarity to CYP1B1, plays a role in the detoxication of environmental 
procarcinogens, and also contributes to the metabolic activation of dietary compounds 
with preventive activity against cancer227. NP inhibitors of this CYP1B1 include 
coumarins, flavonoids, stilbenes and anthraquinones212. The compounds predicted to 
bind to this enzyme from the AfroCancer dataset are stilbenes and flavonoids with a 
hydroxyl and/or methoxy substitution at the 3’ and 4’ positions, which is also required 
for selectivity over CYP1A212. This is beneficial as the CYPs, once modulated by the 
NPs, will be deactivated and hence the xenobiotics, (or other active NPs in this case) 
will not be detoxified in the cells228. 
 
There is evidence from the literature that several of the targets listed in Table 2:3 are 
modulated by natural products. Potassium voltage-gated channel subfamily A member 
3 is important in setting the cell membrane potential and is currently being considered 
as a potentially new anti-cancer target218. It has been found to be overexpressed in 
various cancers including breast, colon, smooth and skeletal muscle and lymph node 
cancers218. Inhibition of this channel arrests the G1 phase of the cell cycle229, thus 
stopping cell proliferation. A recent study found that the flavonoid, 8-prenylnaringenin 
(Humulus lupulus) inhibits the gate at micromolecular concentrations230. DNA 
topoisomerase I and IIα were also predicted to bind compounds from the AfroCancer 
dataset. These enzymes make incisions in the backbone of the DNA, thus catalysing 
the winding and unwinding of the DNA strands. Inhibitors of DNA topoisomerase I 
and DNA topoisomerase II α induce single and double strand breaks respectively, thus 
inhibiting the cell cycle at the G2 stage231. They are both validated anti-cancer targets 
currently inhibited by irinotecan, topotecan and camphotethecin (DNA topoisomerase 
I) and etoposide, doxorubicin and daunorubicin (DNA topoisomerase II). These 
enzymes are also inhibited by phytoalexins, namely genistein232, quercetin233 and 
resveratrol234. Estrogen receptor α and β were predicted to bind compounds in the 
AfroCancer dataset and they are both validated drug targets being inhibited by the pro-
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drug Tamoxifen235 and Fulvestrant236. The phytoestrogens genistein, kaempferol and 
liquiritigenin are known agonists of these proteins 237. 
 
As can be seen from the above, there is broad literature support for NPs acting on the 
predicted targets. The AfroCancer NPs may be acting via the same mechanisms and 
this provides a promising insight into their mechanism of action.  
 
We next investigated which novel proteins (i.e., those not currently targeted by anti-
cancer drugs) are predicted to be targeted by the AfroCancer compounds, in order to 
firstly understand which novel mechanisms might already be used by African 
medicines to treat cancer, and secondly to make concrete suggestions which type of 
chemistry might be active against which target(s) in an in vivo setting.  
 
In this regard, Table 2:4 shows the unique enriched targets and structures (of either the 
top 5 most similar structures or with 0.3 or more similarity to those in the training set, 
whichever is more) that are predicted to bind to them.  
 
NPs in AfroCancer are predicted to bind Mcl-1, which is an anti-apoptotic member of 
the Bcl-2 family. Mcl-1 is a target of interest and inhibitors are being pursued as drugs 
238. Currently, Omacetaxine Mepesuccinate and Seliciclib are marketed drugs that 
inhibit the synthesis of Mcl-,1 but there are no drugs approved as of now that inhibit 
the function of the actual protein. Flap endonuclease is also predicted to be a target. It 
is overexpressed in breast239, prostate240, stomach241, neuroblastoma242, pancreatic243 
and lung cancer244 and is responsible for inaccurate repair of double strand breaks in 
the DNA repair pathway245. Overexpression is associated with cancer because 
inaccurate DNA repair leads to a higher risk of mutations and thus an increased risk of 
cancer. Another unique target predicted for the AfroCancer dataset is HSP70 which 
plays a housekeeping role in conditions of stress. The role of this target and its potential 
as an anticancer target has been recognised and reviewed 246, 247. To date, there are no 
drugs in the market targeting HSP70. NPs from traditional medicines such as the 
datasets analysed here, which are targeting HSP70, could thus be exploited for further 
experimentation to see if they are viable modulators. Tankyrase 1 is another of the novel 
targets predicted for the AfroCancer datasets. Tankyrase 1 binds to telomeric repeat 
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factor 1 (TRF1) which positively regulates telomere length248, 249. It does this by 
poly(ADP-ribosyl)ating TRF1 to release it from telomeres250, hence allowing access of 
telomerase to telomeres. Telomeres consist of tandem repeats of a G base rich DNA 
sequence251. Shortening of the telomeres below a certain threshold leads to end-to-end 
chromosome fusions, cell cycle arrest and/or apoptosis251. Thus, the importance of 
Tankyrase 1 in cancer lies in prevention of telomere shortening and hence prevention 
of cancer cell cycle arrest and apoptosis. Tankyrase is suggested to be a therapeutic 
target252, 253 with one of the reasons being that it was found that inhibition of Tankyrase 
1 accentutated the ability of MST-312 to induce telomere shortening254. Also, over-
expression of Tankyrase 1 was found to promote telomere elongation249. A reduction 
in Tankyrase 1 has been shown by Dynek and Smith255 to cause cells to accumulate in 
the M phase of the cell cycle. It has been found by Chang et al256 to cause abnormal 
spindle structures. Several compounds in the AfroCancer dataset were predicted to bind 
this target. They may be acting by allowing cell cycle arrest and death by inhibiting 
Tankyrase 1. Two mitotic-specific cyclins B2 and B3 were predicted for the 
AfroCancer compounds. They are also involved in control of the cell cycle at G2/M 
transition257. Overexpression of G2/mitotic specific cyclin B2 is associated with poor 
prognosis in patients with non-small cell lung cancer258, whereas a decrease of 
expression leads to an inhibition of both invasion and metastasis in bladder cancer259. 
This means that their modulation by the AfroCancer compounds may lead to cell cycle 
arrest and better prognosis. 
 
Hence, overall it can be seen that NPs from medicinal plants with anti-cancer activity 
are predicted to bind novel cancer-related targets. These results provide insight into 
the mechanism of action of these NPs.
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To determine if there is a relationship between novel scaffolds and novel targets, we 
next study the relationship between the unique targets (predicted for AfroCancer 
compounds and not present in NCI Cancer targets) and the scaffolds of the compounds 
they were predicted to bind. Table 2:5 (a) shows the compounds (and their common 
Murcko scaffold) predicted to bind heat shock protein beta-1.  One of these compounds 
is Quercetin. As this compound has been shown to inhibit heat shock protein by 
Western Blot analysis260, we are confident in the prediction. It is important to note 
however that polyphenols pose as a problem in drug discovery because they bind targets 
promiscuously and have poor pharmacokinetic properties261. Similarly, the scaffold in 
Table 2:5 (b) was unique to the AfroCancer dataset as was the target it was predicted 
to bind, cyclic dependent kinase 14. In Table 2:5 (c) the scaffold from a compound 
predicted to bind G2/mitotic –specific cyclin-B3 was found in both the AfroCancer and 
the Approved DrugBank datasets (yet none of the drugs in the DrugBank dataset are 
known to modulate this target), but not the NCI Cancer dataset. This is relevant since 
we have identified important anti-cancer targets predicted to be modified by compounds 
with unique scaffolds. We have predicted the mechanism of action of NPs of plants 
used against cancer and they have a different mechanism of action to drugs in the 
market, as was predicted due to their different scaffolds.
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Table 2:5 Scaffolds of compounds predicted to bind unique targets. (a) The flavonoid scaffold which is common 
to the three compounds shown in (a) is unique to the AfroCancer dataset. The compounds were predicted to bind 
heat shock protein beta-1. (b) This scaffold was also unique to the AfroCancer dataset. This compound was predicted 
to bind cyclic dependent kinase 14. (c) This scaffold was found in the AfroCancer dataset but not the NCI Cancer 
dataset. It was found in the Approved DrugBank dataset. This compound was predicted to bind G2/mitotic –specific 
cyclin-B3. These unique scaffolds (a and b) are occupied by compounds that are predicted to bind unique targets. 
 
Scaffold Compound 
(a)  
 
 
 
(b)   
                 (c)   
 
2.3.3.2 ANNOTATING TARGET PREDICTIONS FOR THE AFROCANCER DATASET 
WITH PATHWAYS 
We next annotated the predicted targets for the AfroCancer dataset with pathways that 
they are involved in, to further understand their potential molecular mechanism of 
action. From this analysis 102 and 89 WikiPathways were obtained for the 
experimentally validated NCI Cancer targets and predicted AfroCancer targets 
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respectively, and 52 pathways were common to both datasets (see Supplementary Table 
4). 
 
Looking at the pathways modulated by the NCI Cancer compounds (Supplementary 
Table 4) we see that they modulate, among others, the cell cycle and cell death, e.g. 
DNA Replication, Senescence and Autophagy, and Regulation of Microtubule 
Cytoskeleton. The AfroCancer compounds are predicted to also act on the cell cycle, 
but they are predicted do so through different pathways, i.e. G1 to S cell cycle control 
by modulating cyclin-dependent kinase 6 and Apoptosis Modulation and Signalling by 
modulating Bcl2, MAPK3, MCL1 and NFKB1A. 
 
One of the 37 unique pathways modulated by the compounds in the AfroCancer dataset 
with evidence of involvement in cancer is the Keap1-Nrf2 Pathway. The compounds 
are predicted to act by modulating Nrf2 (nuclear factor erythroid 2-related factor 2). 
Nrf2 is highly expressed in pre-malignant and malignant cells and enhances both 
chemo-resistance and growth of tumour cells262. The NP brusatol (a quassinoid isolated 
from Brucea javanica) is known to inhibit Nrf2, and thus increase chemosensitivity and 
reduce tumour size263. The Nrf2 transcription factor is also responsible for 
cytoprotection against chemical and oxidative stress264. No known inhibitors are 
currently in the market due to structural similarity with other bZIP domain containing 
proteins262, causing selectivity problems due to off-target effects. Only one other 
protein, CREBBP, containing the bZip domain was predicted to bind the compounds 
from the AfroCancer dataset and none of the compounds predicted to bind Nrf2 were 
predicted to bind CREBBP, hence indicating possible selectivity (though the target 
prediction models used do not necessarily provide the resolution needed to be certain 
about this type of predictions). These results suggest that the AfroCancer dataset 
comprises some chemopreventive activity through Nrf2 inhibition.  
 
Taken together, these results lead us to believe that the AfroCancer compounds occupy 
a different yet pharmacologically relevant biological space compared to approved 
medicines in the NCI Cancer dataset, and that their activities appear to be achieved by 
somewhat different means, both in target and pathway space.  
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2.3.3.3 CASE STUDY: TARGET PREDICTION OF COMPOUNDS ISOLATED FROM 
PSOROSPERMUM AURANTIACUM 
We then turned our attention to one particular plant in the ConMedNP dataset which 
has a variety of uses, in order to see whether our analyses can provide insight into its 
mode of action. Fruits of the plant Psorospermum aurantiacum, Family Hypericaceae 
are used in Cameroon and other parts of Africa for the treatment of cancer as well as 
gastrointestinal and urinary tract infections, skin infections, venereal diseases, 
gastrointestinal disorder, infertility, epilepsy and microbial infections43. The variety of 
indications seemed surprising to us at first, hence, target prediction was used to shed 
light on why this plant was used for such a wide range of seemingly unrelated 
indications. Results for the target predictions for the 5 NPs isolated and characterised 
from Psorospermum aurantiacum265 are shown in Table 2:6.  
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Compound 1 is predicted to bind to Protein kinase C gamma, and it has previously been 
shown to be linked to keratosis. Neutrophilic cutaneous infiltrates are produced as a 
result of activating Protein kinase C, and they act to prevent relapse of the tumour by 
mediating antibody-dependent cellular toxicity against the tumour cells266, 278. It thus 
appears that the activity of Compound 1 against Protein kinase C gamma may be 
responsible for its utilization for treating skin infections. At the same time, Compound 
1 is also predicted to bind to Leukotriene B4 receptor 1 and Induced myeloid leukaemia 
cell differentiation protein Mcl-1. Elevated levels of Leukotriene B4 receptor 1 have 
been found in a number of inflammatory diseases271, so inhibition may explain the anti-
inflammatory activity associated with this plant. Apart from annotated indications, an 
experimental leukotriene B4 inhibitor was found to inhibit proliferation and induce 
apoptosis in pancreatic cells270, and suppression of induced myeloid leukemia cell 
differentiation protein Mcl-1 is known to induce apoptosis268, so this compound may 
have the potential to also act as an anti-tumour agent. The targets predicted for 
Haronginanthrone can explain the seemingly unrelated annotated bioactivity of this 
plant in treating epilepsy and infertility. This compound was predicted to bind to the 
estrogen receptor and estrogen receptor beta, which play an important role in cancer 279, 
280 and catamenial epilepsy276. More proof that estrogen receptors play a role in epilepsy 
is shown by the fact that reproductive dysfunction is associated with epilepsy281 as well 
as anti-epileptic therapy282. A literature review revealed that estrogen receptor knockout 
mice have been shown to exhibit infertility as well as reduced fertility274. The fact that 
Psorospermum aurantiacum is used to treat infertility indicates that the compounds 
may bind to estrogen receptor β and act as agonists.  
 
Looking at the bioactivity profiles of the compounds in Psorospermum aurantiacum 
and similar compounds in the ChEMBL database we find that these compounds are 
predicted to have activity in a variety of cell lines and targets e.g. Ferruginin C and 
Vismin (>80% similar to compounds in P. aurantiacum) have reported activities 
against cancer lines including MCF-7283.  
 
As we can see, target prediction has allowed us to develop a plausible mode of action 
hypothesis for this plant, despite the rather dissimilar indications for which it is being 
used. Furthermore, combining information from different sources, e.g. ethno-botanical 
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use with target prediction gives further validation and greater confidence in the 
traditional use of these plants as medicines. 
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2.4 CONCLUSION  
In this study we have looked at the scaffolds and the diversity of the African compound 
libraries compared to other NP libraries and approved drugs. We showed that African 
compounds are structurally diverse and share only a proportion of structural space, 
namely 3.6% of scaffolds, with approved drugs. 97% of the scaffolds in ConMedNP 
were unique and not present in the Approved DrugBank compounds, and 43.8% 
scaffolds were unique to the AfroCancer dataset (when compared to the 36.3% 
scaffolds in the NCI Cancer dataset), representing unexplored chemical space with 
some evidence of therapeutically relevant biological activity. We also showed that these 
African compounds share 14 predicted targets with those of the NCI Cancer 
compounds, but that the remainder represents targets with potential novel therapeutic 
value.  
 
Results obtained using the target prediction algorithm gave an indication of the 
mechanism-of-action of the compounds from the AfroCancer dataset. Three targets 
(MCL-1, bcl2 and Flap endonuclease) have been identified as targets that can be 
modulated and the compound-target predictions experimentally validated in further 
studies. Pathway analysis of the AfroCancer dataset revealed 14 cancer related 
pathways similar to those modulated by the cancer drugs in the market, though they 
appear to act via different mechanisms of action as shown by the different targets and 
stages of the pathway modulated. Novel pathways, e.g. the Keap1-Nrf2 Pathway and 
Apoptosis Modulation by HSP70, provide starting points both from the chemical and 
the biological side for future anti-cancer treatments, derived from traditional African 
medicines.  
 
As a more detailed case study, the apparent variety of conditions against which 
Psorospermum aurantiacum is used was also explained using target prediction. This 
finding illustrates the benefit of target-prediction in shedding light into the mechanism 
of action of plants that have not previously been extensively studied. Furthermore, this 
approach can be used to guide the screening of African plants for which no molecular 
targets are currently known.  
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CHAPTER 3: INTEGRATING ETHNO-BOTANICAL 
AND PHYLOGENETIC INFORMATION OF 
MEDICINAL PLANTS WITH THEIR PREDICTED 
MECHANISMS OF ACTION TO IDENTIFY 
PHYLOGENTIC PATTERNS OF USE 
3.1 INTRODUCTION 
The combined knowledge of ethno-medicine and phylogenetic information of plants 
has been utilised to identify promising lineages of medicinal plants for lead 
identification, such as by Hawkins et al145 in the genus Pterocarpus (Leguminosease). 
This was demonstrated by studying plants from the genus Pterocarpus across 
Indomalaya, Tropical Africa and the Neotropics. Plants with medicinal activity were 
concentrated on specific clades, i.e. they were not randomly distributed. This study 
provided a link between biogeography and phylogeny of the plant.  Some studies 146, 
147 have also looked at the possibility of predicting medicinal potential of a plant using 
its phylogeny. The study by Saslis-Lagoudakis et al147 found that phylogenetic patterns 
were shared among the medicinal plant species of the flora of Nepal, New Zealand and 
Cape of South Africa. “Hot nodes”, which are nodes in the phylogenetic tree 
(corresponding to plant families or genera) that are significantly over-represented in 
species with a given property, e.g. anti-Malarial, compared with the rest of the tree, 
comprised on average 133% more medicinal plants than a random sample of the studied 
flora, thus demonstrating that plants descended from related lineages are used for the 
same conditions across continents. A recent study used evolutionary tools to predict 
plant lineages with psychoactive properties284 and narrowed down the prospect of 
psychoactive plants to 8.5% of all land plants. These approaches are based on the 
hypothesis that phylogenetic lineages with plants used in traditional medicine are more 
likely to contain plants with medicinally active products.  
 
The ecology tools used in the studies mentioned above can be applied to TAM, since a 
need exists for more research into TAMs used against endemic disease, e.g. malaria 
and HAT. The hypothesis is that there is a relationship between phylogenetically related 
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plants and their medicinal use in African medicinal flora. Any such relationship is likely 
to be related to the unique metabolites produced by the phylogenetically related plants. 
 
To test this hypothesis, we start by using the newly available NANPDB dataset 42 as a 
background dataset to explore whether plant species in the same family in North Africa 
produce chemically similar natural products (NPs). We then compare the similarity of 
NPs produced by the same family in African, Malay and Ayurveda plants used against 
cancer. Subsequently, we integrate phylogenetic information to determine whether the 
phylogenetic grouping of the plant is correlated with the chemistry and predicted targets 
of the NPs that these plants contain. Next, we identify plant families whose members 
are over-represented as remedies against cancer in African, Malay and Ayurveda 
traditional medicine, and then narrow down the search to the African medicinal flora, 
where we identify the over-represented families used for cancer, malaria and human 
African trypanosomiasis. This is followed by investigating the relationship between the 
unique metabolites produced by the plants, and whether or not this plays a role in their 
over-representation in the medicinal flora of Africa. If present, quantifying this type of 
relationship will have a two-fold benefit: (i) it will guide the phytochemist towards the 
type of plants to explore when looking for modulators of specific targets, and (ii) it will 
help to train prediction models on the type of target classes that compounds from this 
plant may modulate.  
 
3.2 MATERIALS AND METHODS 
3.2.1 DATASETS 
3.2.1.1 ETHNOMEDICINAL INFORMATION - CANCER 
The African compounds analysed in this study were obtained from AfroCancer 44 which 
contains 390 compounds in SD format. The annotations of each compound, containing 
compound name, plant origin and ethnobotanical use, are not freely available and were 
obtained by special permission from the CBIC (Chemical and Bioactivity Information 
Centre, University of Buea, Cameroon). 1,091 compounds from Malay traditional 
medicine, which have reported anti-cancer activity, were derived from the commercial 
database Natural Product Discovery System (NADI)179, hereafter referred to as ‘Malay 
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Cancer’ dataset). 1,043 compounds with reported anti-cancer properties from Ayurveda 
were obtained from Dr. Duke’s Phytochemical and Ethnobotanical Databases180 and 
will henceforth be referred to as the ‘Ayurveda Cancer’ dataset. Structures for the 
compounds from Malay and Ayurveda traditional medicine were downloaded from 
PubChem285, ChemSpider180 or HMDB286, by matching the SMILES strings.  The 
combined NPs from plants from AfroCancer, Malay Cancer and Ayurveda Cancer will 
be referred to as the “AMA” dataset. Plants that have NPs currently used against cancer 
in the market were also added to this dataset, namely Catharanthus roseus and Taxus 
brevifolia. 
 
3.2.1.2 ETHNOMEDICINAL INFORMATION – HAT 
Medicinal plants used traditionally in Africa against HAT were obtained from a recent 
review article23. Here, activity is defined as traditional use against HAT or in vitro and 
in vivo studies. This dataset will be referred to as AfricaTryp.  
 
3.2.1.3 ETHNOMEDICINAL INFORMATION – MALARIA 
Medicinal plants used traditionally in Africa against Malaria were obtained from the 
AfroMalaria dataset by special permission from the CBIC. This dataset contains 
compounds from 95 species and all taxonomic information (family, genus, species) was 
used. 
 
3.2.1.4 INTER-  AND INTRA- FAMILY CHEMICAL SIMILARITY OF NPS IN 
NANPDB AND THE AMA DATASET 
The Northern African Natural Products Database (NANPDB) is a global dataset of 
~4500 North African natural products curated from literature between 1962-2016. In 
an attempt to investigate the relationship between the chemical similarity of compounds 
within plant families and across plant families we used all the NPs in this dataset 
extracted from the Plantae kingdom. Secondary metabolites produced by plants serve 
different purposes in the plant, ranging from defence to pollination. It is therefore 
expected that plants will produce the same or similar compounds regardless of the 
family. At the same time, we know from the study of chemotaxonomy (the process of 
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classifying plants according to the secondary metabolites that they produce and the 
biosynthetic pathways used to produce them) that some plant families and closely 
related families produce unique metabolites. (It is this second fact that we hope to take 
advantage of when using plant phylogeny to predict activity.) To view this information 
we constructed an MDS plot in R182 of the fingerprints of the NANPDB compounds. 
Extended connectivity fingerprints (ECFP_6) 114 were generated using Canvas, version 
1.5, Schrödinger184-186. The structural similarity between the compounds in the AMA 
dataset was visualised in DataWarrior191, generated using 2D RBS (2-dimensional 
rubber band scaling applied as described in 191).  
 
3.2.2 PHYLOGENETIC ANALYSIS AND MANIPULATIONS 
We next analysed the position of phylogenetic clumping in different medicinal groups, 
followed by identifying important families in the African flora for use against cancer, 
malaria and HAT. To this end, metrics from community ecology phylogenetics 
(described below) were used to explore the lineages where the clustering of medicinal 
use is present in the datasets.  
 
To identify the position of phylogenetic clumping from different “medicinal groups” 
on the phylogeny, the “nodesigl” command in Phylocom v4.2287 was used. This 
command identifies nodes that are significantly over-represented in genera having a 
specific medicinal use (i.e. belonging to a “medicinal group”) compared with the rest 
of the tree. In “nodesigl”, the observed pattern for each sample is compared to the 
pattern of random samples using a null model that draws “s” taxa from the phylogeny 
terminals where “s” is the number of taxa in a sample.  The dataset was tested with the 
Zanne162 tree as the background phylogeny to generate the random samples. 
 
To measure the phylogenetic distance between plant families (internal nodes of a 
species tree) we used the dist.nodes function from the “ape” package288 in R182. This 
measures the distances between nodes by computing the pairwise distances between 
the pairs of internal and external nodes from a phylogenetic tree using its branch 
lengths, which in this case each unit correspond to millions of years ago (mya).  
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The phylogenetic similarity between taxa (in this work, plant families) is measured by 
the patristic distance289 calculated from the sum of branch lengths connecting the 
studied taxa. The branch lengths represent the amount of genetic change between the 
taxa studied (family, genus, species etc). Calculating the patristic distance is shown in 
Figure 3:1 below. The patristic distance between terminal taxa (A, B and C) is equal to 
the sum of the branches connecting those taxa. The larger the number, the larger is the 
distance between the taxa and hence the further away they are in evolutionary terms.  
 
Figure 3:1 Calculating the patristic distance. The figure shows an example 
of a simplified phylogenetic tree showing arbitrary branch lengths. The 
pairwise patristic distance calculated between the tree tips A, B and C is 
shown in the table. 
 
3.2.2.1 Binomial analyses 
We next analyse the distribution of medicinal plants in families across the African flora. 
Binomial analysis highlights families that depart from a uniform model of proportion 
of medicinal plants in a given flora- assess the patterns for medicinal plant usage across 
a flora. An exact randomisation Goodness of fit test approximated via Monte Carlo 
simulation was carried out on a contingency table for the African flora (medicinal and 
non-medicinal plants in a family for cancer, malaria and Trypanosoma) to test the 
deviation from the null hypothesis (a uniform proportion of medicinal species among 
families). A small p-value indicates the medicinal (anti-cancer, antimalarial and 
antitrypanosomal) species are not evenly distributed among families in the African 
flora. 
The null hypothesis in our case is; H0: Mi =  pflora x si  ; i.e.  plants belonging to family I 
are no more likely to be used medicinally than would be the case for the flora as a 
whole, i.e. the proportion of medicinal plants in family i(pi) equals the proportion of 
medicinal plants in the total flora (pflora = Σmi/Σsi).  
 A B C 
A 0 10 10 
B 10 0 4 
C 10 4 0 
A B C 
5 
3 
2 2 
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The binomial p-values for over -representation were calculated using the BINMODIST 
in Excel. BINOMDIST gives (a) probability that there are x or fewer successes, and (b) 
that there are exactly X number of successes. The probability of X or more successes 
is (1-(a)) + (b). In this case the number of successes is the number of medicinal species.  
 
The number of species per family for the African flora was curated manually from The 
African Plants Database (version 3.4.0)290.  
 
3.2.3 STRUCTURAL PRE-PROCESSING 
All compounds were obtained from their respective sources in SD format. ChemAxon 
Standardizer181 was used for structure canonicalization, transformation, and conversion 
of compounds in SD format into SMILES.  To standardise the compounds in 
ChemAxon Standardizer, the following options were used: Clean 2D, Mesomerize, 
Neutralize, Remove Explicit Hydrogen and Remove Fragment. Duplicate structures in 
each dataset were removed, using ChemAxon JChem Software181, “remove 
duplicates”. 
 
3.2.4 TARGET AND PATHWAY PREDICTION 
See Section 2.2.4.  
 
3.2.5 CLUSTERING 
The matrix of predicted targets was clustered using pvclust291 in R182. An approximately 
unbiased (AU) p-value of 0.95 was chosen. The AU p-value is calculated by multi-scale 
bootstrap re-sampling. For a cluster with AU p-value > 0.95, the hypothesis that "the 
cluster does not exist" is rejected with significance level 0.05; i.e. it can be assumed 
that these clusters do not only "seem to exist" caused by chance or sampling error, but 
can also be observed if we increase the number of observations.
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3.3 RESULTS AND DISCUSSION 
3.3.1 INTER- AND INTRA- FAMILY STRUCTURAL SIMILARITY OF NATURAL 
PRODUCTS 
We first analysed whether NPs produced in each plant family are more similar to each 
other than those not from the same family, the result of which are shown in Figure 3:2. 
Looking at Figure 3:2, we can see that in structural space NPs from the same family 
share the same structural space. This is important as it indicates that when plants from 
a family are used for a medicinal indication, then NPs from other genera and species in 
that family can be bio-screened, as they will likely occupy the same structural space. A 
few examples have been highlighted in the figure, e.g. NPs from Anacardiaceae (light 
blue) and Chenopodiaceae (black).  In the case of the NPs from Chenopodiaceae it is 
interesting to note that they are in the periphery of the graph, due to their unusual 
chemistry, and all other compounds from that family are clustered in the same area.  
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Figure 3:2 MDS plot of tanimoto similarity between NPs using their Morgan fingerprints. NPs are coloured 
based on plant family. Some NPS from the same families are similar to each other and are clustered together in 
space, whereas others are more diverse and spread out in space.  All metabolites in the dataset were used. 
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Quantifying the results will allow us to draw conclusions about the similarity of natural 
products within a plant family and will aid the hypothesis of the next section of 
identifying patterns in TAM. To this end, we carried out a quantitative chemical 
similarity analysis to better represent this information, the results of which are shown 
in Figure 3:3 and Figure 3:4. The median Tanimoto similarity between compounds in 
each family is much higher, ranging from 0.11 to 0.47 within the same family, but a 
maximum median of only 0.15 for the random samples. A Tanimoto coefficient of 0.3 
between compound pairs is generally accepted to indicate that compounds are 
structurally similar176. In ChEMBL, 95% of compounds had Tc > 0.424 to their active 
nearest neighbours143. These studies increase our confidence in the conclusion natural 
products are more similar within a family than would be expected by chance. 
 
 
 
 
 
 
 
 
99 
 
 
Figure 3:3 Average Tanimoto similarity of the compounds produced by the family to each other. The y-axis 
displays the average Tanimoto similarity of compounds within in each family to other compounds in that Family. 
From this figure we see that the median of average similarity ranges from 0.11 to 0.47. This represents NPs with 
high structural similarity within each plant. 
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Figure 3:4 Here random selections of 25 NPs were drawn without replacement from the NANPDB and 
repeated 63 times (number of families studied), to represent a set of randomised plant families. Each boxplot 
represents a different randomised family. The y-axis is the average Tanimoto similarity of each NP in this specific 
randomised family to all other NPs in the other randomised families. From this figure we see that the median of 
average similarity ranges from 0.11 to 0.15. This represents NPs with low structural similarity within a group of 
random NPs representing a family. 
 
We next investigated the bias of families with a higher number of NPs having lower 
Tanimoto coefficient scores and vice versa. We suspected that families with a high 
number of NPs compared to other families would intrinsically have lower Tanimoto 
similarity scores. This is because by chance the more NPs extracted and studied from a 
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plant family, the more structurally diverse they would be, since they would belong to 
different phytochemical classes. This turned out to not always be the case as can be 
seen from Figure 3:5. We found that in some cases families produced up to 75 NPs 
(The majority of the families contained around 25 compounds) and the similarity score 
was still above 0.3. When this was not the case, it was found that the families contained 
more than one phytochemical class with little structural similarity to each other e.g. 
Euphorbiaceae contains 295 natural products that included but were not limited to 
monoterpenes, triterpenoids, coumarins, lignans and flavones. Similarly, Umbelliferae-
Apiaceae, contains 389 NPs that fall into several phytochemical groups including long 
chain unsaturated hydrocarbons, monoterpenes, sesquiterpenes and furocoumarins. The 
large numbers of NPs having different chemical structures within these families 
contributes to the low structural similarity between the natural products.  
 
     
 
Figure 3:5 Number of NPs per family versus the mean Tanimoto similarity of NPs in each family. For most 
cases, the similarity was lowest when the number of NPs was above average (average number of compound per 
family is 74.25). However, in some cases, the Tanimoto similarity remained high despite there being 75 compounds 
in the family. 
In this section we have shown that NPs in a plant family are structurally more similar 
to each other than to NPs produced in other plant families. 
Number of NPs per Family 
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3.3.2 ROLE OF GEOGRAPHIC ORIGIN OF PLANT ON STRUCTURE AND PREDICTED 
ACTIVITY OF NPS 
 
Plant families with species that display anti-cancer activity are found in different parts 
of the world. To investigate whether use of a plant family in one region of the world 
could help inform use of plants from the same or closely related families in other areas 
of the world we examined whether the increased level of Tanimoto similarity between 
natural products (NPs) within a family, shown in the previous section, is also found for 
NPs produced by members of the same plant family that are found in different 
geographic areas. A global study of the African, Malay and Ayurvadic (AMA) dataset 
was carried out to identify relationships between the chemical structure of NPs, their 
predicted activity and the phylogeny of the plants they are produced by, taking into 
account information about their geographic origin.  
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Figure 3:6 Structural similarities of compounds from families from AfroCancer, Malay and Ayurveda 
libraries. Each data-point represents a compound.  The compounds are clustered by their structural similarity 
calculated using Tanimoto coefficients and coloured according to the family of the plant they come from. Similar 
compounds are clustered together, with connecting lines drawn between those having 95% or higher structural 
similarity. This figure shows that compounds within a family are structurally similar e.g. compounds from 
Simaroubaceae (cluster 1) are grouped together as are those from Lamiaceae (cluster 2). Clusters 3 and 4, contain 
similar compounds from Clusiaceae, while clusters 6 and 7 contain similar compounds from Apocynaceae and 
Leguminoseae respectively. On the other hand, cluster 5 contains compounds that are similar in structure to each 
other but come from more than 5 families. This information can on the one hand be used to suggest novel indications 
for particular plants, and on the other hand to improve the mode of action prediction of compounds from particular 
biological species. 
 
From the plot in Figure 3:6 we see that NPs tend to be grouped together and clustered 
by family regardless of the geographic region from which they originated, e.g. the 
Clusiaceae compounds in clusters 3 and 4 from both the AfroCancer and Malay datasets 
and the Leguminoseae compounds from AfroCancer, Malay and Ayurveda (cluster 7). 
We also see clusters of compounds that are similar in more than one family across all 
three regions, e.g. cluster 5 (structures shown in Table 2). Previously, it has been shown 
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that compounds with Tc ≥ 0.3 display similar bioactivities176. Thus, compounds in the 
AMA dataset that are clustered together in Figure 3:6 are expected to display similar 
bioactivity profiles across the three studied regions. This finding agrees with previous 
studies that show that use of a medicinal plant family in one region of the world can 
predict activity of that family in another region145. 
 
The following Table 3:1 shows a comparison between the similarity of compounds in 
clusters, and those in the periphery of the 2D RBS191 plot. The results from Figure 3:6 
and Table 3:1 are discussed below. 
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Table 3:1 Clusters identified by the 2D RBS plot and the structures of the compounds within those clusters. 
This is not a comprehensive cluster list, but an illustration of structural similarities within clusters with similar 
compounds identified by connecting lines when Tanimoto similarity of ECFP4 fingerprints is over 0.95. 
Cluster 1 
  
   
Cluster 2 
  
 
 
 
Cluster 3 
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Cluster 4 
 
 
 
 
 
Cluster 5 
 
 
   
Cluster 6 
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Cluster 7 
 
 
 
 
 
 
The alkaloids from Catharanthus roseaus (Family Apocynaceae) are grouped together 
with opaque connecting lines (Cluster 6 -Figure 3:6). These alkaloids exhibit anti-
cancer activity by preventing cell division, eventually leading to apoptosis. They do 
this by binding at the “vinca domain” of the β-subunit of the tubulin protein thus 
disrupting microtubule assembly and preventing cell division during the metaphase 
stage of the cell cycle292, 293. The Simaroubaceae quassinoids (Cluster 1) are also closely 
clustered. They display chemo-protective activities through their inhibition of the 
carcinogenic CYP1A1 enzyme294 and cytotoxicity of Simalikalactone D295. The anti-
tumour properties of the Simaroubaceae quassinoids in our dataset display mainly anti-
leukemic activity296. It is important to note that these compounds have not been taken 
into further stages of drug discovery due to their toxicity. This clustering is also true 
for many families whose plants are used traditionally for cancer but for which there is 
currently no clinical evidence of activity, e.g. Clusiaceaae NPs and their anti-
inflammatory activity297. This clustering of families containing NPs that display similar 
activities also has the potential to help direct selection of isolated compounds for 
screening via the following workflow: if a compound falls within a cluster whose 
activity is previously known (traditionally or through in vivo and in vitro experiments), 
then it would be prioritised for screening. Alternatively, if a compound is found to be 
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too toxic, other compounds from the cluster can be screened to identify non-toxic forms. 
This suggests that the distance between NPs with known bioactivity and new NPs in 
chemical space can inform subsequent screening and characterization.  
 
3.3.2.1 ROLE OF PHYLOGENY OF PLANT IN OBSERVED NP SIMILARITY IN PLANT 
FAMILIES 
In the second part of this analysis, we aimed to investigate the relationship between 
plant phylogeny, NP structure and the predicted protein target activity of NPs from the 
AMA dataset. We proceed by analysing the clustering patterns of plant families that 
have been clustered according to both the Tanimoto similarity of the ECFP4 
fingerprints of their NPs, and also the Tanimoto similarity of the corresponding sets of 
predicted targets (Figure 3:7 and Figure 3:8). The results in these figures allow us to 
analyse whether plants that cluster together in chemical space (with similarity defined 
according to their structural fingerprints) are either (i) also clustered together in the 
space of predicted targets as found in, e.g. the cluster containing Leguminoseae and 
Zingiberaceae as well as the cluster containing Ebenaceae, Rutaceae and Acanthaceae, 
or (ii) found in distinct clusters in predicted target space, e.g. Simaroubaceae, Paceae 
and Apocynaceae, which cluster together in structure space but not in predicted target 
space.  
 
 
 
 
109 
 
 
Figure 3:7 Plant families clustered according to the similarity of the ECFP4 fingerprints of the NPs that have 
been isolated from them. The vertical branch lengths are arbitrary and represent distances between tips. Here we 
set a significance threshold for cluster existence. The start on the top left clustergram is for a cluster with AU p-
value > 0.95, where the hypothesis that "the cluster does not exist" is rejected with significance level 0.05. 
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Figure 3:8 Plant families clustered according to the similarity of the predicted targets of compounds that have 
been isolated from them. The vertical branch lengths are arbitrary and represent distances between tips. i.e. the 
longer the branch, the more the distance is between the daughter clusters. Here we set a significance threshold for 
cluster existence. The stars on the top left clustergram is for a cluster with AU p-value > 0.95, where the hypothesis 
that "the cluster does not exist" is rejected with significance level 0.05. 
 
 
 
 
 
111 
 
From Figure 3:7 and Figure 3:8, we can see that Xanthorrhoaeceae does not cluster with 
any of the other families in either structure or predicted target space.  Amaryllidaceae 
is also in its own cluster for predicted target space, and clusters with the large 
Leguminoseae and Zingiberaceae families in structure space. Clusiaceae, 
Simaroubaceae and Meliaceae cluster together in both predicted target space and 
structure space, as do, for example, Acanthaceae, Rutaceae, Apiaceae, Moringaceae, 
Piperacee, Ebenaceae, Compoisitae and Cucurbitaceae. Some plant families that do not 
cluster together in predicted target space and structure space include Solanaceae, 
Annonaceae, Lamiaceae and Meliaceae. Figure 3:9 shows the plant families coloured 
in their respective clusters and projected onto the phylogenetic tree of plants, to show 
the relative position of plants on the tree in relation to the predicted targets and structure 
of the NPs they contain. We can see that some clusters are localised to specific parts in 
the tree (indicated in Figure 3:9) leading to the conclusion that for this dataset, with the 
currently available information, these plants contain chemistries not found in other 
unrelated plants, e.g. the cluster containing Asteraceae and Apiaceae.  
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We next analyse, and incorporate into this analysis, the phylogenetic distances (as 
measured by branch lengths between families in divergence times of million years ago 
(mya)) between plant families and how this relates to both the structures of the NPs 
produced by each family, and the corresponding sets of predicted targets. This is 
inspired by work carried out by Liu et al 298 which classified plants based on their 
metabolite content. Despite working with incomplete data, they found that clustering 
plants according to their metabolite content produced clusters consistent with known 
evolutionary relations of the plant. Here we analyse the plant families in detail. In 
(Table 1 – CD) we report the patristic distances between all pairs of the plant families 
in the AMA dataset, calculated using the Zanne162 tree of land plants, and we report the 
patristic distances between the plants discussed here in Table 3:2. The distances in 
(Table1 - CD) are further clustered in Figure 3:10, revealing the presence of several 
distinct phylogenetic clusters within this set of studied families.  
 
The first cluster contains Rutaceae, Simaroubaceae and Meliaceae; another cluster 
contains Rhizophoraceae, clusiaceae and Achariaceae; a further cluster contains 
Ochnaceae Dichapetalaceae and Phyllanthaceae, with two additional clusters 
containing Anacardiaceae, Sapindaceae and Burseraceae in the first and 
Convuluvlaceae, Plantaginaceae, Rubiaceae, Acanthaceae and Solanacea in the second. 
For all the families in these phylogenetic clusters, we find they also cluster in predicted 
target space and structure space. Therefore, we conclude that among the set of studied 
families, plant families that have both similar compound structures and similar 
predicted targets tend to be closer together on the phylogenetic tree (see Figure 3:9 and 
Figure 3:10). In contrast, those families that have similar compound structures but 
different sets of predicted targets tend to be further apart on the phylogenetic tree.  
 
A closer look at the phytochemical classes responsible for anti-cancer activity reveals 
a putative explanation for the differences and similarities in clustering. We find that 
Apocynaceae, Simaroubaceae and Meliaceae are clustered together according to 
structural similarity but not predicted activity. The high level of structural similarity 
can be explained by the phytochemistry of these plant families. Despite this, the 
families do not all cluster together in predicted target space: Simaroubaceae and 
Meliaceae do cluster together, with a divergence time of 42.82 (mya), as shown in 
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Figure 3:10; however, in the phylogenetic tree, Apocynaceae lies further away from 
Simaroubaceae and Meliaceae (see Figure 3:10). We find that Apocynacea and 
Meliaceae diverged 362.31 (mya), and Apocynaceae and Simaroubaceae 368.04 (mya). 
This observation likely reflects the fact that despite the structural similarity between the 
alkaloids of Apocynanceae and the terpenoids of Simaroubaceae and Meliaceae, they 
exert their activity via different mechanisms of action. The alkaloids inhibit cell 
division by interacting with tubulin and topoisomerase II19, 292, 299, whereas the 
terpenoids and limonoids have been found to inhibit NF-κB 20, 300. In accord with these 
reported findings, in our dataset 58 out of 89 compounds (30.7%) from Simaroubaceae 
and Meliaceae, but only 3 out of 81 (3.7%) of the compounds from Apocynaceae, were 
predicted to modulate NF-κB1. In contrast, 22% of Apocynaceae compounds but just 
4.7% Simaroubaceae and Meliaceae compounds were predicted to modulate tubulin α-
1B chain, and 19 out of 81 (23.5%) of Apocynaceae and 10 out of 189 Simaroubaceae 
and Meliaceae compounds (5.3%) were predicted to bind tubulin α-3C/D chain. 
 
This finding of NPs from Meliaceae and Simaroubaceae acting via different 
mechanisms of action to the NPs in the phylogenetically distant Apocynaceae, despite 
having similar structures, supports the hypothesis that plant families phylogenetically 
further away from each other on the tree are predicted to act by modulating different 
targets. 
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Figure 3:10 Heatmap of the families discussed above; clustered by the phylogenetic distances between them. This 
heatmap shows that the distance between families in the phylogenetic tree can be represented as clusters e.g. the Rutaceae 
and Simaroubaceae cluster. The dark blue represents plant families that are close together phylogenetically, while those in 
yellow and red are further away phylogenetically. The numbers on the coloured bar represent divergence in millions of years 
ago. 
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This analysis supports the hypothesis that the position of a plant on the phylogenetic 
tree, relative to other plants, can help predict the activity of its natural products. When 
plants are close phylogenetically, they produce similar compounds that are predicted to 
act via similar mechanisms of action, as shown by the clustering in Figure 3:7 and 
Figure 3:8. When they are further away phylogenetically, but produce structurally 
similar compounds, they are predicted to act via different mechanisms of action. 
Common processes that occur in different plant species that need to be carried out 
require secondary metabolites to be adapted to the local environment. Our findings 
suggest that these NPs tend to still be structurally similar, while having different 
mechanisms of action. This wide range of chemical space likely gives rise to the 
different predicted mechanisms of action displayed by the AMA plants.   
 
3.3.3 CROSS-CULTURAL PATTERNS IN MEDICINAL FLORAS WITH TRADITIONAL 
ANTI-CANCER ACTIVITY 
In this section we aim to detect plant families whose members are used significantly 
more often in medicinal flora than would be expected by random draw, i.e. families that 
are over-represented in traditional use. First, we wanted to show that NPs within a 
family in the AMA dataset are structurally similar to each other. This would mean that 
when a plant family is identified as over-utilised, then species in that family are 
prioritised for screening because they would produce structurally similar NPs with 
similar activities. In Figure 3:3 we showed that for the NANPDB dataset, species within 
a family tend to produce more similar NPs to each other than would be expected at 
random. The AMA dataset is analysed in detail in Figure 3:6, where NPs produced by 
species within the same family also tend to cluster in structure space. To analyse this in 
more detail, Figure 3:11 displays boxplots that illustrate the Tanimoto similarity of 
natural products within each family of the AMA dataset, and Figure 3:12 shows the 
median Tanimoto similarity of NPs within a family as a function of the number of NPs 
in a plant family.  
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Figure 3:11 Tanimoto similarity of NPs to each other in each family. Each boxplot represents a plant family. 
The y-axis is the average Tanimoto similarity of the compounds produced by the family to each other. From this 
figure we see that the median of average similarity of compounds in the AMA dataset ranges from 0.08 to 0.88. This 
plot shows that NPs within some families have very high Tanimoto similarities to each other, compared to those 
NPs and families analysed above in the NANPDB dataset, where NPs within a family showed a median similarity 
between 0.11 and 0.47, and the random draws only showed median similarity between 0.11 - 0.15.  
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Figure 3:12 Number of NPs per family versus the mean Tanimoto similarity of NPs in each family. For most 
cases, the similarity was lower (less than 0.3) when the number of NPs was above average (average number of 
compound per family is 51.29). However, in some cases, the Tanimoto similarity remained high (0.33) despite there 
being 97 compounds in the family. 
 
The results show that NPs within a plant family are structurally similar to each other 
(Tanimoto coefficient up to 0.88), e.g. Primulaceae contains 6 NPs with median 
Tanimoto similarity of 0.87 to each other and Convulvulacea contains only 3 NPs that 
have a median similarity of 0.87. We also see that the greater the number of NPs per 
family, the lower the similarity, e.g. the 326 NPs in Amaryllidaceae and 278 NPs in 
Xanthorrhoeaceae share a median Tc of only 0.09 and 0.15 respectively. This is not 
always the case, as can be seen for the family Clusiaceae. This family contains 97 NPs 
which have a median Tanimoto similarity of 0.33 to each other. Here we have shown 
that NPs in a family are somewhat structurally similar to each other. 
 
Hot Nodes  
Previous studies147, 284, 301, have looked at the over-representation of medicinal plants 
in different flora across different continents by identifying ‘hot nodes” in plant lineages, 
in order to guide medicinal chemists’ choice of lineages to pursue for drug discovery. 
This previous work has focused on ethno-botanical studies rather than chemistry.  
Moreover, this type of study has not been carried out for African medicinal flora or for 
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medicinal flora from different parts of the world used against cancer. To address these 
questions, we compiled and curated a completely novel dataset of 51 plant families 
(129 species, see Methods), that have been reported to have activity and are used against 
cancer in Africa, Malaysia and India (the AMA dataset). We then analysed this dataset 
to identify phylogenetic lineages in which anti-cancer properties are over-represented. 
Figure 3:13 shows the phylogenetic tree of land plants, with the clades descending from 
the hot nodes coloured in red. In this case we hypothesise that if a node is identified, its 
descendants (terminal taxa) are more likely to belong to the “medicinal use” group (in 
this case against cancer) than would be expected by random chance.  
 
 
Figure 3:13 Distribution of AMA plants and hot nodes on the angiosperm phylogeny. There are 51 plants used 
against cancer in Africa, Malaysia and India (red dots). The hot nodes (red clades) represent lineages that are over-
represented in cancer use. The blue dots represent plant orders that were identified as hot nodes. Blue dots: clades 
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have not been colored in so as not to obscure the families that are over-represented within each clade. This is because 
not all families in the over-represented clade are over-represented for use against cancer in the AMA dataset. 
 
Table 3:3 Hot nodes identified from the AMA dataset. These families are significantly over-represented in genera 
having anti-cancer activity compare with the rest of the tree. The table shows each “hot-node” and the number of 
genera and species within that node. The total species represent 8.5% of land plants that are expected to be of greater 
medicinal value for use against cancer than would be expected by random chance. 
Hot nodes  Genera in node Species in node 
Zingiberaceae 52 1,587 
Clusiaceae 24 1,047 
Ancistrocladaceae 1 21 
Nyssaceae 5 37 
Taxaceae 6 31 
 
Using the 129 cancer-remedying plant species from the AMA dataset, our hot node 
analysis identified 2,574 novel species, which represents ~8.58% of all land plants (see 
Table 3:3). Table 3:3 also contains Nyssaceae and Taxaceae, which do not have any 
plants in the AMA dataset, but were included in the analysis to demonstrate the efficacy 
of the tool and for retrospective validation of the method. We note that Taxol (a 
chemotherapeutic agent) is isolated from various Taxus species that belong to 
Taxaceae, while the quinoline alkaloid Camptothecin (chemotherapeutic agent) is 
produced by both Camptotheca acuminata and Camptothecin lowreyana302 that belong 
to Nyssaceae. The identification of just 2,574 novel species suggests a greatly reduced 
set of plants that could be prioritized for screening for potential anti-cancer activity.  
 
We next look more closely at the taxa identified by the analysis presented above to see 
if there is any primary literature support for anti-cancer activity, since these taxa were 
not represented in the AMA dataset of known anti-cancer plant species compiled from 
existing database resources. This would provide additional confidence in the ability of 
our analysis to identify of taxa with suspected medicinal activity. Table 3:4 shows the 
families identified as “hot-nodes” and other plants in those families that were not 
contained in the AMA dataset, but for which anti-cancer activities have been reported 
in the literature. For example, despite the fact that alkaloids produced by 
Acistrocladaceae member Ancistrocladus korupensis have shown anti-HIV activity303 
as well as anti-malarial activity304, the 30 family members that are not contained in the 
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AMA dataset have not been screened for anti-cancer activity, suggesting that 
Acistrocladaceae alkaloids should be prioritised for anti-cancer screening campaigns. 
 
Table 3:4 Plants with reported anti-cancer activities that were identified by the “hot-nodes”, but were not in 
the input data. 
Family Plants not in dataset with 
reported anti-cancer 
activity 
Zingiberaceae Alpinia galanga305 
Alpinia officinarum306 
Curcuma caesia307 
Curcuma kwangsiensis308 
Curcuma purpurascens309 
Clusiaceae Mesua beccariana310, 311 
Allanblackia gabonensis312 
Garcinia nervosa313 
Garcinia achachairu314 
Acistrocladaceae Ancistrocladus korupensis 
(anti-HIV and anti-malarial 
properties)303, 304 
 
3.3.4 PATTERNS OF AFRICAN MEDICINAL PLANT USE – CANCER, MALARIA AND 
HAT  
The AfroCancer (subset of the AMA dataset - 17 families), AfroMalaria and 
AfricaTryp (see Methods), contain plants with reported activity against endemic 
diseases in Africa, for which the population is highly dependent on traditional medicine. 
We utilised two statistical approaches to better understand the distribution of medicinal 
flora across families and to identify which families are important for cancer, malaria 
and human African Trypanosomiases (HAT) use in Africa. We first establish whether 
specific families are significantly enriched for plant species that are used against cancer, 
malaria and HAT. The goodness of fit test on the collected families showed a significant 
departure of the anti-cancer, anti-malarial and anti-trypanosomal species from 
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homogeneity (for p-values see Table 3:5). The high level of statistical significance 
means that we can now assess the distribution of the medicinal plants within families.  
 
Table 3:5 χ 2 Test for the 3 datasets. We calculated whether the AfroCancer, AfroMalaria and AfricaTryp species 
can be distinguished from the flora as a whole. The chi-square goodness of fit test on the collected families showed 
a significant departure of species from homogeneity (shown by the p-values), i.e. statistically more medicinal 
(cancer, malaria, HAT) species than in the flora as a whole. 
 χ2 p-value 
AfroCancer 69.28 2.07e-12 
AfroMalaria 1039.71 2.20e-16 
AfricaTryp 1378.9 2.20e-16 
 
For the second part of this study, we assessed the distribution of medicinal plants within 
families and how they deviate from a homologous null model of distribution using 
Binomial analysis. This method evaluates the statistical significance of numerical 
deviation from the expected norm. For each of the datasets, the families that statistically 
deviate from the null hypothesis are shown in Figure 3:14, Figure 3:15 and Figure 3:16. 
Significance values (p-values) are only shown for those families that contain more 
medicinal plants than would be expected under the null hypothesis. This is because in 
this study we are looking at plant families that are used medicinally more than would 
be expected by random chance. 
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Figure 3:14 Results of the binomial test on the families in the AfroCancer dataset. p-values less than 0.05 for 
families that are used more than would be expected by random chance are shown. Here, Acistrocladaceae, Clusiaceae 
and Phyllanthaceae depart from a uniform model (over-represented) of proportion of medicinal plants in the African 
flora. 
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Figure 3:15 Results of the binomial test on the families in the AfroMalaria dataset. In this figure p-values less 
than 0.05 for families that are used more than would be expected by random chance are shown. Here, 
Acistrocladaceae, Dioncophyllaceae, Hypericaceae and Zingiberaceae depart from a uniform model (over-
represented) of proportion of medicinal plants in the African flora. 
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Figure 3:16 Results of the binomial test on the families in the AfricaTryp dataset. p-values less than 0.05 for 
families that are used more than would be expected by random chance are shown. Here, Bombaceae, Burseraceae, 
Canellaceae, Clusiaceae, Cochlospermaceae, Combretaceae, Compositae, Cruciferae, LEguminoseae, Meliaceae, 
Moringaceae, Myrtaceae, Rutaceae and Ulmaceae depart from a uniform model (over-represented) of proportion of 
medicinal plants in the African flora. 
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For the medicinal plant families in the AfroCancer dataset, Acitrocladaceae, Clusiaceae 
and Phyllanthaceae were identified by the Binomial method to be over-represented 
medicinally as they differ significantly (p<0.05) from null expectations (Figure 3:14). 
Acistrocladaceae, Dioncophyllaceae, Hypericaceae and Zingiberaceae were identified 
by the Binomial method to be over-represented medicinally for the plant families in the 
AfroMalaria dataset (Figure 3:15). For the AfricaTryp dataset, 14 families were over-
represented medicinally (Figure 3:16). In addition to families that are well known for 
their cancer, malaria and HAT use, e.g. the annonaceous acetognenins from 
Annonaceae are known to display anti-plasmodial activity315 316, and Meliaceae for 
HAT317, 318, we identified others that are less well known, e.g. Acistrocladaceae for 
cancer. Of the identified families, we also found that other species in these plant 
families produce the same active metabolites that are responsible for activity and these 
are discussed in further detail in section 1.3.4.1. This provides a form of validation for 
our approach of narrowing down the search for potential medicinal activity of the 
African flora to the over-represented families and the ones that seem to be overlooked, 
i.e. they contain chemistry with the desired activity, but they are not annotated with a 
potentially suitable use, e.g. Dioncophyllaceae. 
 
Our results are similar to previous studies carried out to investigate phylogeny patterns 
in medicinal plants. Phylogenetic clustering was found when inspecting medicinal 
properties of Plectranthus319 where similar uses were found among the related species. 
This was also the case for Pterocarpus145, Aloes320 and Euphorbia321 genera, where a 
phylogenetic signal was found for medicinal use. Similarly, studies were carried out 
concentrating on plant use for a specific activity, e.g. studies on psychoactive plants284 
and those used against snakebite322. Here the researchers found plant lineages 
displaying over-abundance of plants having psychoactive activity and anti-snakebite 
activity respectively. However, apart from the study on psychoactive plants, no direct 
link was drawn between the chemistry of the secondary metabolites of the plants and 
the observed phylogenetic signal. In the study by Halse-Gramkow et al284 a link 
between the tropane alkaloids produced by the Solanaceae plants and the identified 
psychoactive “hot-node” is made but this is not explored in detail. Following on from 
these studies our results show that for the African medicinal flora, the distribution of 
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medicinal plants departs significantly from a homogenous null model (binomial 
analysis results).  
 
It is important to note here that our analysis relies on data collected from the published 
literature, which suffers from reporting bias. This means that the data is not complete, 
i.e. not all plants in Africa with anti-malarial, anti-trypanosome or anti-cancer activity 
are included in our datasets. 
 
3.3.4.1 RELATIONSHIP BETWEEN UNIQUE METABOLITES AND BIOSYNTHETIC 
PATHWAYS IN OVER-REPRESENTED PLANT FAMILIES AND ACTIVITY 
From the binomial analysis in the previous section, we recovered plant families that are 
over-represented, i.e. used more than would be expected by chance. Acistrocladaceae, 
Rutaceae and Clusiaceae appeared in the results for all three datasets; therefore, a 
literature review was carried out to assess the relationship between the secondary 
metabolites produced by these plant families and their medicinal use. 
 
Ancistrocladaceae and Dioncophyllaceae 
Plants (from our database) in the two small, closely related, tropical Ancistrocladaceae 
and Dioncophyllaceae produce a unique class of compounds called the 
naphthylisoquinolines (NIQs). They are characterised by a biogenetically unique 
scaffold of acetate origin, which has a methyl substituent at C3 and a meta-oxygentation 
pattern at C6 and C8315. The active NPs of these two families, e.g. dioncophyllin A is 
produced by a different biosynthetic pathway to all other isoquinolones in nature and, 
in the plant, the pathway is initiated in response to stress e.g. chemical stress, biotic 
stress or physical stress323. Activity of these NIQs have been reviewed previously, e.g. 
in vivo anti-tumour activity of dioncophylline A22, anti-plasmodial activity of 
dioncophylline C and dioncopeltine A324 and in vitro activity against Trypanosoma 
brucei rhodesiense and Trypanosoma brucei brucei325. The unique chemistry is 
responsible for activity in plants over-represented in medicinal flora. Other species in 
the family producing this unique chemistry are expected to have similar activity. 
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Clusiaceae 
Plants in the Clusiaceae family, as well as the closely related Gentianceae and 
Bannetiaceae (native to neotropics i.e. not present in Africa), uniquely produce 
distinctive xanthones. African plants from Clusiaceae producing xanthones have shown 
in silico binding against tryapanosomal targets, including: xanthchymol326. The in vivo 
anti-tumour activity of xanthones from African NPs have been reviewed21, as has their 
anti-plasmodial activity327. Furthermore, xanthones produced by plants in different 
continents have also been shown to display anti-plasmodial activity, e.g. Swertia alata 
(Gentianceae) in Pakistan328. These findings further increase our confidence in our 
finding that these plant families are used more than average due to their unique 
chemistry. 
 
Rutaceae 
The Rutaceae family is unique in producing C3 substituted coumarins with a 1,1-
dimethylallyl functional group as well as the acridones. The activity of acridones 
isolated from African plants has been reviewed previously, e.g. their potential as cancer 
therapeutics22, and anti-protazoal activity315. Acridone alkaloids isolated from plants 
not indigenous to Africa, e.g. Swinglea glutinosa from the Phillipines329, displayed IC50 
activity of 0.3 to 11.6 μM against Plasmodum falciparum, and five of the acridone 
compounds had IC50 < 10 μM against Trypanosoma brucei rhodesiense. This shows 
that the plant families that we have identified to be used more than average do display 
anti-protozoal activity in other geographic regions of the world. This is useful because, 
knowing that plants from the same families are likely to have NPs with similar structure 
and activity, we can exploit information of known activities from plant families around 
the world and apply this to the African medicinal flora. 
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Table 3:6 Some known NPs from plants in the dataset from the Ancistrocaldaceae, Dioncophyllaceae, 
Clusiaceae and Rutaceae and their predicted or experimental activities. 
Family NP Activity 
Acistrocladaceae 
(NIQs) 
 
 
 
 
 
 
Moderate anti-
protozaol activity 330 
Clusiaceae 
(Xanthones) 
 
 
 
 
Apoptotic and 
antiproliferative 
activities 
331 
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Rutaceae 
(Acridones) 
 
Anti-plasmodial 
activity 332 
 
From the examples in Table 3:6 we can see that NPs that are uniquely produced by the 
over-represented families are responsible for activity and may be responsible for the 
family being over-represented and over-utilised. As such, we can validate our 
recommendation of further investigating plant species in over-represented families in 
the hope of finding novel bioactive NPs. In our study we have shown a phylogenetic 
correlation between African medicinal plants, their secondary metabolites and their 
predicted activities/known activities. To our knowledge this correlation has not been 
made before and none of the previous predictive phylogenetic studies have been carried 
out on African medicinal flora. 
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3.4 LIMITATIONS OF THE STUDY 
Despite the apparent connection that we have found in this study between the 
phylogeny of a plant and its predicted activity, several limitations exist. Firstly, as in 
many studies involving natural product datasets, we are limited by the information 
available in the datasets. In this type of database (e.g. NANPDB) not all secondary 
metabolites in a plant are recorded, as, through bioactivity-guided fractionation, only 
bioactive phyto-constituents are characterised and analysed. Thus, it is not possible to 
predict protein targets for compounds in a plant (which may be active) beyond what is 
available in the dataset. Also, when trying to extrapolate the mode of action of a NP 
from the predicted target, we must keep in mind that ethno-botanic use includes 
ameliorative effects of symptoms associated with a disease and not necessarily 
treatment or cure of a disease. It is also important to note how data for each medicinal 
plant is presented. For each plant (in one of the African medicinal plant datasets) 
annotated with an activity e.g. cancer, all compounds isolated from the active extract 
are included. The active constituent cannot be determined by querying the dataset. 
Furthermore, diverse assays are presented within a database, e.g. for the AfroCancer 
dataset, more than 40 assays are recorded that determine anticancer activity with 
recorded activities being anti-proliferative, cytotoxic etc. on different cell lines 
including ovarian cancer cell line, human colon cancer cell line, fibrosarcoma and 
melanoma. Several activity values e.g. IC50 and ED50 are used. It is thus important to 
determine the mechanism of action of these NPs. 
 
Secondly, for the regression and binomial analysis to identify “hot nodes” it is 
important to remember that not all plants with medicinal activity are recorded and used 
traditionally. This may be due to several reasons, e.g. the plant not being accessible 
geographically. Therefore, lack of ethno-botanic use of a plant does not indicate that 
the NPs in the said plant are inactive for a disease.  
 
Thirdly, we are using the current Angiosperm Phylogney Group (APG) III 
classification system of plants. This classification is constantly being reviewed and 
updated and plants from one family are moved to another family upon discovery of new 
molecular data. As such, the relationships that we draw between phylogeny and 
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predicted activity are not exact; rather, they are based on the currently accessible 
material and the accuracy of the present classification system.
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3.5 CONCLUSION 
In this chapter we have shown that for the NANPDB dataset, compounds share higher 
Tanimoto similarity to compounds in the same family than they do to compounds in 
other families.  We have also shown that plant families produce these similar 
compounds regardless of the geographic origin of the plant, where we see that, e.g. 
Leguminoseae in Africa, Malay and Indian traditional medicine produced structurally 
similar compounds having Tanimoto coefficient 0.95 or more. We have shown that 
compounds that are closely related to each other phylogenetically produce compounds 
that are similar to each other and these compounds bind similar targets. Plants further 
away in the phylogeny tree produce diverse compounds that act on different targets. 
We were able to rationalise when this was not the case. Furthermore, we have 
statistically identified plants that are over-represented and under-represented in African 
traditional medicine for use against cancer, malaria and human African 
trypanosomiases. These families are known to produce unique metabolites via unique 
biosynthetic pathways, e.g. the napthoisoquinolones in Ancistrocladaceae and 
Dioncophyllaceae, and we have made the connection between these unique 
metabolites, bioactivity and over-utilisation. Based on our initial finding that plant 
families produce similar compounds and have similar predicted activities, we 
recommend that these plant families be prioritised for screening for bioactive 
metabolites. 
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CHAPTER 4: INTEGRATING STRUCTURAL AND 
CHEMOGENOMIC SPACE TO PREDICT THE 
MECHANISM OF ACTION OF PHENOTYPICALLY 
ACTIVE SMALL MOLECULES AND NATURAL 
PRODUCTS IN TRYPANOSOMA BRUCEI 
 
4.1 INTRODUCTION 
Human African trypanosomiasis (HAT) is a parasitic disease caused by the protozoan 
parasite Trypanosoma brucei. This disease is fatal if left untreated333. A need exists, in 
particular in Africa, to identify effective drugs for this disease. The current approaches 
to trypanosome drug discovery include: 
(i) Development of new molecules inspired by known anti-trypanosomal 
agents, e.g. the bisamidines that were developed based on the structure of 
Pentamidine. These compounds failed in clinical trials due to 
nephrotoxicity334. 
(ii)  Target based screening, used to identify, e.g. DDD85646, which showed 
activity against N-myristoyltransferase (NMT)335. This compound could not 
penetrate into the CNS therefore was not deemed useful for Stage 2 of the 
disease.  
(iii) Phenotypic screening, used to identify candidates such as Fexinidazole28, 
which entered Phase 2 and Phase 3 trials in 2012 and Oxaborole336, which 
entered clinical trials in March 2012.  
 
Previous work has been carried out to identify targets of compounds that have shown 
activity against several infectious diseases by integrating publicly available structural, 
chemical and bioassay data. Martínez-Jiménez et al337 identified 139 target proteins 
modulated by compounds from an HTS against Mycobacterium tuberculosis by 
integrating bioinformatics and cheminformatics. A study by Spitzmüller and Mestres338 
on results from an HTS on Plasmodium falciparum identified 39 putative targets by 
using computational target prediction to predict protein targets followed by statistical 
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analysis to detect enrichment of the compounds in Plasmodium falciparum targets. 
Ekins et al339 used a Bayesian machine learning algorithm to identify 11 compounds 
which had an EC50 below 10µM on Trypanosoma cruzi, and their potential targets.  
 
Recently, HTS results have been deposited in ChEMBL-NTD to mediate drug 
discovery for HAT. In 2011, the Drugs for Neglected Diseases Initiative (DNDi) 
released the results of a screening and optimization of specific chemical series against 
human African Trypanosomiasis containing 4,927 compounds, 1,415 of which have an 
IC50 below 10µM (IC50 values for the currently marketed HAT drugs Pentamidine, 
Nifurtimox, Eflornithine and Melarsoprol are 0.01 µM26, 5 µM26, 81-693 µM340 and 
2.1ng/ml26 respectively). In 2015 DNDi released the results of an antiprotozoal activity 
profiling of approved drugs. Similarly, the Swiss Tropical and Public Health Institute 
(SwissTPH) released a screening hits dataset containing 28 compounds in 2016. In 
March 2015 GSK deposited the GSK TCAKS Dataset (hits from Leishmania donovani, 
Trypanosoma cruzi and Trypanosoma brucei brucei phenotypic screening). Combining 
the wealth of information in these datasets with literature searches of the results of 
natural product screens against Trypanosoma brucei and target-based assays provides 
a promising starting point for in silico target identification.  
 
In this study we introduce an approach in which bioinformatics and orthology 
information are integrated to predict and prioritise putative targets in Trypanosoma 
brucei. The goal is to elucidate the mechanism of action of these phenotypically active 
compounds. We start by characterising the structural and chemical features of the 
compounds from both the high throughput screens and literature search. A preliminary 
search for activity of the screened compounds on other organisms is carried out, and in 
the case of experimental activity or predicated activity, Trypanosoma brucei 
orthologues (if they exist) are identified. We then predict the protein targets of 
compounds using a ligand-based machine-learning algorithm that uses a Random 
Forest. The predicted protein targets from non-Trypanosomal organisms are then 
projected by orthology onto the Trypanosoma brucei genome to identify putative 
targets within this species. In addition, experimentally validated targets of the 
compounds from the screening datasets and literature review are obtained from 
ChEMBL and their trypanosomal orthologues identified. The biological processes 
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modulated by these predicted targets will also be studied and the difference between 
the NPs and SHs will be compared.  
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4.2 MATERIALS AND METHODS 
4.2.1 DATASETS 
To identify the target space of trypanocidal agents, several datasets comprised of 
phenotypic screen hits were used. These datasets were made up of 3 different datasets 
of compounds screened against Trypanosoma, which were downloaded from 
ChEMBL-NTD (www.ebi.ac.uk/chemblntd). These datasets contain results of 
phenotypic screens carried out on the bloodstream form of Trypanosoma brucei. All 
active and inactive data were pooled together as they were tested on members of the 
same species of Trypanosoma.  The resazurin fuorescent T. brucei whole-cell viability 
assay341 was used to screen compounds in two of the datasets, namely, 
“DNDi_T.b.brucei Dataset” and “GSK TCAKS Dataset”. The cut-off for this assay was 
>80% growth inhibition of the T. brucei parasite. The STIB900 acute mouse model342 
was used to screen the compounds in the “DNDi Dataset: Antiprotozoal activity 
profiling of approved drugs”. Mice in this assay are considered cured when there is no 
parasitaemia relapse detected in tail-blood over a 60-day observation period. For the 
purpose of this study, compounds (from these three datasets) with IC50 <10μm were 
considered active. The datasets are shown in Table 4:1 below and will collectively be 
referred to as the Screen Hits Dataset (SH). 
 
Table 4:1 Datasets downloaded from ChEMBL-NTD for the Screen Hits Dataset (SH) 
Name of Dataset Active 
Compounds 
Inactive 
Compounds 
Reference 
DNDi_T.b.brucei 
Dataset 
638 511 343 
DNDi Dataset: 
Antiprotozoal activity 
profiling of approved 
drugs 
39 66 342 
GSK TCAKS Dataset 249 343 344 
 
A second dataset comprised of NPs screened or traditionally used against HAT was 
also studied. A literature review of articles with the keywords “Africa”, “natural 
product”, “medicinal plant”, “HAT”, “trypanosoma” and “parasite” revealed 862 
compounds 23, 41, 315, 345, 346. Plants used with activity against Trypanosoma brucei from 
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the NPASS347 dataset were also downloaded and added to this dataset. This dataset will 
be referred to as the NP dataset. 
 
A schematic showing the steps taken to identify the predicted target space of 
Trypanosoma brucei interacting with the phenotypically active compounds from the 
NP and SH dataset is shown in Figure 4:1. 
 
 
 
Figure 4:1 Schematic of the steps used to identify the targets of Trypanosoma brucei. For each of the two datasets 
(SH and NP) experimental activity of the active compounds was extracted directly from ChEMBL. In addition, 
targets were also predicted using PIDGIN v2. Trypanosomal targets as well as targets from different organisms were 
identified. Orthologues of the non-trypanosomal targets were obtained from PantherDB. Targets essential for the 
survival of the trypanosome were obtained from TriTrypDB. We obtained the phenotypically relevant target space 
of Trypanosoma brucei by overlapping the predicted and experimental targets with the essential targets.  
 
  
Small Molecules 
(SH) 
     Natural Products 
                         (NP) 
Experimental activity on all organisms Target Prediction 
Trypanosmal targets 
(predicted) 
Trypanosomal  
targets (predicted) 
Other organisms Other organisms 
(predicted) 
Orthologue search 
Trypanosmal targets 
Trypanosmal targets 
Orthologue search 
Apply DDU “essentiality” criteria for ideal trypanosomal targets 
Druggable target space of Trypanosoma brucei 
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4.2.2 STRUCTURAL PRE-PROCESSING 
Compounds in the SH dataset were downloaded in SD Format and converted into 
canonical SMILES using OpenBabel348. Compounds in the NP dataset were converted 
from PDF to canonical smiles using Document2Structure JChem 17.21.0, ChemAxon 
(http://www.chemaxon.com). ChemAxon Standardizer181 was used for structure 
canonicalization, transformation, and conversion of compounds from SD format to 
SMILES. To standardise the compounds in ChemAxon Standardizer, the following 
options were used: Clean 2D, Mesomerize, Neutralize, Remove Explicit Hydrogen and 
Remove Fragment. Duplicate structures in each dataset were removed, using 
ChemAxon JChem Software181, “remove duplicates”.   
 
4.2.3 CHEMICAL SPACE ANALYSIS 
4.2.3.1 FINGERPRINT CALCULATION AND MDS VISUALISATION 
To visualise the chemical space of the two datasets, we calculated the Morgan 
fingerprints349 (radius 2) on KNIME version 3.3.1350 and projected this information on 
an MDS plot in R182. To quantify this information further, the average Tanimoto 
similarity of each compound to all was calculated in KNIME and a density plot was 
constructed to visualise the results using R182.  
 
4.2.3.2 SCAFFOLD GENERATION 
The Murcko scaffolds of the compounds in both datasets were generated using 
Datawarrior191. The options “Analyse Scaffolds” followed by “Murcko Scaffold” were 
used. This was carried out to compare the scaffolds in both datasets to scaffolds of 
compounds with known anti-trypanosomal activity. This gave a table of the generated 
scaffolds and the number of compounds populating those scaffolds. The top 10 
scaffolds were retained and are shown in the results. 
 
4.2.3.3 FRAGMENT ENRICHMENT ANALYSIS 
To obtain the fragments that are more common in one active dataset over the other, the 
compounds were decomposed into fragments using the MoSS351 node in KNIME350. 
The options “ignore pure carbon fragments” and “use ring mining” were used. To 
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extract the most common fragments in the SH dataset compared to the NP dataset, a 
fragment had to occur in a minimum of 10% of the fragments of the SH dataset and a 
maximum of 5% in the NP dataset. To extract the most common fragments in the NP 
dataset compared to the SH dataset, a fragment had to occur in a minimum of 10% of 
the fragments of the NP dataset and a maximum of 5% in the SH dataset. 
4.2.3.4 PLOGBB CALCULATION 
The log BB, which is a prediction of blood brain barrier permeation, was calculated for 
the active compounds in the SH dataset to predict which of these compounds will cross 
the blood brain barrier, as this is an important feature for drugs required for the phase 
two part of HAT. Compounds with log BB >0.3 cross the blood brain barrier readily, 
whereas those with log BB <-1 do not cross so readily352, 353. The predicted log BB, 
which defined as the logarithm of the ratio of the concentration of a drug in the brain 
and in the blood, measured at equilibrium, was predicted using the QikProp plogBB 
function on Canvas Schrodinger software354.  
 
4.2.4 CHEMOGENOMIC SPACE ANALYSIS 
4.2.4.1 TARGET PREDICTION AND ORTHOLOGUE SEARCH 
PIDGIN v2 355 was used to predict enriched targets and pathways for both the NP and 
the SH datasets. Target enrichment is calculated in PIDGIN v2 using the prediction 
ratio, defined in Equation 5: 
Prediction ratio =  
Ft Nt⁄
Fb Nb⁄
 
Equation 5 – Prediction Ratio 
Where: 
Ft = Frequency of prediction in the test set i.e. the number of active predictions 
[p(activity) above threshold] across the entire set of input molecules. 
Nt = Number of predictions in test set  
Fb = Frequency of prediction in a background distribution set 
Nb = Number of predictions in a background distribution set 
 
 
 
 
 
142 
 
The lower the prediction ratio, the more enriched the target is in the phenotypic library. 
Since the models vary in size, chemical space and ratio of active:inactive molecules, an 
Odds ratio and Fisher’s exact test is carried out by PIDGIN v2 to correct for over and 
under prediction of promiscuous and/or selective models. The targets and pathways 
with an Odds ratio below 0.1 were kept for all organisms. Orthologues of the predicted 
targets to Trypanosoma targets were identified using PantherDB137.  The “least 
diverged orthologues” (LDO), i.e. genes in two different organisms that have diverged 
the least since their most common recent ancestor (expected to retain similar functional 
activity across organisms), were kept.  
 
4.2.4.2 KNOWN BIOACTIVITY  
For both datasets, the experimentally validated targets against all organisms were 
obtained from ChEMBL356 and the actives were determined using the following 
criteria: IC50 < 10µm, target_type = single protein, confidence score > 8 
activity_comment = active or inhibitor. Trypanosoma brucei orthologues of these 
targets were also obtained from the PantherDB137 and the LDO, i.e. most nearly 
equivalent were kept.   
 
4.2.4.3 TARGET ESSENTIALITY 
In order to identify essential Trypanosoma brucei targets the TDR Targets database 
version 5357 was used and the following criteria were applied: for all queries, target 
organism = Trypanosoma brucei, target is an enzyme, target is a receptor, target is a 
transporter and evidence that target is essential in any species, resulting in 1,809 genes.  
4.2.4.4 NETWORK CONSTRUCTION  
This was carried out to visualise the multi-target prediction of compounds in the small 
molecules hits dataset. Cytoscape358 was used to construct the target-compound 
network of the active screening hits. The target-compound pairs were obtained from 
the PIDGINv2 predictions of the active compounds of the SH dataset as well as the 
bioactivity data of these compounds which was extracted from ChEMBL as described 
above in 4.3.4.2. The network was analysed using the “Network Analyser” function of 
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Cytoscape. The average node degree of the generated network is 22.305, so any node 
with a higher degree (i.e. more connectedness) was considered a “hub” in our analysis.  
 
4.2.4.5 ENRICHED BIOLOGICAL PROCESSES 
For each dataset, the list of trypanosomal orthologues of predicted targets was used to 
obtain a list of enriched Trypanosoma brucei GO biological processes. This was carried 
out using TriTrypDB359, with the option “Analyse Results” to find the biological 
process terms enriched in the gene list at a p-value < 0.05. The p-value is a statistical 
measure of the likelihood that a certain GO term appears among the input genes, more 
often than it appears in the set of all genes in Trypansoma brucei (background). A tree 
map representation of the enriched GO terms was generated using REVIGO360 and 
plotted using R182. 
 
 
 
 
144 
 
4.3 RESULTS AND DISCUSSION 
4.3.1 CHEMICAL SPACE ANALYSIS 
We first analysed the chemical space of the two datasets (SH, 872 molecules and NP, 
826 molecules) to see if they share chemical space or if they occupy different regions 
of chemical space. The results are shown in Figure 4:2. Despite the difficulty of 
representing chemical diversity in low dimensions, it can be seen that compounds from 
the two datasets have little overlap in chemical space, and that the NPs occupy space 
that is not occupied by the SMs. Furthermore, Figure 4:2 suggests that the NPs are more 
spread out in chemical space and are thus more chemically and structurally diverse than 
the SMs. We therefore expect these two datasets to display different mechanisms of 
action since their chemistries appear to be different. 
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Figure 4:2 MDS plot calculated from the Euclidean distance between Morgan fingerprints of the NP and SM 
datasets. Each data point corresponds to a compound in the datasets. Green data points are NP compounds and red 
data points are small molecule hit (SH) compounds. It can be seen from the MDS image that compounds from the 
two libraries share a small amount of chemical space and the NPs expand into an area of space not covered by the 
small molecules. 
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Figure 4:3 Density plot of Tanimoto similarity of all vs all compounds in each dataset. Natural products have 
the lowest intra library similarity compared to the small molecule hits and the combined library. The mean similarity 
for the SH dataset is 0.095 ±0.012, while the mean similarity for the NP dataset is 0.0827 ±0.016. 
 
To quantify this further, the average Tanimoto similarities of each compound to all 
compounds in both its corresponding dataset were calculated and projected onto a 
density plot; see Figure 4:3. Here we see clearly that NPs have lower intra-similarity 
(mean average Tanimoto coefficient of 0.0827 ±0.016) when compared to the SH 
dataset. This indicates that they occupy a broader chemical space and this can also be 
seen in Figure 4:2 where the NPs are more spread out in chemical space. The SH dataset 
has a mean average intra-similarity Tanimoto coefficient of 0.095 ±0.012 indicating 
that they are more similar to each other than members of the NP dataset.  
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A previous study176 identified an activity-relevant Tanimoto coefficient value of ≥ 0.3 
for bioactive compound pairs. The Tanimoto similarities that we have calculated 
suggest both that these two datasets are each chemically diverse, and moreover that the 
datasets occupy different regions of chemical space. 
 
In an effort to understand the chemical diversity present in these datasets in greater 
detail, we decomposed the compounds in the two datasets into their Murcko188 
scaffolds. The NPs were found to have 413 scaffolds whereas the SHs were found to 
occupy 712 scaffolds, with 25 scaffolds shared between the two datasets. 
 
Table 4:2 shows the ten most populated scaffolds in each dataset (active compounds). 
It is important to note that none of the top ten populated scaffolds overlap between the 
two datasets, further illustrating the chemical diversity of the two datasets shown in the 
MDS plot (Figure 4:2). There was an overlap of just 25 scaffolds in total between the 
databases. Ten of these 25 overlapping scaffolds were in the top 100 most populated 
NP scaffolds with only seven of the overlapping scaffolds appearing in the 100 most 
populated SH scaffolds. Further insight into the diversity within the libraries was shown 
by the percentage of scaffolds that were represented by only one compound. This was 
73.4% for the NPs and 87.2% for the SMD. This also explains why the compounds are 
so spread out in the MDS plot. As we have shown above in the Tanimoto coefficient 
density plot, the compounds in the SH dataset are structurally more similar to each 
other, than the NPs are to each other. So, despite having more scaffolds occupied by 
only one compound than the NP dataset, the SH dataset is still less chemically diverse 
than the NP dataset. One reason for this may be that the SH dataset contains compound 
series intentionally designed to have similar scaffolds for high throughput screening.  
 
No evidence of anti-parasitic activity was found for the third, fourth, fifth, sixth, ninth 
and tenth most populated scaffolds in the NP dataset. The top two most populated 
scaffolds in the NP dataset, (flavonoids and isoflavonoids) are occupied by compounds 
that are known to have activity against trypanomastids as well as other parasites, e.g. 
Plasmodium parasites. These are reviewed extensively by Schmidt et al315. Indolizidine 
alkaloids (the seventh most populated scaffold in the NP dataset) have shown activity 
against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium 
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falciparum with IC50 values of between 39-120 ng/ml respectively. (Chloroquine 
standard activity is 17 and 140 ng/ml respectively). The eighth most populated scaffold 
in the NP dataset is also known to have potent anti-trypanosomal activity361. Evidence 
for anti-parasitic activity was found for the ninth and tenth most populated scaffolds in 
the SH dataset. We found that the ninth most populated scaffold in the SH dataset is 
similar in structure to 4-anilinoquinazoline which is a scaffold of compounds known to 
display anti-trypanosomal activity362. The tenth most populated scaffold is an amino 
thiazole, also known to have potent anti-trypanosomal activity361. Taken together these 
results show that even though the scaffolds in the two datasets are different, they are 
nonetheless associated with compounds with known anti-trypanosomal activity. We 
expect them to act by modulating different targets due to the differences in their 
structures. 
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Table 4:2 Top 10 populated Murcko scaffolds in the NP library and small molecule hits library (SH). It can 
be seen that none of the top 10 populated scaffolds are shared between the two datasets. Benzene was not included 
as a scaffold. 
NP Scaffold Frequency SH Scaffold Frequency 
 
60 
 
7 
 
23 
 
7 
 
10 
 
6 
 
10 
 
6 
 
9 
 
6 
 
9 
 
5 
 
9 
 
4 
 
8 
 
4 
 
8 
 
4 
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8 
 
4 
 
To explore the diversity of the chemistry of these compounds even further, the 
molecules in each dataset were decomposed into molecular fragments, and the 
fragments that were most enriched in each dataset were identified (see Methods for 
details of the analysis). Supplementary Table 5 shows the fragments enriched in the SH 
dataset against the NP dataset and Supplementary Table 6 shows the fragments enriched 
in the NP dataset against the SM dataset. Supplementary Table 7 shows the fragments 
enriched in all the active compounds against all the inactive compounds. From 
Supplementary Tables 5 and 6 it is clear that the fragments are different in both datasets. 
The NP fragments tend to be the polyphenols whereas the small molecules are amines. 
This further illustrates the different chemical space of these datasets. The enriched 
fragments shown in Supplementary Table 7 are important because knowing which 
fragments are enriched in phenotypically active compounds can help with the design of 
new screening libraries.  
 
4.3.2 CHEMOGENOMIC SPACE ANALYSIS 
4.3.2.1 TARGET PREDICTION 
In an effort to identify the target space of Trypanosoma brucei, in silico target 
prediction and a database search were carried out on 871 active screen compounds, 569 
inactive screen compounds and 826 active NPs. The NP compounds were enriched 
against a background of over 2,000,000 compounds from PubMed using PIDGIN v2143 
to produce 186 enriched targets (see Methods for details). At least one target was 
predicted for 772 compounds of the active screen dataset and 391 compounds for the 
NPs, thus 11.4% of the screen compounds and 2.5% of the NPs were outside the 
applicability domain of the model. 1,544 proteins were predicted for the active screen 
compounds of which 1,539 were predicted for non-trypanosome organisms and 1,646 
for the NPs, 1,640 of which were for non-trypanosome organisms. An orthologue 
search for these proteins was carried out on Panther DB to map 101 proteins of the 131 
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enriched predicted proteins for the screening compounds and 275 for the NPs; this 
mapping was six for the bioactivity search for the screen compounds and 109 for the 
NP bioactivity search. To obtain a prioritised set of targets, an enrichment calculation 
was carried out between the predicted targets of the active dataset and the inactive 
dataset of the screen compounds. This approach takes advantage of the negative dataset, 
to further prioritise the targets. The active compounds enriched 131 proteins over the 
inactive compounds and only 5 proteins were predicted to bind only the active 
compounds. A full list of enriched targets is provided in the Appendix of the thesis, 
Supplementary Table 11 and 13. 
 
In this work, we assume shared bioactivity between targets from different organisms, 
e.g Homo sapiens, Rattus norvegicus, Bos taurus etc, and their orthologues in T. brucei. 
A recent study143 found that annotations across orthologues are overall compatible, 
where it was found that only 1,363 of 124,540 (1.2%) orthologue bioactivities have 
conflicting annotations with the corresponding compounds inactive in humans.  At the 
target level, 75.9% human-orthologue HomoloGene target pairs were found to be not 
conflicting. Another study363 on ChEMBL bioactivity data found a statistically 
significant relationship between bioactivity in human and rat targets (R=0.71, p<2e-16). 
Furthermore, a recent study involved carrying out a systematic search for bioactive 
small molecules shared by orthologous targets364. This study identified compound-
orthologue pairs, covering 938 orthologues, 358 unique targets across 98 organisms. 
Of these, a total of 158 orthologous target pairs involving human orthologues were 
identified.364 On the other hand, a study365 which generated both phylogenetic and 
bioactivity tree representations of kinases found that in 57% of the studied cases, 
kinases that cluster together in protein structure space do not necessarily cluster 
together in bioactivity space. This study highlights that implicit assumptions of 
bioactivity across orthologues cannot be assumed based on protein structure similarity. 
Taken together, the results from these studies show that bioactivity data can be 
extrapolated with some confidence from one organism to another. This has been 
demonstrated by a study337 that mined Homo sapiens bioactivity data in combination 
with structural and historical assay space searches to identify active target-compound 
links. The data from the targets identified from Homo sapiens targets was used to 
propose the equivalent Mycobacterium tuberculosis targets via an orthology search.  
 
 
 
 
152 
 
 
4.3.2.1.1 Checking confidence of predictions before analysing target prediction 
results 
We carried out a retrospective confidence check of our predictions in three ways. 
Firstly, we compared the predicted results to the known targets of trypanocidal drugs 
in the market used against HAT (Eflornithine, Pentamidine, Suramin, Melarsoprol and 
Nifurtimox), shown in Supplementary Table 8. Currently, the only validated drug target 
of any of the drugs is ornithine decarboxylase, the target of eflornithine, which was 
correctly predicted for Eflornithine at a tpr >0.9.  
 
Secondly, we compared the chemical similarity of NP in the dataset to experimentally 
validated trypansomal target inhibitors. We looked at two validated trypanosomal 
targets and compared their experimental inhibitors with those predicted from the NP 
dataset. First, we looked at ornithine decarboxylase (ODC), which is the drug target of 
the suicide inhibitor Elfornithine, in which 2 drug moieties irreversibly bind ODC and 
physically block ornithine from binding. Ornithine decarboxylase is an enzyme that 
catalyses the first reaction in polyamine synthesis366. Polyamines are (i) responsible for 
stabilising the structure of DNA, (ii) responsible for the DNA double-strand-break 
repair pathway, and (iii) antioxidants. Lack of ornithine decarboxylase leads to DNA 
damage induced apoptosis. Ornithine decarboxylase is also targeted by the molecule 
Heterophyllin, found in the NP dataset. The flavanol Herbacetin has previously been 
shown to allosterically inhibit ornithine decarboxylase367 and we hypothesise that this 
is also the case for Heterophyllin, since the compounds are similar in structure. The 
structures of these compounds are shown in Table 4:3. 
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Table 4:3 Structure of Ornithine (natural ligand of ornithine decarboxylase), Eflornithine (Stage 2 Human 
African trypanosomiases drug) Heterophyllin (NP previously shown to bind ornithtine decarboxylase) and 
Herbacetin (NP predicted to bind ornithime decarboxylase). 
Name Structure 
Heterophyllin 
 
Herbacetin 
 
Ornithine 
 
Eflornithine 
 
 
We identified mitochondrial Trypanothione reductase (TryR) (Tb10.406.0520) as a 
potential target of the NPs. Trypanosomes have a unique metabolic redox metabolism 
called the trypanothione redox metabolism. This has been investigated as a potential 
therapeutic target due to its essentiality for the survival of the trypanosome39. 
Trypanothione is responsible for defence against oxidative stress, therefore enzymes 
that make and use it can be targeted. Despite numerous efforts, no clinical compounds 
have been developed due to the presence of a large hydrophobic site in TryR. The NP 
cynaropicrin interacts with targets in the trypanosome redox pathway including 
ornithine decarboxylase, trypanothione reductase, trypanothione synthase and 
glutathione-S-transferase to produce anti-trypanosomal activity368. Cynaropicrin has 
been shown to exhibit this anti-trypanosomal activity via its α,β-unsaturated methylene 
moiety which acts as Michael acceptor for glutathione and trypanothione, thus 
depleting intracellular glutathione and trypanothione369. Michael addition is the 
nucleophilic addition of a carbanion or another nucleophile to an α,β-unsaturated 
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carbonyl compound. Xanthohumol also contains an α,β-unsaturated methylene moiety 
and may thus act via the same mechanism as Cynaropicrin. Xanthohumol has 
previously been shown to modify both NF-κB370 and Keap1371 protein by acting as a 
Michael acceptor to cysteine residues in these proteins. The structures of the 
compounds Xanthohumol (identified from the NP dataset) and Cynaropicrin 
(experimentally validated trypanothione redox modulator) are shown in Table 4:4. This 
suggests the mechanism of action of the phenotypically active NP (Xanthohumol) from 
our dataset. 
 
Table 4:4 Structure of Cynaropicrin, a known modulator of the trypanothione redox pathway, and 
Xanthohumol, a NP predicted to modulate trypanothione reductase. 
Name Structure 
Cynaropicrin 
 
Xanthohumol 
 
 
These two examples demonstrate that we can use the target prediction results with some 
confidence in our further analysis, i.e. biological process and mechanism of action 
elucidation. 
 
In order to prioritise the predicted targets for both datasets, and understand their 
underlying molecular mechanism of action, we proceeded to carry out target predictions 
for the five marketed trypanocidal drugs. This analysis allows us to ascertain whether 
potential new molecules have predicted targets that overlap with the predicted targeted 
of these validated drugs, providing greater insight into their mechanism of action. We 
also constructed a list of essential targets of the whole T.brucei genome and compared 
the overlap with our predicted targets from both datasets as well as the 5 drugs. 
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Figure 4:4 Overlap of genes between the different datasets. It can be seen that NPs share 134 predicted targets 
with the TDR Essential dataset. The Screen Hits targets share 43 targets with the TDR Essential targets. There is an 
overlap of 19 targets between the 5 HAT drugs and the NP targets, and 17 targets between the Screen HITS targets 
and the 5 Drugs. 
 
From Figure 4:4 we see that 19 of the targets predicted for the natural products (NPs) 
are shared with the 5 HAT drugs and of these, 11 are in the TDR Essential set. This 
overlap between the predicted targets of the 5 marketed drugs, the TDR essential drugs 
and the predicted targets of the compounds from our datasets serves to increase 
confidence in the predictions. Of the 134 targets shared between NPs and TDR 
Essential, there were targets essential for tryapanosome survival. One of these targets 
shared between NPs and the TDR essential list is rhodesain. This cysteine protease 
plays a role in impassivity (allows BBB crossing), immune evasion (turnover of VSGs) 
and is responsible for degrading host immunoglobulins37. Allicin has been found to 
bind this target with a Ki value of 5.31μm from the NP Bioactivity dataset.  The primary 
carbon atom in the vicinity of the thio-sulphinate sulphur atom is attracted by the 
cysteine residue in the active site of rhodesain. Another protein identified as a target for 
the phenotypically active compounds is the flagellum surface protein, voltage-
dependent calcium channel type A subunit alpha-1 (Tb10.70.4750) identified in both 
datasets (including the screen compounds). This protein is present in the flagellar 
attachment zone (FAZ), which is a unique feature of Trypanosoma brucei 
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trypanomastid. Knockdown studies of this gene resulted in flagellar detachment and 
deficient growth of the trypanomastid372. Another family of targets predicted that are 
also essential are the heat shock proteins. The HAT drug Suramin acts on HSPs. With 
the exception of ornithine decarboxylase, and the heat shock proteins, none of the other 
trypanosomal genes predicted for the NPs or SHs are targeted by drugs in the market. 
 
Here we have predicted that the phenotypically active compounds from both the NP 
dataset and SH datasets exert their anti-trypanosomal activity by modulating targets 
that are essential to the survival of the parasite. 
 
4.3.2.2 Suitability of phenotypically active compounds from SM and NP 
datasets for Stage 2 HAT 
We proceeded to look into the possibility that these compounds have the potential to be 
active against Stage 2 HAT. Stage 2 HAT is characterised by the traversal of the BBB 
by the parasite. Unlike other parasitic diseases, trypanosome traversal is not dependent 
on the level of parasitaemia373, rather, it depends on the host immune response373. In 
order to achieve Stage 2 activity, the compounds must (i) be able to cross the BBB and 
modulate targets that are essential for the survival of the parasite and/or (ii) act on 
human targets involved in the host response system facilitating parasite traversal, e.g. 
chemokines, TNF- α and interferons374. Supplementary Table 14 shows a list of the 
compounds with favourable plogBB values and the essential Trypanosoma brucei 
targets they are predicted to modulate. We therefore deem these compounds favourable 
for prioritisation for in vivo Stage 2 HAT models.  
 
4.3.2.3 ANALYSING MULTI-TARGET ACTIVITY OF PHENOTYPICALLY ACTIVE 
SMALL MOLECULE HITS COMPOUNDS 
It is generally advantageous for therapeutic drugs to target multiple proteins involved 
in multiple stages of the life cycle 375 as trypanosomes have multiple host life cycles 
376. To visualise if the phenotypically active compounds from the SH dataset display 
multiple protein modulation we constructed a target network. The target network 
showing the connections of the 871 phenotypically active SH dataset compounds to the 
enriched set of targets is shown in Figure 4:5. The figure also shows the compounds 
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that are predicted to penetrate the BBB (coloured in red). This is important for the 
treatment of the second stage of the disease, as the parasite crosses into the brain and 
causes mental deterioration followed by the induction of a coma and eventually leading 
to death. Eflornithine is predicted to have a log BB of -0.328 and is one of the drugs 
suitable for use in the second stage of the disease.  
 
From the network we identified several multi-target compound hubs, the most 
prominent of which are labelled in Figure 4:5. In this case, a hub is a node for which 
the number of links exceeds the average number of degrees (connectedness), which in 
this case is 22.305. There were 78 targets that exceeded the average number of degrees, 
ranging from 22.3 to 90 degrees (connections to compounds). The transporters had the 
highest number of degrees at 90. The identified hubs show the most promiscuous targets 
binding to the active compounds in the SH dataset. We predict that compounds from 
the SH dataset are exerting their activity by modulating the targets in these hubs. We 
can also see that unlike the compounds predicted to bind transporters and 
oxidoreductases, some of the compounds binding the kinases have poor distribution in 
the brain.  
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The first multi-target hub identified is of the compounds predicted to bind transporters. 
Several glucose transporters were identified as targets from the phenotypically active 
compounds, shown in Supplementary Tables 12 and 13, namely glucose transporter 
(Tb10.6k15.2030), glucose transporter, putative (Tb927.4.2290) and a hexose 
transporter (Tb10.6k15.2040), all belonging to the family “facilitated glucose 
transporter protein 1”.  This is significant because one of the most important pathways 
in African trypanosomes is glycolysis, the enzymes of which are packaged in the 
glycosome. Blood stage African trypanosomes rely solely on glycolysis for the 
production of ATP, thus enzymes and transporters involved in this pathway represent 
viable drug targets. It is ideal to have compounds, some of which are shown in Figure 
4:4, with the ability to cross the BBB 377 that will target the transporters.  
 
Another set of multi-target compounds of particular relevance to HAT were identified 
in the kinase hub of Figure 4:5. It has been suggested that it would be advantageous to 
develop kinase inhibitors that target multiple kinases within a family378 to reduce 
resistance that arises from point mutations at the residues involved in the binding site 
between the compound and the kinase379. In our predictions we have identified targets 
including serine/threonine kinases, Mitogen activated kinases, and more (shown in 
Supplementary Tables 12 and 13). Similar targets were predicted for Plasmodium 
falciparum 338, including a number of putative protein kinases, serine/threonine kinases 
and MAP kinases. A potential therapeutic kinase target that was predicted (for 
compounds shown in Table 3 – CD) in the kinase hub was Aurora Kinase A, which 
plays an important role in metaphase-anaphase transition and the initiation of 
cytokinesis380. Knockdown studies showed an essential contribution to infection in 
mice380. Small molecule inhibitors, e.g. hesperidin, have been shown to inhibit this 
protein380. 276 phenotypically active compounds from the screen dataset were predicted 
to bind Aurora A; these molecules are shown using the smiles representation in Table 
3 – CD. The fact that they inhibit Aurora A is relevant because it means that we can 
begin to understand the putative mechanisms of action of these compounds.   
 
Glycogen synthase kinase 3 (GSK3) was also identified as a target of 37 compounds. 
This target is present in the list of highly prioritised targets for trypanosoma drug 
discovery. It is expressed in the bloodstream form of Trypanomastids. RNAi 
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knockdown studies of this gene resulted in defects in mitosis and cytokinesis, thus 
leading to GSK3 being investigated as a therapeutic drug target381, 382. During host 
infection, i.e. bloodstream form, the trypanosome relies on the glycolysis of host sugar 
for the production of ATP383. Consequently, enzymes involved in the process have been 
investigated as potential therapeutic targets. Phosphofructokinases catalyse the 
phosphorylation of fructose-6-phosphate to fructose-6-biphosphate, which is the key 
rate-limiting step of glycolysis (the sole pathway for ATP production in African 
trypanosomes). As a consequence, these kinases are being actively pursued as 
targets384, and it is promising that they are predicted by our analysis as members of the 
kinase hub.  
 
It is important to note that there are limitations to targeting kinases. Humans also have 
numerous kinases and the kinome is important for human survival, hence it is important 
to avoid cross-reactivity with members of the human kinome. We are attempting to 
identify targets in Trypanosoms brucei, which is evolutionarily very distant from 
humans. This evolutionary distance suggests that there may be differences between the 
human and trypanosome kinome that can be exploited. For example, the selectivity of 
Eflornithine to trypanosomal ornithine decarboxylase (not a kinase) arises from the 
difference in turnover for this enzyme between humans and the parasite385. In humans 
the turnover is much faster385, and so suicidal binding386 of Eflorntihine to the 
tryapnsome enzyme affects the trypanosome more than the human enzyme. Human 
enzyme activity is maintained by a protein whose turnover is significantly different 
from the trypanosome version. These evolutionary differences will become important 
at the lead optimisation stage, when these compounds would need to be modified in 
such a way that they do not interact in a detrimental way with the human kinome. In 
summary our analysis shows that individual phenotypically active compounds are 
predicted to modulate multiple targets in the trypanosome parasite. These results 
suggest that a number of these compounds may make good potential therapeutic 
candidates.  
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4.3.2.4 ENRICHED BIOLOGICAL PROCESSES 
Target prediction alone does not provide the full picture with respect to understanding 
the mode of action of phenotypically active compounds. To address this question in 
more detail we analysed the enriched Trypanosoma brucei GO biological processes of 
the predicted targets from the two datasets. The results are represented in Figure 4:6.
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Figure 4:6 Treemap showing the biological processes GO term clusters. Each rectangle is a single cluster 
representative. The size of the rectangle represents the p-value of the GO term (all levels were considered). The top 
figure corresponds to the biological processes of the small molecule gene list whereas the bottom figure corresponds 
to the biological processes enriched in the NP genelist. It can be seen that the major difference between the two is 
the absence of “response to stress” and “response to stimulus” in the SM biological process profile. “Biological 
process” as a GO term refers to annotation of gene products whose biological process is unknown. The p-values 
corresponding to these biological processes are shown in Supplementary Tables 15 and 
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Biological processes involved in protein phosphorylation are enriched in both sets of 
gene lists (these gene lists contain the predicted targets and known biological targets of 
both datasets). Protein kinases, which are the enzymes responsible for protein 
phosphorylation, play an important role in many cellular processes. These include, but 
are not limited to, cell cycle propagation and differentiation as well as transcription 
control. Kinases have been the focus of current kinetoplastid drug discovery 
programs361, 387.  The “kinase library” subset of the SH dataset contained compounds 
that were likely to hit kinases388. Here we have identified the genes they are predicted 
to modulate (Supplementary Tables 10-13) and the biological processes that they enrich 
in order to have the observed cidal and static effects reported by Thompson et al387. 
 
We can see from Figure 4:5 that processes which are essential to the survival of the 
parasite such as glucose and folate metabolism389, 390 as well as cell death are predicted 
to be modulated by compounds in both datasets. This is shown by the presence of the 
GO terms “growth”, “metabolism” and the “cell cycle” in both the top and bottom 
panels of Figure 4:5. The cell cycle has been identified as an important target for 
exploitation in other parasitic diseases caused by Plasmodia, Trypanosoma and 
Leishmania391. An interesting set of biological processes that was found for both sets is 
“regulation of symbiosis, encompassing mutualism through parasitism” and 
“modulation of development of symbiont involved in interaction with host”. Disruption 
of these genes has been shown to be vital for quorum sensing signalling in the 
trypanosome392. Deletion of one of these genes, the differentiation inhibitory kinase 
(Tb927.11.9270), has been shown to increase the rate of differentiation between the 
bloodstream form (pathogenic form) to the stumpy non-dividing form393. The genes in 
each dataset responsible for this observation in the small molecules dataset are:  
 CMGC/DYRK protein kinase, putative (Tb927.10.15020),  
 NEK family Serine/threonine-protein kinase, putative (Tb927.10.5940),  
 Serine/threonine-protein kinase NEK17, putative (Tb927.10.5950),  
 Differentiation inhibitory kinase (Tb927.11.9270),  
 5'-AMP-activated protein kinase catalytic subunit alpha, putative 
(Tb927.3.4560) ,  
 Repressor of differentiation kinase 2 (Tb927.4.5310).  
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In the natural product (NP) dataset, the genes were:  
 5'-AMP-activated protein kinase catalytic subunit alpha, putative 
(Tb927.3.4560),  
 Serine threonine-protein phosphatase PP1, putative (Tb927.4.3620),  
 Serine threonine-protein phosphatase PP1, putative (Tb927.4.3630),  
 Serine threonine-protein phosphatase PP1, putative (Tb927.4.3640).  
 
Note that all these targets are putative kinases, further reinforcing the importance of 
kinases as drug targets for Trypanosoma brucei. The most common scaffolds of the 
compounds predicted to bind the genes enriched in these processes is shown in Table 4 
CD. We can see that the compounds share no scaffolds and that they modulate a 
completely different set of trypanosomal genes, yet they are involved in the same 
biological process. An approach to modulate different kinases simultaneously has been 
suggested to be an advantage for kinetoplastid drug discovery as discussed above. A 
combination of molecules from the NP and SH datasets will likely achieve this as we 
have shown they target different genes involved in the same biological processes. 
 
Other processes that are of particular importance to trypanosome integrity were only 
enriched in the SH gene list, e.g. “homeostasis” and “monosaccharide transport”, the 
importance of which was discussed above. In particular, Ca++ homeostasis, which is an 
essential messenger, is important as its disruption causes apoptosis and necrosis (i.e. 
disruption is lethal to the trypanosome). We have already shown that small molecules 
at the molecular level are predicted to regulate transport mechanisms, and here we see 
the biological processes that are affected. Other biological processes were only enriched 
for the NP gene list, e.g. “cytoskeleton organisation” and “sterol metabolism”. This 
finding is in agreement with previous studies, where sterol metabolism has been 
investigated as a target for the closely related Trypanosoma cruzi394 and Leishmania 
species395. Psilostacyn C, a NP sesquiterpene lactone, induced cell death by apoptosis 
in T. cruzi by interfering with sterol synthesis396. One of the drugs used in 
Leishmaniasis is the NP Amphotericin B, which has a high affinity for egosterol and 
thus inhibits sterol metabolism397. The process of cytoskeleton organisation is 
important as it is responsible for orchestrating the extreme changes in cellular 
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morphology of the trypanosome, during both its life cycle and various different cell 
cycles372, 398. These morphological changes require a high level of integration and 
coordination. Disrupting these processes will therefore lead to growth defects372.   
 
Beyond these biological processes, we note that “response to stress”, “organic 
substance metabolism” and “purine-containing compound metabolism” are absent from 
the SH map in Figure 4:6. One reason that these processes are present in the NP map is 
that those compounds responsible for predicting targets enriched in these processes are 
also responsible for similar processes in the plant that the compounds have been 
extracted from. It is well documented that secondary metabolites in plants are 
responsible for defence against stress399. For example, compounds responsible for 
“cellular response to DNA damage stimulus” included flavonoids, glucosides and 
flavonoids, e.g. caffeic acid, sennoside A, sennoside B, shickimic acid and tannic acid. 
These secondary metabolites protect plant cells from UV-a and UV-B stress via various 
mechanisms400. Furano-coumarins were responsible for “DNA repair response”. The 
furano-coumarins are produced in plants in response to UV-A damage. They are 
activated by UV-A and lead to cell death by blocking transcription through inserting 
themselves into the DNA double-helix and binding to the pyramidine bases400.  
 
Here we have shown that phenotypically active compounds are predicted to modulate 
biological processes that are essential for the survival of the Trypanosoma brucei 
parasite. We have predicted their target genes, and identified the biological processes 
that are enriched for those genes. This analysis provides a deeper layer of understanding 
regarding the mechanism of action of the phenotypically active anti-trypanosomal 
compounds in the two datasets. 
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4.4 CONCLUSION 
In this study we have shown that the chemical space spanned by our small molecule 
(SH) and natural product (NP) datasets are quite different, as shown by the spread of 
the compounds on the MDS plot. The density plot in Figure 4:3 reveals that the NP 
molecules have less chemical similarity to each other than the small molecule dataset 
compounds do, despite the fact that the SH datasets compounds also display low 
similarity to one another. This means that while both datasets are highly diverse in 
chemical space, the NP dataset is more diverse than the small molecule one.  
 
We have made use of negative and orthologue data to identify therapeutic targets of 
phenotypically active HITS and NPs. Our analysis identified overlaps between the sets 
of predicted targets and those genes that are essential for the trypanosome, identifying 
these genes as targets that should be highly prioritised. This analysis is timely and 
relevant, in particular because none of these genes are currently targeted by drugs in 
the market. 
 
We predicted the activity of the small compounds in second stage HAT by predicting 
their logBB values, and found not only that some compounds are predicted to penetrate 
the blood brain barrier (important for Stage 2 of the disease) but also that they are 
predicted to modulate multiple targets. We identified multi-target activity of the small 
molecules, where we show that they are predicted to modulate multiple orthologues of 
the same kinase, e.g. Aurora Kinase A and the MAP Kinases. We have identified 
distinct but therapeutically relevant target spaces for members of both the NP and SH 
datasets of compounds.  
 
We have taken this further and explored the biological processes modulated by these 
compounds. The most interesting finding was the enrichment of processes affecting 
host-parasite interaction, namely “regulation of symbiosis, encompassing mutualism 
through parasitism” and “modulation of development of symbiont involved in 
interaction with host”. We found that compounds from both datasets modulate this 
process through their predicted activity against different targets.  
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CONCLUSION 
 
Throughout the studies in this thesis the aim was to utilise in silico target prediction to 
understand the mechanism of action of African natural products.  
 
In Chapter 2, a Random Forest algorithm was used to predict targets and pathways 
modulated by natural products from African medicinal plants with anti-cancer activity. 
From our study we were able to establish several links between the suggested MOAs 
of the natural products with experimental evidence. Compounds from plants used in 
cancer were predicted to bind primary cancer targets, e.g. the apoptosis regulator Bcl2, 
as well as targets involved in the metabolism and hence resistance to cancer drugs, e.g. 
CYP1B1. We also identified targets that may exhibit novel mechanisms of action that 
are not currently targeted by drugs in the market, e.g. Induced myeloid leukaemia cell 
differentiation protein Mcl-1 and Tankyrase 1. Furthermore, we identified the pathways 
that these compounds modulated and not only were some directly involved in cancer, 
e.g. Apoptosis pathways, but some were not modulated by drugs in the market, e.g. the 
Kaep1-Nrf2 pathway. Similar results were obtained in our case study for 
Psorospermum aurantiacum, where the primary targets associated with the medicinal 
uses of the plant were predicted, e.g. protein kinase C gamma type (linked to skin 
infections), oestrogen receptor β (linked to infertility), Mcl-1 (linked to cancer). 
However, there are limitations of applying an in silico target prediction algorithm 
trained on ChEMBL data to natural products, specifically the applicability domain (the 
physic-chemical structural or biological domain for which it is valid to make 
predictions for new compounds). A target prediction algorithm trained on natural 
product data will go towards addressing this problem. This will require access to 
complete (not sparse) databases containing natural product structure data as well as 
bioactivity data. This should be possible in the near future as more databases are curated 
and updated, e.g. NANPDB, NPASS, etc. 
 
In our novel approach to integrate phylogenetic data with in silico target prediction we 
were able to identify relationships between the phylogeny of a medicinal plant and its 
medicinal use. Plant families in this study mostly cluster together in structure space, 
predicted target space and phylogeny space. Furthermore, over-represented plant 
 
 
 
 
169 
 
families were identified for medicinal uses (cancer, malaria and HAT) in Africa 
including Acistrocladaceae, Clusiaceae and Rutaceae. The over-represented presence 
of medicinal plants within these families was directly linked to the unique 
phytochemicals produced by these plants. Taken together these findings provide a basis 
for predicting the use of a medicinal plant based on its phylogenetic relationship to 
other medicinal plants. Limitations to this study include incomplete data and 
experimental annotations of the NPs from the medicinal species of Africa. As more 
information is curated and added to the databases, more concrete results can be 
obtained. 
 
Phenotypic studies have identified both natural products and small molecules with anti-
tryapnosomal activity. In Chapter 4, in silico target prediction, combined with an 
orthology search, revealed predicted Trypanosoma brucei targets and biological 
processes modulated by the phenotypic compounds that are essential for the survival of 
the trypanosome including glycogen synthase kinase. In addition to predicting the 
targets of these compounds, we were able to predict their activity in stage 2 HAT by 
predicting their ability to cross the blood brain barrier. This study elucidates the mode 
of action of ANPs used in HAT as well as identifying the difference in target space 
between NPs and small molecules. The major limitation in this study is the 
extrapolation of orthologue data from different species to Trypansoma brucei. To 
address this limitation, a similarity cut-off of the predicted target to the tryapnosomal 
target can be applied, e.g. >80% sequence similarity.  
 
Despite the limitations discussed above, in silico target prediction can be used to 
elucidate and understand the mechanism of action of African natural products. 
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FUTURE WORK 
 
In Chapter 2 we attempted to elucidate the mechanism of action of NP from TAMs by 
showing that targets predicted to be modulated by NPs from TAM play a role in cancer. 
We have also shown the molecular pathways that these NP are predicted to modulate. 
In order to fully understand the mechanism of action of these compounds it is vital to 
experimentally validate these predictions. The next step after these predictions is to 
predict binding and interaction of the compounds to the targets. Molecular docking of 
NPs to targets will give us a score of the predicted binding affinity and binding mode 
of NPs to their target proteins. Further steps would be taken for the most promising of 
these predictions to experimentally validate binding. Should these opportunities 
become available the two targets to prioritise would be Tankyrase 1 and Thioredoxin 
reductase 2. Assays to validate NP binding to Tankyrase 1 include those developed by 
Thomson et al401 and assays that can be carried out for Thioredoxin reductase 2 include 
those described in 402-404. 
 
As more NP datasets are curated and made public it will be valuable to build a DNN 
model trained on NP data. DNNs have been shown to outperform RF102, 108 on QSAR 
based protocols when trained on ChEMBL data108 but they require a large amount of 
descriptors and features to train a model, which are not available yet for NPs. The 
applicability domain of the model will improve, as the model will be trained on 
compounds with similar chemical space to the test compounds. 
 
In Chapter 3, we identified over-represented families in Africa used against cancer 
malaria and HAT. This knowledge can be use to prioritize screening of plants from 
over-represented families e.g. Acistrocladaceae and Dioncophyllacea for anti-
trypanosomal activity. It would also be useful to identify biosynthetic gene clusters 
(BGC) in plants where it was found that medicinal activity was due to unique 
metabolites e.g. NIQs in Ancistrocladaceae, Xanthones in Clusiaceae and Acridones in 
Rutaceae. Identifying these BGCs in one of the plants known to produce a medicinally 
active NPs is useful when genome mining other plants in the same family for novel 
medicinally active NPs405, 406. 
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In Chapter 4 we predicted the biological targets of phenotypically active compounds. 
The next step would be to validate these predictions. This can be achieved by first 
carrying out docking studies to determine binding affinities and binding modes of 
compounds predicted to bind two prioritized targets. Compounds to be prioritized 
would be those that are predicted to cross the BBB, have good ADMET properties and 
predicted to modulate targets essential to the Trypanosoma bruceii parasite. The two 
targets that can be prioritized from our results are Glucose transporter and hexose 
transporter inhibitor407, 408 and GSK3382, 409.  
 
Another extension of this work would be to expand on the network analysis carried out 
in this Chapter to uncover novel druggable target space in Trypanosoma bruceii. To 
carry this out, a network of the Trypanosoma bruceii proteome, obtained from 
STRING410 database will be constructed. The STRING database contains information 
predicted and known protein-protein interactions. This network can be mapped out, 
visualized and analyzed using Cytoscape358. Several functions scores can be calculated 
including the Betweeness Centrality, which shows which nodes (in this case targets) 
are more likely to be in communication paths between other nodes. It is useful in 
determining which targets can be modulated where the protein network would break 
apart i.e. modulating a target with high Betweeness Centrality will cause a larger 
downstream effect. This measure demonstrates how likely the target is to be the most 
direct route between two targets in the network. Other useful measures that can be 
calculated include Eigenvectors, which determine how well a target is connected to 
other well connected targets and Degree which shows how many targets a particular 
target interacts with directly. 
 
The next step would be to identify which of the compounds in our SH and NP dataset 
are predicted to  (or experimentally known to) modulate these targets (targets with high 
Betweeness Centrality, Eigenvectors and Degree). It would also be useful find out if 
the compounds in the SH and NP datasets bind orthologues in other kinetoplastids of 
these targets.  Experimentally validating these predictions will potentially uncover 
novel target space in Trypanosoma bruceii. 
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SUPPLEMENTARY MATERIAL 
Supplementary Table 1 List of cancer drugs obtained from NCI (NCI Cancer) 
 ChEMBL ID Drug Name Canonical SMILES 
1 CHEMBL34259 Methotrexate 
(BAN, FDA, 
INN, JAN, 
USAN, USP); 
Methotrexate 
Sodium (FDA); 
CN (Cc1cnc2nc (N)nc (N)c2n1)c3ccc (cc3)C 
(=O)N[C@@H] (CCC (=O)O)C (=O)O 
2 CHEMBL428647 Paclitaxel 
(BAN, FDA, 
INN, USAN, 
USP); 
CC (=O)O[C@H]1C (=O)[C@]2 (C)[C@@H] 
(O)C[C@H]3OC[C@@]3 (OC 
(=O)C)[C@H]2[C@H] (OC (=O)c4ccccc4)[C@]5 
(O)C[C@H] (OC (=O)[C@H] (O)[C@@H] (NC 
(=O)c6ccccc6)c7ccccc7)C (=C1C5 (C)C)C 
3 CHEMBL1742994 Brentuximab 
Vedotin (FDA, 
INN, USAN); 
 
4 CHEMBL1398373 Pirarubicin 
(INN, JAN, 
MI); 
COc1cccc2C (=O)c3c (O)c4C[C@] (O) (C[C@H] 
(O[C@H]5C[C@H] (N)[C@H] 
(O[C@H]6CCCCO6)[C@H] (C)O5)c4c (O)c3C 
(=O)c12)C (=O)CO 
5 CHEMBL185 Fluorouracil 
(BAN, FDA, 
INN, JAN, 
USAN, USP); 
FC1=CNC (=O)NC1=O 
6 CHEMBL1908360 Everolimus 
(FDA, INN, 
USAN); 
CO[C@@H]1C[C@H] (C[C@@H] 
(C)[C@@H]2CC (=O)[C@H] (C)\C=C 
(/C)\[C@@H] (O)[C@@H] (OC)C (=O)[C@H] 
(C)C[C@H] (C)\C=C\C=C\C=C (/C)\[C@H] 
(C[C@@H]3CC[C@@H] (C)[C@@] (O) (O3)C 
(=O)C (=O)N4CCCC[C@H]4C 
(=O)O2)OC)CC[C@H]1OCCO 
7 CHEMBL1201258 Pemetrexed 
(BAN, INN); 
Pemetrexed 
Disodium 
(FDA, USAN); 
NC1=Nc2[nH]cc (CCc3ccc (cc3)C (=O)N[C@H] 
(CCC (=O)O)C (=O)O)c2C (=O)N1 
8 CHEMBL852 Melphalan HCl 
(FDA); 
Melphalan 
(BAN, FDA, 
INN, JAN, 
USAN, USP); 
N[C@@H] (Cc1ccc (cc1)N (CCCl)CCCl)C (=O)O 
9 CHEMBL834 Pamidronate 
Disodium 
(FDA, JAN, 
USAN); 
Pamidronic 
Acid (BAN, 
INN, MI); 
NCCC (O) (P (=O) (O)O)P (=O) (O)O 
10 CHEMBL1399 Anastrozole 
(BAN, FDA, 
INN, USAN); 
CC (C) (C#N)c1cc (Cn2cncn2)cc (c1)C (C) (C)C#N 
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11 CHEMBL1200374 Exemestane 
(BAN, FDA, 
INN, USAN); 
C[C@]12CC[C@H]3[C@@H] (CC (=C)C4=CC 
(=O)C=C[C@]34C)[C@@H]1CCC2=O 
12 CHEMBL1201112 Nelarabine 
(BAN, FDA, 
INN, USAN); 
COc1nc (N)nc2c1ncn2[C@@H]3O[C@H] 
(CO)[C@@H] (O)[C@@H]3O 
13 CHEMBL1201836 Ofatumumab 
(FDA, INN, 
USAN); 
 
14 CHEMBL1201583 Bevacizumab 
(FDA, INN); 
 
15 CHEMBL1201604 Tositumomab 
(FDA, INN); 
 
16 CHEMBL513 Carmustine 
(BAN, FDA, 
INN, USAN); 
ClCCNC (=O)N (CCCl)N=O 
17 CHEMBL3039590 Bleomycin 
(INN); 
Bleomycin 
Sulfate (FDA, 
USAN, USP); 
C[C@@H] (O)[C@H] (NC (=O)[C@@H] 
(C)[C@H] (O)[C@@H] (C)NC (=O)[C@@H] (NC 
(=O)c1nc (nc (N)c1C)[C@H] (CC 
(=O)N)NC[C@H] (N)C (=O)N)[C@@H] 
(O[C@@H]2O[C@@H] (CO)[C@@H] (O)[C@H] 
(O)[C@@H]2O[C@H]3O[C@H] (CO)[C@@H] 
(O)[C@H] (OC (=O)N)[C@@H]3O)c4c[nH]cn4)C 
(=O)NCCc5nc (cs5)c6ncc (s6)C (=O)NCCC[S+] 
(C)C 
18 CHEMBL288441 Bosutinib (INN, 
USAN); 
Bosutinib 
Monohydrate 
(FDA); 
COc1cc (Nc2c (cnc3cc (OCCCN4CCN (C)CC4)c 
(OC)cc23)C#N)c (Cl)cc1Cl 
19    
20 CHEMBL1201587 Alemtuzumab 
(BAN, FDA, 
INN, USAN); 
 
21 CHEMBL481 Irinotecan 
(BAN, INN); 
Irinotecan HCl 
(FDA, JAN, 
USAN); 
CCc1c2CN3C (=O)C4=C (C=C3c2nc5ccc (OC 
(=O)N6CCC (CC6)N7CCCCC7)cc15)[C@@] (O) 
(CC)C (=O)OC4 
22 CHEMBL24828 Vandetanib 
(BAN, FDA, 
INN, USAN); 
COc1cc2c (Nc3ccc (Br)cc3F)ncnc2cc1OCC4CCN 
(C)CC4 
23 CHEMBL409 Bicalutamide 
(BAN, FDA, 
INN, USAN); 
CC (O) (CS (=O) (=O)c1ccc (F)cc1)C (=O)Nc2ccc 
(C#N)c (c2)C (F) (F)F 
24 CHEMBL514 Lomustine 
(BAN, FDA, 
INN, USAN); 
ClCCN (N=O)C (=O)NC1CCCCC1 
25 CHEMBL178 Daunorubicin 
(BAN, INN); 
Daunorubicin 
Citrate (FDA); 
Daunorubicin 
HCl (FDA, 
JAN, USAN, 
USP); 
COc1cccc2C (=O)c3c (O)c4C[C@] (O) (C[C@H] 
(O[C@H]5C[C@H] (N)[C@H] (O)[C@H] 
(C)O5)c4c (O)c3C (=O)c12)C (=O)C 
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26 CHEMBL1750 Clofarabine 
(BAN, FDA, 
INN, USAN); 
Nc1nc (Cl)nc2c1ncn2[C@@H]3O[C@H] 
(CO)[C@@H] (O)[C@@H]3F 
27 CHEMBL2105717 Cabozantinib 
(INN, USAN); 
Cabozantinib S-
Malate (FDA, 
USAN); 
COc1cc2nccc (Oc3ccc (NC (=O)C4 (CC4)C 
(=O)Nc5ccc (F)cc5)cc3)c2cc1OC 
28 CHEMBL1554 Dactinomycin 
(BAN, FDA, 
INN, USAN, 
USP); 
Actinomycin D 
(JAN); 
CC (C)[C@H]1NC (=O)[C@@H] (NC (=O)C2=C 
(N)C (=O)C (=C3Oc4c (C)ccc (C 
(=O)N[C@H]5[C@@H] (C)OC (=O)[C@H] (C 
(C)C)N (C)C (=O)CN (C)C 
(=O)[C@@H]6CCCN6C (=O)[C@H] (NC5=O)C 
(C)C)c4N=C23)C)[C@@H] (C)OC (=O)[C@H] (C 
(C)C)N (C)C (=O)CN (C)C 
(=O)[C@@H]7CCCN7C1=O 
29 CHEMBL1743062 Ramucirumab 
(FDA, INN, 
USAN); 
 
30 CHEMBL803 Cytarabine 
(BAN, FDA, 
INN, JAN, 
USAN, USP); 
Cytarabine HCl 
(USAN); 
NC1=NC (=O)N (C=C1)[C@@H]2O[C@H] 
(CO)[C@@H] (O)[C@@H]2O 
31 CHEMBL88 Cyclophospham
ide (BAN, JAN, 
USP, BAN, 
FDA, INN, 
JAN, USP); 
ClCCN (CCCl)P1 (=O)NCCCO1 
32 CHEMBL476 Dacarbazine 
(BAN, FDA, 
INN, JAN, 
USAN, USP); 
CN (C)N=Nc1[nH]cnc1C (=O)N 
33 CHEMBL1201129 Decitabine 
(BAN, FDA, 
INN, USAN); 
NC1=NC (=O)N (C=N1)[C@H]2C[C@H] 
(O)[C@@H] (CO)O2 
35 CHEMBL1201302 Dexamethasone 
Sodium 
Phosphate 
(BAN, FDA, 
JAN, USP); 
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC 
(=O)C=C[C@]4 (C)[C@@]3 (F)[C@@H] 
(O)C[C@]2 (C)[C@@]1 (O)C (=O)COP (=O) (O)O 
39 CHEMBL92 Docetaxel 
(BAN, FDA, 
INN, USAN); 
CC (=O)O[C@@]12CO[C@@H]1C[C@H] 
(O)[C@]3 (C)[C@@H]2[C@H] (OC 
(=O)c4ccccc4)[C@]5 (O)C[C@H] (OC 
(=O)[C@H] (O)[C@@H] (NC (=O)OC (C) 
(C)C)c6ccccc6)C (=C ([C@@H] (O)C3=O)C5 
(C)C)C 
40 CHEMBL53463 Doxorubicin 
(BAN, INN, 
USAN); 
Doxorubicin 
HCl (FDA, 
JAN, USP); 
COc1cccc2C (=O)c3c (O)c4C[C@] (O) (C[C@H] 
(O[C@H]5C[C@H] (N)[C@H] (O)[C@H] 
(C)O5)c4c (O)c3C (=O)c12)C (=O)CO 
41 CHEMBL467 Hydroxycarbam
ide (INN); 
Hydroxyurea 
NC (=O)NO 
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(BAN, FDA, 
USAN, USP); 
42 CHEMBL1201199 Leuprolide 
Acetate (FDA, 
USAN); 
Leuprorelin 
(BAN, INN); 
CCNC (=O)[C@@H]1CCCN1C (=O)[C@H] 
(CCCNC (=N)N)NC (=O)[C@H] (CC (C)C)NC 
(=O)[C@@H] (CC (C)C)NC (=O)[C@H] (Cc2ccc 
(O)cc2)NC (=O)[C@H] (CO)NC (=O)[C@H] 
(Cc3c[nH]c4ccccc34)NC (=O)[C@H] 
(Cc5c[nH]cn5)NC (=O)[C@@H]6CCC (=O)N6 
43 CHEMBL417 Epirubicin 
(BAN, INN); 
Epirubicin HCl 
(FDA, JAN, 
USAN); 
COc1cccc2C (=O)c3c (O)c4C[C@] (O) (C[C@H] 
(O[C@H]5C[C@H] (N)[C@@H] (O)[C@H] 
(C)O5)c4c (O)c3C (=O)c12)C (=O)CO 
44 CHEMBL414804 Oxaliplatin 
(BAN, FDA, 
INN, USAN); 
 
45 CHEMBL2108989 Asparaginase 
(FDA, USAN); 
Colaspase 
(BAN); L-
Asparaginase 
(JAN); 
 
46 CHEMBL1575 Estramustine 
(BAN, INN, 
USAN); 
C[C@]12CC[C@H]3[C@@H] (CCc4cc (OC 
(=O)N 
(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2O 
47 CHEMBL1201577 Cetuximab 
(FDA, INN, 
USAN); 
 
48 CHEMBL473417 Vismodegib 
(FDA, INN, 
USAN); 
CS (=O) (=O)c1ccc (C (=O)Nc2ccc (Cl)c 
(c2)c3ccccn3)c (Cl)c1 
49 CHEMBL1863514 Asparaginase 
Erwinia 
Chrysanthemi 
(FDA, USAN); 
 
50 CHEMBL1006 Amifostine 
(BAN, FDA, 
INN, USAN, 
USP); 
NCCCNCCSP (=O) (O)O 
51 CHEMBL44657 Etoposide 
(BAN, FDA, 
INN, JAN, 
USAN, USP); 
COc1cc (cc (OC)c1O)[C@H]2[C@@H]3[C@H] 
(COC3=O)[C@H] 
(O[C@@H]4O[C@@H]5CO[C@@H] 
(C)O[C@H]5[C@H] 
(O)[C@H]4O)c6cc7OCOc7cc26 
52 CHEMBL806 Flutamide 
(BAN, FDA, 
INN, USAN, 
USP); 
CC (C)C (=O)Nc1ccc (c (c1)C (F) (F)F)[N+] 
(=O)[O-] 
53 CHEMBL917 Floxuridine 
(FDA, INN, 
USAN, USP); 
OC[C@H]1O[C@H] (C[C@@H]1O)N2C=C (F)C 
(=O)NC2=O 
54 CHEMBL1655 Toremifene 
Citrate (FDA, 
USAN); 
Toremifene 
(BAN, INN); 
CN (C)CCOc1ccc (cc1)\C (=C 
(\CCCl)/c2ccccc2)\c3ccccc3 
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55 CHEMBL1358 Fulvestrant 
(BAN, FDA, 
INN, USAN); 
C[C@]12CC[C@H]3[C@@H] ([C@H] 
(CCCCCCCCC[S+] ([O-])CCCC (F) (F)C (F) 
(F)F)Cc4cc (O)ccc34)[C@@H]1CC[C@@H]2O 
56 CHEMBL1444 Letrozole 
(BAN, FDA, 
INN, USAN, 
USP); 
N#Cc1ccc (cc1)C (c2ccc (cc2)C#N)n3cncn3 
57 CHEMBL415606 Degarelix (INN, 
USAN); 
Degarelix 
Acetate (FDA, 
USAN); 
CC (C)C[C@H] (NC (=O)[C@@H] (Cc1ccc (NC 
(=O)N)cc1)NC (=O)[C@H] (Cc2ccc (NC 
(=O)[C@@H]3CC (=O)NC (=O)N3)cc2)NC 
(=O)[C@H] (CO)NC (=O)[C@@H] 
(Cc4cccnc4)NC (=O)[C@@H] (Cc5ccc (Cl)cc5)NC 
(=O)[C@@H] (Cc6ccc7ccccc7c6)NC (=O)C)C 
(=O)N[C@@H] (CCCCNC (C)C)C 
(=O)N8CCC[C@H]8C (=O)N[C@H] (C)C (=O)N 
58 CHEMBL1096882 Fludarabine 
(INN); 
Fludarabine 
Phosphate 
(BAN, FDA, 
USAN, USP); 
Nc1nc (F)nc2c1ncn2[C@@H]3O[C@H] (COP 
(=O) (O)O)[C@@H] (O)[C@@H]3O 
60 CHEMBL1201746 Pralatrexate 
(FDA, INN, 
USAN); 
Nc1nc (N)c2nc (CC (CC#C)c3ccc (cc3)C 
(=O)N[C@@H] (CCC (=O)O)C (=O)O)cnc2n1 
61 CHEMBL1743048 Obinutuzumab 
(INN, USAN); 
 
62 CHEMBL888 Gemcitabine 
HCl (FDA, 
USAN, USP); 
Gemcitabine 
(BAN, INN, 
USAN); 
NC1=NC (=O)N (C=C1)[C@@H]2O[C@H] 
(CO)[C@@H] (O)C2 (F)F 
63 CHEMBL1173655 Afatinib 
Dimaleate 
(FDA, USAN); 
Afatinib (INN, 
USAN); 
CN (C)C\C=C\C (=O)Nc1cc2c (Nc3ccc (F)c 
(Cl)c3)ncnc2cc1O[C@H]4CCOC4 
64 CHEMBL941 Imatinib 
mesylate 
(FDA); Imatinib 
(BAN, INN); 
CN1CCN (Cc2ccc (cc2)C (=O)Nc3ccc (C)c 
(Nc4nccc (n4)c5cccnc5)c3)CC1 
66 CHEMBL1683590 Eribulin 
mesylate (FDA, 
USAN); 
Eribulin (INN); 
CO[C@H]1[C@@H] (C[C@H] 
(O)CN)O[C@H]2C[C@H]3O[C@@H] 
(CC[C@@H]4O[C@@H] 
(CC[C@@]56C[C@H]7O[C@@H]8[C@@H] 
(O[C@H]9CC[C@H] (CC 
(=O)C[C@H]12)O[C@@H]9[C@@H]8O5)[C@H]
7O6)CC4=C)C[C@@H] (C)C3=C 
67 CHEMBL1201585 Trastuzumab 
(BAN, FDA, 
INN); 
 
68 CHEMBL1455 Altretamine 
(BAN, FDA, 
INN, USAN, 
USP); 
CN (C)c1nc (nc (n1)N (C)C)N (C)C 
69 CHEMBL84 Topotecan 
(BAN, INN); 
CC[C@@]1 (O)C (=O)OCC2=C1C=C3N (Cc4cc5c 
(CN (C)C)c (O)ccc5nc34)C2=O 
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Topotecan HCl 
(FDA, USAN); 
71 CHEMBL1171837 Ponatinib HCl 
(FDA, USAN); 
Ponatinib (INN, 
USAN); 
CN1CCN (Cc2ccc (NC (=O)c3ccc (C)c 
(c3)C#Cc4cnc5cccnn45)cc2C (F) (F)F)CC1 
72 CHEMBL1117 Idarubicin 
(BAN, INN); 
Idarubicin HCl 
(FDA, INN, 
USAN, USP); 
C[C@@H]1O[C@H] (C[C@H] 
(N)[C@@H]1O)O[C@H]2C[C@@] (O) (Cc3c 
(O)c4C (=O)c5ccccc5C (=O)c4c (O)c23)C (=O)C 
73 CHEMBL1024 Ifosfamide 
(BAN, FDA, 
INN, JAN, 
USAN, USP); 
ClCCNP1 (=O)OCCCN1CCCl 
74 CHEMBL1873475 Ibrutinib (FDA, 
INN, USAN); 
Nc1ncnc2c1c (nn2[C@@H]3CCCN (C3)C 
(=O)C=C)c4ccc (Oc5ccccc5)cc4 
75 CHEMBL1289926 Axitinib (FDA, 
INN, USAN); 
CNC (=O)c1ccccc1Sc2ccc3c 
(\C=C\c4ccccn4)n[nH]c3c2 
76 CHEMBL1201561 Peginterferon 
alfa-2b (BAN, 
FDA, INN); 
 
77 CHEMBL939 Gefitinib (BAN, 
FDA, INN, 
USAN); 
COc1cc2ncnc (Nc3ccc (F)c 
(Cl)c3)c2cc1OCCCN4CCOCC4 
78 CHEMBL1213490 Romidepsin 
(FDA, INN, 
USAN); 
C\C=C\1/NC (=O)[C@@H] (CS)NC (=O)[C@H] 
(CC (=O)C[C@H] (OC (=O)[C@@H] (NC1=O)C 
(C)C)\C=C\CCS)C (C)C 
79 CHEMBL1201752 Ixabepilone 
(FDA, INN, 
USAN); 
C[C@H]1CCC[C@@]2 (C)O[C@H]2C[C@H] 
(NC (=O)C[C@H] (O)C (C) (C)C (=O)[C@H] 
(C)[C@H]1O)\C (=C\c3csc (C)n3)\C 
80 CHEMBL1789941 Ruxolitinib 
Phosphate 
(FDA, USAN); 
Ruxolitinib 
(INN, USAN); 
N#CC[C@H] (C1CCCC1)n2cc 
(cn2)c3ncnc4[nH]ccc34 
81 CHEMBL1201748 Cabazitaxel 
(FDA, INN, 
USAN); 
CO[C@H]1C[C@H]2OC[C@@]2 (OC 
(=O)C)[C@H]3[C@H] (OC (=O)c4ccccc4)[C@]5 
(O)C[C@H] (OC (=O)[C@H] (O)[C@@H] (NC 
(=O)OC (C) (C)C)c6ccccc6)C (=C ([C@@H] 
(OC)C (=O)[C@]13C)C5 (C)C)C 
82 CHEMBL1743082 Ado-
Trastuzumab 
Emtansine 
(FDA); 
Trastuzumab 
Emtansine 
(INN, USAN); 
 
83 CHEMBL451887 Carfilzomib 
(FDA, INN, 
USAN); 
CC (C)C[C@H] (NC (=O)[C@H] (CCc1ccccc1)NC 
(=O)CN2CCOCC2)C (=O)N[C@@H] 
(Cc3ccccc3)C (=O)N[C@@H] (CC (C)C)C 
(=O)[C@@]4 (C)CO4 
84 CHEMBL515 Chlorambucil 
(BAN, FDA, 
INN, USP); 
OC (=O)CCCc1ccc (cc1)N (CCCl)CCCl 
85 CHEMBL1201670 Sargramostim 
(BAN, FDA, 
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INN, USAN, 
USP); 
86 CHEMBL1619 Cladribine 
(BAN, FDA, 
INN, USAN); 
Nc1nc (Cl)nc2c1ncn2[C@H]3C[C@H] 
(O)[C@@H] (CO)O3 
88 CHEMBL1670 Mitotane (FDA, 
INN, JAN, 
USAN, USP); 
ClC (Cl)C (c1ccc (Cl)cc1)c2ccccc2Cl 
89 CHEMBL90555 Vincristine 
Sulfate (FDA, 
JAN, USAN, 
USP); 
Vincristine 
(BAN, INN); 
CC[C@]1 (O)C[C@H]2CN (CCc3c 
([nH]c4ccccc34)[C@@] (C2) (C (=O)OC)c5cc6c 
(cc5OC)N (C=O)[C@H]7[C@] (O) ([C@H] (OC 
(=O)C)[C@]8 
(CC)C=CCN9CC[C@]67[C@H]89)C (=O)OC)C1 
90 CHEMBL1321 Procarbazine 
(BAN, INN); 
Procarbazine 
HCl (FDA, 
JAN, USAN, 
USP); 
CNNCc1ccc (cc1)C (=O)NC (C)C 
91 CHEMBL1201139 Megestrol 
(BAN, INN); 
Megestrol 
Acetate (FDA, 
USAN, USP); 
CC (=O)O[C@@]1 (CC[C@H]2[C@@H]3C=C 
(C)C4=CC (=O)CC[C@]4 
(C)[C@H]3CC[C@]12C)C (=O)C 
92 CHEMBL2103875 Trametinib 
(INN, USAN); 
Trametinib 
Dimethyl 
Sulfoxide 
(FDA, USAN); 
CN1C (=O)C (=C2N (C (=O)N (C3CC3)C 
(=O)C2=C1Nc4ccc (I)cc4F)c5cccc (NC 
(=O)C)c5)C 
96 CHEMBL427 Chlormethine 
(BAN, INN); 
Nitrogen 
Mustard N-
Oxide HCl 
(JAN); 
Mechlorethamin
e HCl (FDA, 
USP); 
CN (CCCl)CCCl 
97 CHEMBL105 Mitomycin 
(BAN, FDA, 
INN, USAN, 
USP); 
Mitomycin C 
(JAN); 
CO[C@]12[C@H]3N[C@H]3CN1C4=C 
([C@H]2COC (=O)N)C (=O)C (=C (C)C4=O)N 
98 CHEMBL820 Busulfan (BAN, 
FDA, INN, 
JAN, USP); 
CS (=O) (=O)OCCCCOS (=O) (=O)C 
99 CHEMBL1201506 Gemtuzumab 
Ozogamicin 
(FDA, INN, 
USAN); 
 
100 CHEMBL553025 Vinorelbine 
(BAN, INN); 
Vinorelbine 
Tartrate (FDA, 
USAN, USP); 
CCC1=C[C@@H]2CN (C1)Cc3c 
([nH]c4ccccc34)[C@@] (C2) (C (=O)OC)c5cc6c 
(cc5OC)N (C)[C@H]7[C@] (O) ([C@H] (OC 
(=O)C)[C@]8 
(CC)C=CCN9CC[C@]67[C@H]89)C (=O)OC 
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102 CHEMBL1201568 Pegfilgrastim 
(BAN, FDA, 
INN, USAN); 
 
103 CHEMBL1201567 Tbo-Filgrastim 
(FDA); 
Filgrastim 
(BAN, FDA, 
INN, USAN); 
Filgrastim-sndz 
(FDA); 
 
104 CHEMBL1336 Sorafenib (INN, 
USAN); 
Sorafenib 
Tosylate (FDA, 
USAN); 
CNC (=O)c1cc (Oc2ccc (NC (=O)Nc3ccc (Cl)c 
(c3)C (F) (F)F)cc2)ccn1 
105 CHEMBL1274 Nilutamide 
(BAN, FDA, 
INN, MI, 
USAN); 
CC1 (C)NC (=O)N (C1=O)c2ccc (c (c2)C (F) 
(F)F)[N+] (=O)[O-] 
106 CHEMBL1580 Pentostatin 
(BAN, FDA, 
INN, JAN, 
USAN); 
OC[C@H]1O[C@H] 
(C[C@@H]1O)n2cnc3[C@H] (O)CNC=Nc23 
107 CHEMBL83 Tamoxifen 
(BAN, INN); 
Tamoxifen 
citrate (FDA, 
JAN, USAN, 
USP); 
CC\C (=C (/c1ccccc1)\c2ccc (OCCN 
(C)C)cc2)\c3ccccc3 
108 CHEMBL58 Mitoxantrone 
(INN); 
Mitoxantrone 
HCl (FDA, 
JAN, USAN, 
USP); 
Mitozantrone 
(BAN); 
OCCNCCNc1ccc (NCCNCCO)c2C (=O)c3c (O)ccc 
(O)c3C (=O)c12 
109 CHEMBL2108546 Pegaspargase 
(FDA, INN, 
USAN); 
 
111 CHEMBL1201550 Denileukin 
diftitox (BAN, 
FDA, INN, 
USAN); 
 
113 CHEMBL705 Alitretinoin 
(BAN, FDA, 
INN, USAN); 
C\C (=C\C=C\C (=C\C (=O)O)\C)\C=C\C1=C 
(C)CCCC1 (C)C 
115 CHEMBL2007641 Pertuzumab 
(BAN, FDA, 
INN, USAN); 
 
116 CHEMBL11359 Cisplatin (BAN, 
FDA, INN, 
JAN, USAN, 
USP); 
 
118 CHEMBL43452 Pomalidomide 
(FDA, INN, 
USAN); 
Nc1cccc2C (=O)N (C3CCC (=O)NC3=O)C 
(=O)c12 
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119 CHEMBL635 Prednisone 
(BAN, FDA, 
INN, USP); 
C[C@]12CC (=O)[C@H]3[C@@H] (CCC4=CC 
(=O)C=C[C@]34C)[C@@H]1CC[C@]2 (O)C 
(=O)CO 
120 CHEMBL1201438 Aldesleukin 
(BAN, FDA, 
INN, USAN); 
 
121 CHEMBL1425 Mercaptopurine 
(BAN, JAN, 
USP, BAN, 
FDA, INN, 
JAN, USP); 
Sc1ncnc2nc[nH]c12 
122 CHEMBL924 Zoledronate 
Trisodium 
(USAN); 
Zoledronate 
Disodium 
(USAN); 
Zoledronic acid 
(BAN, FDA, 
INN, USAN); 
OC (Cn1ccnc1) (P (=O) (O)O)P (=O) (O)O 
123 CHEMBL848 Lenalidomide 
(BAN, FDA, 
INN, USAN); 
Nc1cccc2C (=O)N (Cc12)C3CCC (=O)NC3=O 
125 CHEMBL1201576 Rituximab 
(BAN, FDA, 
INN, USAN); 
 
126 CHEMBL2108508 Interferon Alfa-
2A (BAN, FDA, 
INN, USAN); 
Interferon Alfa-
2A (Genetical 
Recombination) 
(JAN); 
 
128 CHEMBL1680 Octreotide 
Pamoate 
(USAN); 
Octreotide 
(BAN, INN, 
USAN); 
Octreotide 
hydrochloride 
(USAN); 
Octreotide 
Acetate (FDA, 
JAN, USAN); 
C[C@@H] (O)[C@@H] (CO)NC 
(=O)[C@@H]1CSSC[C@H] (NC (=O)[C@H] 
(N)Cc2ccccc2)C (=O)N[C@@H] (Cc3ccccc3)C 
(=O)N[C@H] (Cc4c[nH]c5ccccc45)C 
(=O)N[C@@H] (CCCCN)C (=O)N[C@@H] 
([C@@H] (C)O)C (=O)N1 
130 CHEMBL1421 Dasatinib (FDA, 
INN, USAN); 
Cc1nc (Nc2ncc (s2)C (=O)Nc3c (C)cccc3Cl)cc 
(n1)N4CCN (CCO)CC4 
132 CHEMBL1946170 Regorafenib 
(FDA, INN, 
USAN); 
CNC (=O)c1cc (Oc2ccc (NC (=O)Nc3ccc (Cl)c 
(c3)C (F) (F)F)c (F)c2)ccn1 
133 CHEMBL1201255 Histrelin 
Acetate (FDA); 
Histrelin (INN, 
USAN); 
CCNC (=O)[C@@H]1CCCN1C (=O)[C@H] 
(CCCNC (=N)N)NC (=O)[C@H] (CC (C)C)NC 
(=O)[C@@H] (Cc2cn (Cc3ccccc3)cn2)NC 
(=O)[C@H] (Cc4ccc (O)cc4)NC (=O)[C@H] 
(CO)NC (=O)[C@H] (Cc5c[nH]c6ccccc56)NC 
(=O)[C@H] (Cc7cnc[nH]7)NC 
(=O)[C@@H]8CCC (=O)N8 
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134 CHEMBL535 Sunitinib (INN); 
Sunitinib Malate 
(FDA); 
CCN (CC)CCNC (=O)c1c (C)[nH]c (\C=C\2/C 
(=O)Nc3ccc (F)cc23)c1C 
136 CHEMBL1743070 Siltuximab 
(FDA, INN, 
USAN); 
 
137 CHEMBL46286 Omacetaxine 
Mepesuccinate 
(FDA, INN, 
USAN); 
COC (=O)C[C@] (O) (CCCC (C) (C)O)C 
(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN5CCC
[C@]25C=C1OC 
139 CHEMBL727 Thioguanine 
(FDA, USAN, 
USP); 
Tioguanine 
(BAN, INN); 
NC1=Nc2[nH]cnc2C (=S)N1 
140 CHEMBL2028663 Dabrafenib 
Mesylate (FDA, 
USAN); 
Dabrafenib 
(INN, USAN); 
CC (C) (C)c1nc (c2cccc (NS (=O) (=O)c3c 
(F)cccc3F)c2F)c (s1)c4ccnc (N)n4 
141 CHEMBL553 Erlotinib HCl 
(FDA, INN, 
USAN); 
Erlotinib (INN); 
COCCOc1cc2ncnc (Nc3cccc 
(c3)C#C)c2cc1OCCOC 
142 CHEMBL1023 Bexarotene 
(BAN, FDA, 
INN, USAN); 
Cc1cc2c (cc1C (=C)c3ccc (cc3)C (=O)O)C (C) 
(C)CCC2 (C)C 
143 CHEMBL255863 Nilotinib (INN, 
USAN); 
Nilotinib 
Hydrochloride 
Monohydrate 
(FDA); 
Cc1cn (cn1)c2cc (NC (=O)c3ccc (C)c (Nc4nccc 
(n4)c5cccnc5)c3)cc (c2)C (F) (F)F 
146 CHEMBL810 Temozolomide 
(BAN, FDA, 
INN, USAN); 
CN1N=Nc2c (ncn2C1=O)C (=O)N 
147 CHEMBL671 Thiotepa (BAN, 
FDA, INN, 
JAN, USP); 
S=P (N1CC1) (N2CC2)N3CC3 
148 CHEMBL468 Thalidomide 
(BAN, FDA, 
INN, USAN, 
USP); 
O=C1CCC (N2C (=O)c3ccccc3C2=O)C (=O)N1 
152 CHEMBL1201182 Temsirolimus 
(FDA, INN, 
USAN); 
CO[C@@H]1C[C@H] (C[C@@H] 
(C)[C@@H]2CC (=O)[C@H] (C)\C=C 
(/C)\[C@@H] (O)[C@@H] (OC)C (=O)[C@H] 
(C)C[C@H] (C)\C=C\C=C\C=C (/C)\[C@H] 
(C[C@@H]3CC[C@@H] (C)[C@@] (O) (O3)C 
(=O)C (=O)N4CCCC[C@H]4C 
(=O)O2)OC)CC[C@H]1OC (=O)C (C) (CO)CO 
153 CHEMBL487253 Bendamustine 
HCl (FDA, 
USAN); 
Bendamustine 
(INN); 
Cn1c (CCCC (=O)O)nc2cc (ccc12)N (CCCl)CCCl 
154 CHEMBL1201334 Triptorelin 
(BAN, INN, 
USAN); 
CC (C)C[C@H] (NC (=O)[C@@H] 
(Cc1c[nH]c2ccccc12)NC (=O)[C@H] (Cc3ccc 
(O)cc3)NC (=O)[C@H] (CO)NC (=O)[C@H] 
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Triptorelin 
Pamoate (FDA, 
USAN); 
(Cc4c[nH]c5ccccc45)NC (=O)[C@H] 
(Cc6c[nH]cn6)NC (=O)[C@@H]7CCC (=O)N7)C 
(=O)N[C@@H] (CCCNC (=N)N)C 
(=O)N8CCC[C@H]8C (=O)NCC (=O)N 
156 CHEMBL462019 Trofosfamide 
(INN, MI); 
ClCCN (CCCl)P1 (=O)OCCCN1CCCl 
157 CHEMBL1200978 Arsenic 
Trioxide (FDA, 
JAN, USAN); 
O=[As]O[As]=O 
158 CHEMBL554 Lapatinib 
(INN); 
Lapatinib 
Ditosylate 
(FDA, USAN); 
CS (=O) (=O)CCNCc1oc (cc1)c2ccc3ncnc (Nc4ccc 
(OCc5cccc (F)c5)c (Cl)c4)c3c2 
159 CHEMBL1096885 Valrubicin 
(FDA, INN, 
USAN, USP); 
CCCCC (=O)OCC (=O)[C@@]1 (O)C[C@H] 
(O[C@H]2C[C@H] (NC (=O)C (F) (F)F)[C@H] 
(O)[C@H] (C)O2)c3c (O)c4C (=O)c5c (OC)cccc5C 
(=O)c4c (O)c3C1 
161 CHEMBL1201827 Panitumumab 
(FDA, INN, 
USAN); 
 
162 CHEMBL159 Vinblastine 
Sulfate (FDA, 
JAN, USAN, 
USP); 
Vinblastine 
(BAN, INN); 
CC[C@]1 (O)C[C@@H]2CN (CCc3c 
([nH]c4ccccc34)[C@@] (C2) (C (=O)OC)c5cc6c 
(cc5OC)N (C)[C@H]7[C@] (O) ([C@H] (OC 
(=O)C)[C@]8 
(CC)C=CCN9CC[C@]67[C@H]89)C (=O)OC)C1 
163 CHEMBL325041 Bortezomib 
(BAN, FDA, 
INN, USAN); 
CC (C)C[C@H] (NC (=O)[C@H] (Cc1ccccc1)NC 
(=O)c2cnccn2)B (O)O 
165 CHEMBL38 Tretinoin (BAN, 
FDA, INN, 
USAN, USP); 
C\C (=C/C=C/C (=C/C (=O)O)/C)\C=C\C1=C 
(C)CCCC1 (C)C 
166 CHEMBL1489 Azacitidine 
(FDA, INN, 
USAN); 
NC1=NC (=O)N (C=N1)[C@@H]2O[C@H] 
(CO)[C@@H] (O)[C@H]2O 
169 CHEMBL477772 Pazopanib HCl 
(FDA, USAN); 
Pazopanib 
(INN); 
CN (c1ccc2c (C)n (C)nc2c1)c3ccnc (Nc4ccc (C)c 
(c4)S (=O) (=O)N)n3 
170 CHEMBL452231 Teniposide 
(BAN, FDA, 
INN, USAN); 
COc1cc (cc (OC)c1O)[C@H]2[C@@H]3[C@H] 
(COC3=O)[C@H] 
(O[C@@H]4O[C@@H]5CO[C@H] 
(O[C@H]5[C@H] 
(O)[C@H]4O)c6cccs6)c7cc8OCOc8cc27 
171 CHEMBL1908841 Levoleucovorin 
Calcium (FDA, 
USAN); 
Calcium 
Levofolinate 
(BAN, INN); 
NC1=NC (=O)C2=C (NC[C@H] (CNc3ccc (cc3)C 
(=O)N[C@@H] (CCC (=O)O)C (=O)O)N2C=O)N1 
172 CHEMBL601719 Crizotinib 
(FDA, INN, 
USAN); 
C[C@@H] (Oc1cc (cnc1N)c2cnn 
(c2)C3CCNCC3)c4c (Cl)ccc (F)c4Cl 
173 CHEMBL1773 Capecitabine 
(BAN, FDA, 
INN, USAN); 
CCCCCOC (=O)NC1=NC (=O)N 
(C=C1F)[C@@H]2O[C@H] (C)[C@@H] 
(O)[C@H]2O 
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174 CHEMBL1082407 Enzalutamide 
(FDA, INN, 
USAN); 
CNC (=O)c1ccc (cc1F)N2C (=S)N (C (=O)C2 
(C)C)c3ccc (C#N)c (c3)C (F) (F)F 
175 CHEMBL1789844 Ipilimumab 
(FDA, INN, 
USAN); 
 
176 CHEMBL1742982 Ziv-Aflibercept 
(FDA); 
Aflibercept 
(FDA, INN, 
USAN); 
 
177 CHEMBL1651906 Streptozocin 
(FDA, INN, 
USAN); 
CN (N=O)C (=O)N[C@H]1C (O)O[C@H] 
(CO)[C@@H] (O)[C@@H]1O 
178 CHEMBL1229517 Vemurafenib 
(FDA, INN, 
USAN); 
CCCS (=O) (=O)Nc1ccc (F)c (C (=O)c2c[nH]c3ncc 
(cc23)c4ccc (Cl)cc4)c1F 
179 CHEMBL1201606 Ibritumomab 
tiuxetan (BAN, 
INN, USAN); 
 
180 CHEMBL1201247 Goserelin 
(BAN, INN, 
USAN); 
Goserelin 
Acetate (FDA, 
JAN, JAN); 
CC (C)C[C@H] (NC (=O)[C@@H] (COC (C) 
(C)C)NC (=O)[C@H] (Cc1ccc (O)cc1)NC 
(=O)[C@H] (CO)NC (=O)[C@H] 
(Cc2c[nH]c3ccccc23)NC (=O)[C@H] 
(Cc4cnc[nH]4)NC (=O)[C@@H]5CCC (=O)N5)C 
(=O)N[C@@H] (CCCNC (=N)N)C 
(=O)N6CCC[C@H]6C (=O)NNC (=O)N 
181 CHEMBL98 Vorinostat 
(FDA, INN, 
USAN); 
ONC (=O)CCCCCCC (=O)Nc1ccccc1 
184 CHEMBL2403108 Ceritinib (FDA, 
INN, USAN); 
CC (C)Oc1cc (C2CCNCC2)c (C)cc1Nc3ncc (Cl)c 
(Nc4ccccc4S (=O) (=O)C (C)C)n3 
185 CHEMBL254328 Abiraterone 
(BAN, INN); 
C[C@]12CC[C@H]3[C@@H] (CC=C4C[C@@H] 
(O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5 
 
 
Supplementary Table 2 The predicted and experimental targets for both the AfroCancer and NCI Cancer 
datasets. Targets in bold are shared between both datasets 
AfroCancer predicted target NCI Cancer experimental target 
Bile acid receptor  Bile acid receptor FXR 
Carbonic anhydrase I Carbonic anhydrase I 
Carbonic anhydrase II Carbonic anhydrase II 
Carbonic anhydrase VII Carbonic anhydrase VII 
Carbonic anhydrase XII Carbonic anhydrase XII 
DNA topoisomerase I  DNA topoisomerase I 
DNA topoisomerase II alpha  DNA topoisomerase II alpha 
Estrogen receptor alpha Estrogen receptor alpha 
Estrogen receptor beta  Estrogen receptor beta 
Glucocorticoid receptor  Glucocorticoid receptor 
Receptor-type tyrosine-protein kinase FLT3  Receptor-type tyrosine-protein kinase FLT3  
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Retinoic acid receptor beta  Retinoic acid receptor beta 
Retinoic acid receptor gamma  Retinoic acid receptor gamma 
Steroid 17-alpha-hydroxylase/17,20 lyase  Steroid 17-alpha-hydroxylase/17,20 lyase  
1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase gamma-1  
Acetylcholinesterase 
15-hydroxyprostaglandin dehydrogenase [NAD Adenosine A2a receptor 
3-hydroxyacyl-CoA dehydrogenase type-2  Adenosine deaminase 
3-oxo-5-alpha-steroid 4-dehydrogenase 1  ALK tyrosine kinase receptor 
3-oxo-5-alpha-steroid 4-dehydrogenase 2  Androgen Receptor 
5'-AMP-activated protein kinase catalytic 
subunit alpha-2  
Beta-1 adrenergic receptor 
7-dehydrocholesterol reductase  Beta-3 adrenergic receptor 
Acid ceramidase  Carbonic anhydrase IV 
Aldehyde dehydrogenase, mitochondrial  Cholecystokinin A receptor 
Aldo-keto reductase family 1 member B10  Cytochrome P450 11B1 
Aldose reductase  Cytochrome P450 19A1 
Alkaline phosphatase, placental-like  Dihydrofolate reductase 
Alkaline phosphatase, tissue-nonspecific isozyme  Discoidin domain-containing receptor 2 
Amine oxidase [flavin-containing] A  Dopamine D1 receptor 
Amyloid beta A4 protein  Dopamine D2 receptor 
Apoptosis regulator Bcl-2 Dopamine D3 receptor 
Arachidonate 12-lipoxygenase, 12S-type  Dopamine transporter 
Arachidonate 15-lipoxygenase  Dual specificity mitogen-activated protein kinase 
kinase 1 
Arachidonate 5-lipoxygenase  Dual specificity mitogen-activated protein kinase 
kinase 2 
Aryl hydrocarbon receptor  Ephrin type-A receptor 2 
ATP-binding cassette sub-family G member 2  Epidermal growth factor receptor erbB1 
ATP-dependent DNA helicase Q1  Farnesyl diphosphate synthase 
ATPase family AAA domain-containing protein 
5  
Fibroblast growth factor receptor 1 
Beta-glucuronidase  Fibroblast growth factor receptor 2 
Bloom syndrome protein  Fibroblast growth factor receptor 3 
Carbonic anhydrase 13  Glutathione reductase 
Carbonic anhydrase 14  Gonadotropin-releasing hormone receptor 
Carbonic anhydrase 3  Growth hormone-releasing hormone receptor 
Carbonic anhydrase 5A, mitochondrial  Hepatocyte growth factor receptor 
Carbonic anhydrase 5B, mitochondrial  HERG 
Carbonic anhydrase 6  Histamine H2 receptor 
Carbonic anhydrase 9  Histone deacetylase 1 
Carbonyl reductase [NADPH] 1  Histone deacetylase 2 
Casein kinase II subunit beta  Histone deacetylase 3 
Catechol O-methyltransferase  Histone deacetylase 6 
Cocaine esterase  Insulin receptor 
Corticosteroid 11-beta-dehydrogenase isozyme 2  Insulin-like growth factor I receptor 
Cyclin-dependent kinase 14  Kappa opioid receptor 
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Cyclin-dependent kinase 5 activator 1  Macrophage colony stimulating factor receptor 
Cyclin-dependent kinase 6  MAP kinase p38 beta 
Cytochrome P450 1A1  Matrix metalloproteinase-1 
Cytochrome P450 1B1  Mineralocorticoid receptor 
Cytosolic phospholipase A2  Mu opioid receptor 
D-amino-acid oxidase  Muscarinic acetylcholine receptor M1 
DNA polymerase beta  Muscarinic acetylcholine receptor M2 
DNA polymerase eta  Muscarinic acetylcholine receptor M3 
DNA polymerase iota  Neurokinin 1 receptor 
DNA polymerase kappa  Norepinephrine transporter 
DNA- (apurinic or apyrimidinic site) lyase  Platelet-derived growth factor receptor beta 
Dual specificity protein kinase CLK1  Progesterone receptor 
Dual specificity protein kinase CLK3  Receptor protein-tyrosine kinase erbB-2 
Dual specificity tyrosine-phosphorylation-
regulated kinase 2  
Receptor protein-tyrosine kinase erbB-4 
Estradiol 17-beta-dehydrogenase 1  Serine/threonine-protein kinase B-raf 
Estradiol 17-beta-dehydrogenase 2  Serine/threonine-protein kinase RAF 
Flap endonuclease 1  Serotonin 1a (5-HT1a) receptor 
G-protein coupled bile acid receptor 1  Serotonin 2a (5-HT2a) receptor 
G-protein coupled receptor 35  Serotonin 2b (5-HT2b) receptor 
G2/mitotic-specific cyclin-B2 Serotonin 2c (5-HT2c) receptor 
G2/mitotic-specific cyclin-B3 Serotonin transporter 
Galactokinase  Sigma opioid receptor 
Gamma-aminobutyric acid receptor subunit 
beta-1  
Smoothened homolog 
Glutaminase kidney isoform, mitochondrial  Somatostatin receptor 1 
Heat shock 70 kDa protein 1A  Somatostatin receptor 2 
Heat shock protein beta-1  Somatostatin receptor 3 
Heat shock protein HSP 90-alpha  Somatostatin receptor 5 
Heat shock protein HSP 90-beta  Stem cell growth factor receptor 
Hydroxycarboxylic acid receptor 2  Thymidylate synthase 
Induced myeloid leukemia cell differentiation 
protein Mcl-1  
Thyroid stimulating hormone receptor 
Interleukin-2  Tyrosine-protein kinase ABL 
Intestinal-type alkaline phosphatase  Tyrosine-protein kinase BRK 
L-lactate dehydrogenase A chain  Tyrosine-protein kinase BTK 
Lactoylglutathione lyase  Tyrosine-protein kinase FRK 
Lethal (3)malignant brain tumor-like protein 1  Tyrosine-protein kinase HCK 
Lysine-specific demethylase 4E  Tyrosine-protein kinase ITK/TSK 
Lysosomal alpha-glucosidase  Tyrosine-protein kinase JAK1 
Macrophage migration inhibitory factor  Tyrosine-protein kinase JAK2 
Major prion protein  Tyrosine-protein kinase LCK 
Maltase-glucoamylase, intestinal  Tyrosine-protein kinase Lyn 
Microtubule-associated protein tau  Tyrosine-protein kinase receptor RET 
Mitogen-activated protein kinase 3  Tyrosine-protein kinase SRC 
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Multidrug resistance protein 1  Tyrosine-protein kinase TIE-2 
Multidrug resistance-associated protein 1  Vascular endothelial growth factor receptor 2 
NAD (P)H dehydrogenase [quinone] 1   
NADPH oxidase 4   
NF-kappa-B inhibitor alpha   
Nuclear factor erythroid 2-related factor 2   
Oxoeicosanoid receptor 1   
P-selectin   
P2X purinoceptor 1   
Peroxisome proliferator-activated receptor 
gamma  
 
PH domain leucine-rich repeat-containing 
protein phosphatase 2  
 
Poly (ADP-ribose) glycohydrolase   
Potassium voltage-gated channel subfamily A 
member 3  
 
Prostaglandin G/H synthase 1   
Receptor tyrosine-protein kinase erbB-3   
Retinoic acid receptor alpha   
Ribosyldihydronicotinamide dehydrogenase 
[quinone]  
 
Sex hormone-binding globulin   
Sodium/glucose cotransporter 1  
Sodium/glucose cotransporter 2   
Solute carrier family 22 member 3   
Squalene monooxygenase   
Steroid hormone receptor ERR1   
Steroid hormone receptor ERR2   
Tankyrase-1   
Tankyrase-2   
Telomerase reverse transcriptase   
Testosterone 17-beta-dehydrogenase 3   
Thioredoxin reductase 2, mitochondrial   
Thyroid hormone receptor beta   
Transcription factor p65   
Transthyretin   
Troponin C, slow skeletal and cardiac muscles   
Tubulin alpha-1A chain   
Tubulin alpha-1B chain   
Tubulin alpha-1C chain   
Tubulin alpha-3C/D chain   
Tubulin alpha-3E chain   
Tubulin alpha-4A chain   
Tubulin beta chain   
Tubulin beta-1 chain  
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Tubulin beta-2A chain   
Tubulin beta-2B chain  
Tubulin beta-3 chain   
Tubulin beta-4A chain   
Tubulin beta-4B chain   
Tubulin beta-6 chain   
Tubulin beta-8 chain  
Tumor necrosis factor   
Tumor susceptibility gene 101 protein   
Tyrosinase   
Tyrosine-protein phosphatase non-receptor type 
1  
 
Tyrosine-protein phosphatase non-receptor type 
2  
 
Xanthine dehydrogenase/oxidase   
 
 
Supplementary Table 3 Top 100 most enriched targets in the AfroCancer dataset 
 Uniprot 
 
Pref_Name Afro 
Cance
rHits 
Afro 
Cancer % 
Hits 
PubChe
m Hits 
PubChem 
% Hits 
Odds_R
atio 
Fishers 
Test p-
value 
Predi
ction 
Ratio 
P04792 Heat shock protein 
beta-1 
5 0.014 18 0 6.46E-04 6.51E-15 0.001 
Q9NPH5 NADPH oxidase 4 38 0.104 350 0 1.50E-03 6.76E-91 0.002 
P16152 Carbonyl reductase 
[NADPH] 1 
32 0.088 473 0 2.45E-03 2.12E-70 0.003 
P05091 Aldehyde 
dehydrogenase, 
mitochondrial 
1 0.003 21 0 3.81E-03 0.003995
653 
0.004 
Q16678 Cytochrome P450 1B1 21 0.058 437 0 3.57E-03 1.38E-43 0.004 
P60568 Interleukin-2 1 0.003 26 0 4.72E-03 0.004901
533 
0.005 
Q9NNW7 Thioredoxin reductase 
2, mitochondrial 
1 0.003 33 0 5.99E-03 0.006168
385 
0.006 
P33527 Multidrug resistance-
associated protein 1 
37 0.102 1790 0.001 7.92E-03 1.15E-62 0.009 
O95718 Steroid hormone 
receptor ERR2 
8 0.022 419 0 9.32E-03 2.67E-14 0.01 
P22001 Potassium voltage-
gated channel 
subfamily A member 3 
6 0.016 318 0 9.49E-03 5.09E-11 0.01 
Q14534 Squalene 
monooxygenase 
3 0.008 162 0 9.75E-03 4.30E-06 0.01 
P04798 Cytochrome P450 1A1 1 0.003 61 0 1.11E-02 0.011219
729 
0.011 
P0DMV8 Heat shock 70 kDa 
protein 1A 
1 0.003 63 0 1.14E-02 0.011579
558 
0.011 
P37058 Testosterone 17-beta-
dehydrogenase 3 
11 0.03 722 0 1.16E-02 4.22E-18 0.012 
P37059 Estradiol 17-beta-
dehydrogenase 2 
10 0.027 635 0 1.12E-02 1.02E-16 0.012 
P14061 Estradiol 17-beta-
dehydrogenase 1 
12 0.033 853 0 1.25E-02 3.24E-19 0.013 
P15559 NAD (P)H 
dehydrogenase 
27 0.074 1996 0.001 1.25E-02 3.97E-41 0.013 
P47989 Xanthine 
dehydrogenase/oxidase 
33 0.091 2343 0.001 1.18E-02 1.36E-50 0.013 
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[Includes: Xanthine 
dehydrogenase 
P08236 Beta-glucuronidase 3 0.008 234 0 1.41E-02 1.27E-05 0.014 
O95067 G2/mitotic-specific 
cyclin-B2 
6 0.016 480 0 1.43E-02 5.74E-10 0.015 
P14920 D-amino-acid oxidase 8 0.022 718 0 1.60E-02 1.83E-12 0.016 
P19174 1-phosphatidylinositol 
4,5-bisphosphate 
phosphodiesterase 
gamma-1 
21 0.058 1831 0.001 1.50E-02 8.65E-31 0.016 
P54646 5'-AMP-activated 
protein kinase catalytic 
subunit alpha-2 
19 0.052 1852 0.001 1.68E-02 4.42E-27 0.018 
Q8N1Q1 Carbonic anhydrase 13 66 0.181 6604 0.003 1.50E-02 3.36E-91 0.018 
Q9UBM7 7-dehydrocholesterol 
reductase 
6 0.016 670 0 2.00E-02 4.07E-09 0.02 
P15121 Aldose reductase 73 0.201 8866 0.004 1.77E-02 5.31E-95 0.022 
Q86W56 Poly(ADP-ribose) 
glycohydrolase 
3 0.008 365 0 2.20E-02 4.69E-05 0.022 
P10415 Apoptosis regulator 
Bcl-2 
5 0.014 640 0 2.30E-02 1.62E-07 0.023 
P46063 ATP-dependent DNA 
helicase Q1 
79 0.217 10749 0.005 1.95E-02 3.65E-99 0.025 
Q9UNQ0 ATP-binding cassette 
sub-family G member 
2 
41 0.113 5547 0.003 2.19E-02 2.05E-51 0.025 
P10696 Alkaline phosphatase, 
placental-like 
15 0.041 2174 0.001 2.53E-02 3.84E-19 0.026 
P14679 Tyrosinase 20 0.055 2836 0.001 2.44E-02 2.93E-25 0.026 
P08183 Multidrug resistance 
protein 1 
94 0.258 13754 0.007 1.99E-02 1.06E-
115 
0.027 
P80365 Corticosteroid 11-beta-
dehydrogenase 
isozyme 2 
15 0.041 2234 0.001 2.60E-02 5.72E-19 0.027 
O60218 Aldo-keto reductase 
family 1 member B10 
9 0.025 1384 0.001 2.73E-02 8.42E-12 0.028 
P04278 Sex hormone-binding 
globulin 
72 0.198 11279 0.006 2.30E-02 6.59E-86 0.029 
P11387 DNA topoisomerase 1 45 0.124 7117 0.004 2.53E-02 2.10E-53 0.029 
P13866 Sodium/glucose 
cotransporter 1 
23 0.063 3608 0.002 2.68E-02 7.13E-28 0.029 
Q96RI1 Bile acid receptor 27 0.074 4505 0.002 2.82E-02 8.35E-32 0.03 
Q8TDS5 Oxoeicosanoid 
receptor 1 
2 0.005 348 0 3.15E-02 0.001934
041 
0.032 
P11388 DNA topoisomerase 2-
alpha 
114 0.313 20434 0.01 2.26E-02 1.03E-
131 
0.033 
P16083 Ribosyldihydronicotin
amide dehydrogenase 
[quinone] 
6 0.016 1095 0.001 3.27E-02 7.19E-08 0.033 
P23280 Carbonic anhydrase 6 58 0.159 10421 0.005 2.76E-02 1.13E-65 0.033 
P07900 Heat shock protein 
HSP 90-alpha 
34 0.093 6306 0.003 3.07E-02 2.96E-38 0.034 
Q92731 Estrogen receptor beta 88 0.242 17068 0.009 2.70E-02 1.39E-97 0.035 
Q9H2K2 Tankyrase-2 9 0.025 1812 0.001 3.58E-02 8.82E-11 0.037 
O43451 Maltase-glucoamylase, 
intestinal [Includes: 
Maltase 
18 0.049 3864 0.002 3.72E-02 9.97E-20 0.039 
Q6ZVD8 PH domain leucine-
rich repeat-containing 
protein phosphatase 2 
5 0.014 1085 0.001 3.90E-02 2.10E-06 0.039 
P35218 Carbonic anhydrase 
5A, mitochondrial 
52 0.143 11420 0.006 3.45E-02 1.74E-54 0.04 
Q8WWL7 G2/mitotic-specific 
cyclin-B3 
5 0.014 1159 0.001 4.16E-02 2.88E-06 0.042 
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Q92630 Dual specificity 
tyrosine-
phosphorylation-
regulated kinase 2 
6 0.016 1370 0.001 4.09E-02 2.63E-07 0.042 
P03372 Estrogen receptor 69 0.19 16604 0.008 3.58E-02 8.29E-70 0.044 
P16050 Arachidonate 15-
lipoxygenase 
50 0.137 12163 0.006 3.84E-02 2.93E-50 0.044 
Q99714 3-hydroxyacyl-CoA 
dehydrogenase type-2 
59 0.162 14187 0.007 3.69E-02 1.34E-59 0.044 
O75751 Solute carrier family 
22 member 3 
1 0.003 248 0 4.50E-02 0.044305
221 
0.045 
O43570 Carbonic anhydrase 12 43 0.118 10869 0.005 4.08E-02 1.34E-42 0.046 
P21964 Catechol O-
methyltransferase 
8 0.022 2036 0.001 4.53E-02 6.01E-09 0.046 
Q9ULX7 Carbonic anhydrase 14 39 0.107 9912 0.005 4.15E-02 1.30E-38 0.046 
P49761 Dual specificity 
protein kinase CLK3 
4 0.011 1036 0.001 4.66E-02 4.50E-05 0.047 
O95271 Tankyrase-1 6 0.016 1585 0.001 4.73E-02 6.10E-07 0.048 
P43166 Carbonic anhydrase 7 50 0.137 13497 0.007 4.27E-02 4.29E-48 0.049 
Q8TDU6 G-protein coupled bile 
acid receptor 1 
6 0.016 1616 0.001 4.82E-02 6.82E-07 0.049 
Q9HC97 G-protein coupled 
receptor 35 
35 0.096 9609 0.005 4.54E-02 1.28E-33 0.05 
P18054 Arachidonate 12-
lipoxygenase, 12S-
type 
59 0.162 16424 0.008 4.28E-02 5.30E-56 0.051 
P31639 Sodium/glucose 
cotransporter 2 
5 0.014 1424 0.001 5.12E-02 7.74E-06 0.052 
P68371 Tubulin beta-4B chain 22 0.06 6317 0.003 4.93E-02 3.69E-21 0.052 
Q00534 Cyclin-dependent 
kinase 6 
20 0.055 5754 0.003 4.96E-02 2.45E-19 0.052 
Q3ZCM7 Tubulin beta-8 chain 32 0.088 9174 0.005 4.78E-02 2.98E-30 0.052 
Q9UNA4 DNA polymerase iota 64 0.176 18394 0.009 4.35E-02 6.04E-60 0.052 
P27695 DNA-(apurinic or 
apyrimidinic site) 
85 0.234 24806 0.012 4.12E-02 1.33E-79 0.053 
Q9UBT6 DNA polymerase 
kappa 
131 0.36 38150 0.019 3.46E-02 6.61E-
126 
0.053 
P10276 Retinoic acid receptor 
alpha 
5 0.014 1480 0.001 5.32E-02 9.30E-06 0.054 
P54132 Bloom syndrome 
protein 
84 0.231 24829 0.012 4.19E-02 3.45E-78 0.054 
Q13748 Tubulin alpha-3C/D 
chain 
30 0.082 8871 0.004 4.96E-02 4.80E-28 0.054 
P47712 Cytosolic 
phospholipase A2 
2 0.005 612 0 5.54E-02 0.005773
856 
0.056 
Q9BVA1 Tubulin beta-2B chain 32 0.088 9829 0.005 5.12E-02 2.43E-29 0.056 
Q9Y2D0 Carbonic anhydrase 
5B, mitochondrial 
33 0.091 10155 0.005 5.12E-02 3.36E-30 0.056 
P06746 DNA polymerase beta 72 0.198 22605 0.011 4.64E-02 6.22E-65 0.057 
P17706 Tyrosine-protein 
phosphatase non-
receptor type 2 
22 0.06 6832 0.003 5.33E-02 1.90E-20 0.057 
P23219 Prostaglandin G/H 
synthase 1 
20 0.055 6330 0.003 5.46E-02 1.50E-18 0.058 
P11474 Steroid hormone 
receptor ERR1 
5 0.014 1626 0.001 5.84E-02 1.46E-05 0.059 
Q16236 Nuclear factor 
erythroid 2-related 
factor 2 
12 0.033 3871 0.002 5.69E-02 1.41E-11 0.059 
P00338 L-lactate 
dehydrogenase A 
chain 
2 0.005 664 0 6.01E-02 0.006752
025 
0.06 
P13631 Retinoic acid receptor 
gamma 
5 0.014 1653 0.001 5.94E-02 1.57E-05 0.06 
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Q13509 Tubulin beta-3 chain 24 0.066 7901 0.004 5.62E-02 1.29E-21 0.06 
Q13510 Acid ceramidase 6 0.016 2018 0.001 6.03E-02 2.42E-06 0.061 
Q9BQE3 Tubulin alpha-1C 
chain 
35 0.096 11755 0.006 5.56E-02 1.04E-30 0.061 
P08238 Heat shock protein 
HSP 90-beta 
22 0.06 7497 0.004 5.85E-02 1.31E-19 0.062 
Q71U36 Tubulin alpha-1A 
chain 
35 0.096 11903 0.006 5.63E-02 1.57E-30 0.062 
Q9Y468 Lethal(3)malignant 
brain tumor-like 
protein 1 
48 0.132 16453 0.008 5.46E-02 1.90E-41 0.062 
B2RXH2 Lysine-specific 
demethylase 4E 
76 0.209 26131 0.013 5.02E-02 8.93E-66 0.063 
P68363 Tubulin alpha-1B 
chain 
20 0.055 7081 0.004 6.11E-02 1.24E-17 0.064 
Q04760 Lactoylglutathione 
lyase 
4 0.011 1410 0.001 6.35E-02 0.000146
121 
0.064 
P39748 Flap endonuclease 1 96 0.264 34065 0.017 4.84E-02 1.43E-82 0.065 
O14746 Telomerase reverse 
transcriptase 
36 0.099 13044 0.007 5.98E-02 1.92E-30 0.066 
O94921 Cyclin-dependent 
kinase 14 
1 0.003 362 0 6.57E-02 0.063930
888 
0.066 
P14174 Macrophage migration 
inhibitory factor 
29 0.08 10498 0.005 6.10E-02 9.69E-25 0.066 
P36888 Receptor-type 
tyrosine-protein kinase 
FLT3 
7 0.019 2542 0.001 6.49E-02 5.77E-07 0.066 
P00915 Carbonic anhydrase 1 27 0.074 9981 0.005 6.26E-02 6.96E-23 0.067 
P07451 Carbonic anhydrase 3 39 0.107 14977 0.007 6.29E-02 5.55E-32 0.07 
 
 
 
 
 
Supplementary Table 4 Pathways predicted for the AfroCancer and NCI Cancer datasets based 
on the predicted targets of AfroCancer compounds and experimental targets of NCI Cancer 
(Pathways in bold are common to both datasets) 
Pathway_Name NCI 
Cance
r % 
Hits 
PubC
hem 
% 
Hits 
χ 2 
p-
valu
e 
Pathway Name AfroC
ancer 
% Hits 
PubC
hem 
% 
Hits 
χ 2 
p-
valu
e 
AhR pathway 4.88E-
05 
2.96E-
05 
0.00
175
815
2 
AhR pathway 0.0001
31079 
8.48E-
05 
1.86
E-
06 
Allograft Rejection 2.38E-
06 
1.31E-
06 
0.70
695
725
7 
Allograft 
Rejection 
5.74E-
06 
5.56E-
06 
0.88
796
637
6 
BDNF signaling 
pathway 
0.0003
62852 
0.000
35788
6 
0.83
223
544
9 
Androgen 
receptor signaling 
pathway 
9.38E-
05 
7.71E-
05 
0.07
341
290
4 
Corticotropin-
releasing hormone 
0.0001
58227 
0.000
15594
2 
0.90
123
158
6 
B Cell Receptor 
Signaling 
Pathway 
0.0001
89442 
0.000
17122 
0.18
703
313
2 
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Cytoplasmic 
Ribosomal Proteins 
3.33E-
05 
3.33E-
05 
0.92
856
810
9 
BDNF signaling 
pathway 
0.0003
22434 
0.000
30010
5 
0.21
888
231
5 
Delta-Notch Signaling 
Pathway 
0.0001
17778 
8.78E-
05 
0.00
404
665
2 
Cell cycle 0.0001
14813 
8.44E-
05 
0.00
169
192
5 
Estrogen signaling 
pathway 
9.04E-
05 
6.35E-
05 
0.00
251
693
8 
Corticotropin-
releasing 
hormone 
0.0002
06664 
0.000
19251
5 
0.33
743
664
9 
Focal Adhesion 0.0003
92594 
0.000
29735
5 
4.87
E-
07 
Cytokines and 
Inflammatory 
Response 
5.74E-
06 
5.56E-
06 
0.88
796
637
6 
FSH signaling 
pathway 
9.28E-
05 
7.23E-
05 
0.03
174
451
3 
Cytoplasmic 
Ribosomal 
Proteins 
1.05E-
05 
8.55E-
06 
0.63
019
766
1 
Gastric cancer 
network 2 
1.67E-
05 
9.98E-
06 
0.07
765
154 
Delta-Notch 
Signaling 
Pathway 
0.0001
23424 
0.000
11126
7 
0.28
203
785
5 
IL-1 Signaling 
Pathway 
2.02E-
05 
1.54E-
05 
0.32
845
190
6 
Endochondral 
Ossification 
3.35E-
05 
2.22E-
05 
0.02
745
047
7 
IL-5 Signaling 
Pathway 
0.0001
82021 
0.000
17645
5 
0.73
157
457
5 
Estrogen 
metabolism 
5.36E-
05 
3.35E-
05 
0.00
125
467
4 
IL-6 Signaling 
Pathway 
0.0003
21214 
0.000
25619
7 
0.00
022
455 
Estrogen 
signaling pathway 
0.0001
08116 
0.000
10442
5 
0.76
159
597
6 
IL-7 Signaling 
Pathway 
0.0001
65366 
0.000
12839
7 
0.00
325
574
8 
Fluoropyrimidine 
Activity 
6.22E-
05 
5.56E-
05 
0.42
677
733
9 
IL17 signaling 
pathway 
6.66E-
05 
5.95E-
05 
0.44
040
790
3 
Focal Adhesion 7.56E-
05 
6.53E-
05 
0.23
728
502
3 
Integrated Pancreatic 
Cancer Pathway 
0.0004
00922 
0.000
32940
9 
0.00
034
073
3 
FSH signaling 
pathway 
7.18E-
05 
6.51E-
05 
0.45
688
853
1 
MicroRNAs in 
cardiomyocyte 
hypertrophy 
0.0002
2485 
0.000
19000
7 
0.02
274
993
8 
Gastric cancer 
network 2 
1.72E-
05 
1.65E-
05 
0.96
263
463
6 
Mitochondrial Gene 
Expression 
3.57E-
06 
7.10E-
07 
0.01
386
274
7 
Id Signaling 
Pathway 
9.76E-
05 
7.63E-
05 
0.02
119
616 
Neural Crest 
Differentiation 
0.0001
17778 
9.21E-
05 
0.01
663
IL-1 Signaling 
Pathway 
1.91E-
06 
5.99E-
07 
0.35
500
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217
2 
790
4 
Notch Signaling 
Pathway 
1.67E-
05 
9.27E-
06 
0.04
104
129
3 
IL-2 Signaling 
pathway 
0.0001
36819 
0.000
12349
7 
0.26
127
060
4 
Nuclear Receptors 0.0001
40382 
0.000
12235
6 
0.14
859
227
5 
IL-5 Signaling 
Pathway 
0.0002
09534 
0.000
19867
3 
0.47
335
703
6 
Parkin-Ubiquitin 
Proteasomal System 
pathway 
7.38E-
05 
6.27E-
05 
0.22
475
709 
IL-6 Signaling 
Pathway 
0.0002
43022 
0.000
22108 
0.15
986
689 
Pathogenic 
Escherichia coli 
infection 
0.0001
36813 
0.000
10798
8 
0.01
276
706
1 
IL-7 Signaling 
Pathway 
0.0001
1003 
1.00E-
04 
0.35
246
331
3 
RANKL/RANK 
Signaling Pathway 
0.0001
52279 
0.000
11786 
0.00
429
029
5 
IL17 signaling 
pathway 
0.0001
11943 
0.000
10040
6 
0.28
377
489
3 
RB in Cancer 0.0001
05882 
7.74E-
05 
0.00
372
552
4 
Integrated 
Pancreatic 
Cancer Pathway 
0.0006
28603 
0.000
54786
9 
0.00
084
535
4 
Regulation of 
Microtubule 
Cytoskeleton 
0.0001
57038 
0.000
12275
5 
0.00
531
743
6 
Interleukin-11 
Signaling 
Pathway 
0.0001
06202 
0.000
10314
2 
0.80
678
142
5 
Signaling of 
Hepatocyte Growth 
Factor Receptor 
0.0001
02313 
7.95E-
05 
0.02
228
826
5 
MAPK Cascade 5.74E-
05 
5.38E-
05 
0.68
060
627
4 
Signaling Pathways in 
Glioblastoma 
0.0002
85523 
0.000
19517
6 
3.88
E-
09 
MicroRNAs in 
cardiomyocyte 
hypertrophy 
0.0001
38733 
0.000
13179
3 
0.58
471
747
8 
Steroid Biosynthesis 8.33E-
06 
1.82E-
06 
6.06
E-
05 
Mitochondrial 
Gene Expression 
4.78E-
06 
2.48E-
06 
0.28
521
302
2 
TCR Signaling 
Pathway 
0.0001
91539 
0.000
16248
3 
0.04
068
637 
mRNA processing 2.20E-
05 
9.15E-
06 
0.00
015
584
6 
Androgen receptor 
signaling pathway 
0.0001
21347 
9.47E-
05 
0.01
426
924
4 
Neural Crest 
Differentiation 
8.71E-
05 
6.91E-
05 
0.04
198
447
6 
B Cell Receptor 
Signaling Pathway 
0.0003
54525 
0.000
28097
1 
6.60
E-
05 
NOD pathway 7.18E-
05 
6.05E-
05 
0.17
811
168
4 
Cell cycle 0.0001
41572 
0.000
13174
5 
0.46
091
001
5 
Notch Signaling 
Pathway 
8.61E-
06 
6.41E-
06 
0.52
276
36 
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Cytokines and 
Inflammatory 
Response 
2.38E-
06 
1.04E-
06 
0.50
718
705
4 
Nuclear 
Receptors 
0.0003
60705 
0.000
35851
8 
0.93
131
664
2 
Endochondral 
Ossification 
9.04E-
05 
7.71E-
05 
0.18
332
733
8 
Osteoblast 
Signaling 
3.83E-
06 
2.65E-
06 
0.69
885
369
1 
Estrogen metabolism 5.95E-
06 
3.52E-
06 
0.37
173
466
1 
Osteopontin 
Signaling 
0.0001
07159 
9.71E-
05 
0.34
352
365
1 
Fluoropyrimidine 
Activity 
3.21E-
05 
1.43E-
05 
3.01
E-
05 
Oxidative Stress 0.0001
25338 
7.55E-
05 
6.22
E-
08 
Id Signaling Pathway 9.87E-
05 
6.77E-
05 
0.00
068
048
4 
Parkin-Ubiquitin 
Proteasomal 
System pathway 
0.0003
53051 
0.000
2446 
3.12
E-
11 
IL-2 Signaling 
pathway 
0.0001
58227 
0.000
11841
2 
0.00
095
370
5 
Pathogenic 
Escherichia coli 
infection 
0.0003
63576 
0.000
26230
3 
1.98
E-
09 
Interleukin-11 
Signaling Pathway 
0.0001
4752 
0.000
10882
8 
0.00
081
540
7 
Prostate Cancer 0.0001
83701 
0.000
18122
6 
0.88
698
463
7 
MAPK Cascade 7.73E-
05 
5.77E-
05 
0.02
188
457
1 
RANKL/RANK 
Signaling 
Pathway 
0.0001
47344 
0.000
12965
5 
0.14
191
298
5 
mRNA processing 3.57E-
05 
3.55E-
05 
0.94
541
467
8 
RB in Cancer 7.46E-
05 
6.30E-
05 
0.17
498
760
3 
NOD pathway 4.16E-
05 
3.89E-
05 
0.74
853
797
5 
Regulation of 
Microtubule 
Cytoskeleton 
8.71E-
05 
5.64E-
05 
0.00
012
315
9 
Osteoblast Signaling 3.81E-
05 
2.38E-
05 
0.00
996
565
9 
Serotonin 
Receptor 4/6/7 
and NR3C 
Signaling 
7.65E-
05 
6.78E-
05 
0.33
191
772
1 
Osteopontin Signaling 4.64E-
05 
4.45E-
05 
0.85
636
728
3 
Signaling of 
Hepatocyte 
Growth Factor 
Receptor 
7.37E-
05 
6.82E-
05 
0.56
233
162
1 
Oxidative Stress 2.50E-
05 
2.26E-
05 
0.72
356
429
2 
Signaling 
Pathways in 
Glioblastoma 
0.0001
47344 
0.000
14359
5 
0.79
213
587
9 
Prostate Cancer 0.0001
82021 
0.000
17032
8 
0.43
565
208
6 
Steroid 
Biosynthesis 
3.54E-
05 
1.62E-
05 
1.35
E-
05 
Serotonin Receptor 
4/6/7 and NR3C 
Signaling 
7.26E-
05 
6.68E-
05 
0.55
979
TCR Signaling 
Pathway 
0.0001
36819 
0.000
13410
2 
0.85
275
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500
9 
745
2 
TNF-alpha/NF-kB 
Signaling Pathway 
0.0002
39126 
0.000
21121
6 
0.08
489
771
9 
TNF-alpha/NF-
kB Signaling 
Pathway 
0.0002
16232 
0.000
18430
5 
0.02
443
662
1 
TOR signaling 4.64E-
05 
4.57E-
05 
0.98
569
789
1 
TOR signaling 2.58E-
05 
2.45E-
05 
0.86
632
063
3 
TSH signaling 
pathway 
0.0001
61797 
0.000
12260
5 
0.00
139
743
8 
TSH signaling 
pathway 
7.75E-
05 
6.67E-
05 
0.22
115
936
2 
TWEAK Signaling 
Pathway 
9.99E-
05 
9.53E-
05 
0.70
718
973
2 
TWEAK 
Signaling 
Pathway 
0.0001
3969 
0.000
12726 
0.30
305
200
6 
Vitamin A and 
Carotenoid 
Metabolism 
2.74E-
05 
1.31E-
05 
0.00
052
379 
Adipogenesis 0.0001
9614 
0.000
18259
5 
0.34
655
635
4 
Vitamin A and 
carotenoid 
metabolism 
2.74E-
05 
1.31E-
05 
0.00
052
379 
Apoptosis 0.0001
32035 
0.000
11408
9 
0.11
233
806
1 
Alpha6-Beta4 Integrin 
Signaling Pathway 
0.0002
02246 
0.000
13936
6 
1.32
E-
06 
Apoptosis 
Modulation and 
Signaling 
0.0001
21511 
0.000
11032
6 
0.32
201
289
2 
Cardiac Progenitor 
Differentiation 
7.85E-
05 
6.57E-
05 
0.16
549
876
4 
ATM Signaling 
Pathway 
3.83E-
06 
1.80E-
06 
0.29
110
293
8 
DNA damage response 
(only ATM dependent) 
0.0001
16589 
9.63E-
05 
0.06
626
551
8 
Benzo (a)pyrene 
metabolism 
2.77E-
05 
1.76E-
05 
0.02
845
791 
DNA Replication 1.43E-
05 
9.16E-
06 
0.17
142
930
4 
Biogenic Amine 
Synthesis 
5.07E-
05 
4.80E-
05 
0.75
531
041
2 
ErbB signaling pathway 0.0001
4871 
0.000
11589
3 
0.00
607
644
9 
Codeine and 
morphine 
metabolism 
8.99E-
05 
6.28E-
05 
0.00
120
924
3 
Eukaryotic 
Transcription Initiation 
1.43E-
05 
9.66E-
06 
0.23
614
723
8 
Diurnally 
regulated genes 
with circadian 
orthologs 
2.30E-
05 
1.68E-
05 
0.18
075
684
5 
IL-9 Signaling Pathway 8.80E-
05 
6.74E-
05 
0.02
514
327
5 
DNA damage 
response 
9.09E-
05 
7.18E-
05 
0.03
410
743 
Inflammatory Response 
Pathway 
2.14E-
05 
1.06E-
05 
0.00
386
400
2 
Dopamine 
metabolism 
6.98E-
05 
5.35E-
05 
0.03
686
353
7 
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Insulin Signaling 0.0003
49766 
0.000
33471
8 
0.46
889
487
1 
Drug Induction of 
Bile Acid Pathway 
0.0001
66479 
0.000
16147 
0.72
967
349
3 
Integrin-mediated cell 
adhesion 
0.0002
17711 
0.000
17751
8 
0.00
644
098
2 
Energy 
Metabolism 
9.57E-
05 
8.99E-
05 
0.58
705
135
9 
Kit Receptor Signaling 
Pathway 
0.0002
33177 
0.000
15413
9 
6.97
E-
09 
FAS pathway and 
Stress induction of 
HSP regulation 
2.97E-
05 
2.41E-
05 
0.32
111
864
9 
MAPK signaling 
pathway 
0.0003
12886 
0.000
26372
3 
0.00
611
163
2 
Folate Metabolism 4.59E-
05 
4.43E-
05 
0.87
129
036
9 
miRNAs involved in 
DDR 
3.33E-
05 
2.70E-
05 
0.31
523
530
7 
G1 to S cell cycle 
control 
6.22E-
05 
5.56E-
05 
0.42
677
733
9 
Nifedipine Activity 2.26E-
05 
1.28E-
05 
0.01
890
822
6 
G13 Signaling 
Pathway 
2.87E-
06 
2.22E-
06 
0.93
504
249 
NLR proteins 2.26E-
05 
1.80E-
05 
0.38
456
537
2 
Glucocorticoid 
&amp; 
Mineralcorticoid 
Metabolism 
2.87E-
05 
1.68E-
05 
0.00
854
394
7 
Nucleotide Metabolism 1.07E-
05 
1.34E-
06 
3.55
E-
12 
Glycogen 
Metabolism 
6.70E-
06 
2.57E-
06 
0.03
798
366
6 
Oncostatin M Signaling 
Pathway 
0.0001
98677 
0.000
16778
1 
0.03
199
985
4 
Hedgehog 
Signaling Pathway 
2.10E-
05 
1.17E-
05 
0.01
457
435
2 
One Carbon 
Metabolism 
1.78E-
05 
1.97E-
06 
2.40
E-
23 
Influenza A virus 
infection 
4.78E-
06 
3.85E-
06 
0.83
776
983
8 
Physiological and 
Pathological 
Hypertrophy of the 
Heart 
3.81E-
05 
3.48E-
05 
0.67
804
559
5 
Irinotecan Pathway 9.19E-
05 
6.29E-
05 
0.00
055
534
7 
pilocytic astrocytoma 4.76E-
06 
3.00E-
06 
0.53
650
875
3 
Keap1-Nrf2 
Pathway 
3.64E-
05 
2.58E-
05 
0.05
777
093
6 
Proteasome 
Degradation 
9.52E-
06 
7.54E-
06 
0.64
571
576
3 
Matrix 
Metalloproteinases 
1.44E-
05 
7.95E-
06 
0.04
805
673 
Senescence and 
Autophagy 
0.0001
1302 
9.03E-
05 
0.03
306
617
8 
metapathway 
biotransformation 
0.0001
32035 
0.000
10049
1 
0.00
276
133
3 
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AGE/RAGE pathway 0.0002
30798 
0.000
21548 
0.35
785
641
9 
Nicotine Activity 
on Dopaminergic 
Neurons 
1.63E-
05 
1.49E-
05 
0.82
722
882
5 
Angiogenesis 0.0001
499 
9.47E-
05 
2.72
E-
07 
Nuclear receptors 
in lipid metabolism 
and toxicity 
0.0002
27713 
0.000
21338
3 
0.35
575
029
9 
Cholesterol 
biosynthesis 
5.95E-
06 
5.54E-
06 
0.94
105
379
3 
Ovarian Infertility 
Genes 
0.0001
3969 
0.000
12828
7 
0.34
839
192
3 
EBV LMP1 signaling 9.04E-
05 
8.14E-
05 
0.39
289
295
2 
Phase I, non P450 1.34E-
05 
1.26E-
05 
0.93
376
211
6 
EGFR1 Signaling 
Pathway 
0.0002
34367 
0.000
22075
6 
0.42
192
478
4 
Polyol pathway 6.98E-
05 
4.11E-
05 
2.83
E-
05 
EPO Receptor 
Signaling 
8.80E-
05 
6.65E-
05 
0.01
882
975
2 
Prostaglandin 
Synthesis and 
Regulation 
9.19E-
05 
7.18E-
05 
0.02
594
746
6 
Gastric cancer network 
1 
2.02E-
05 
1.34E-
05 
0.12
049
207 
Selenium 
Metabolism and 
Selenoproteins 
5.36E-
05 
5.02E-
05 
0.69
380
685
8 
Heart Development 1.19E-
05 
6.87E-
06 
0.12
107
342
5 
Selenium Pathway 0.0002
10491 
0.000
18635
8 
0.09
190
037
1 
IL-3 Signaling Pathway 0.0003
10507 
0.000
23823
1 
2.07
E-
05 
Striated Muscle 
Contraction 
8.90E-
05 
8.46E-
05 
0.68
040
746
3 
IL-4 signaling Pathway 0.0002
2247 
0.000
18678
7 
0.01
859
774
8 
TGF Beta 
Signaling Pathway 
7.27E-
05 
6.78E-
05 
0.60
402
245
4 
Integrated Breast 
Cancer Pathway 
0.0002
81954 
0.000
23868 
0.01
132
409
8 
Tryptophan 
metabolism 
4.31E-
05 
3.70E-
05 
0.37
900
390
4 
Interferon type I 9.52E-
05 
7.03E-
05 
0.00
793
504
1 
Vitamin B12 
Metabolism 
4.59E-
05 
4.42E-
05 
0.86
128
287
4 
Leptin signaling 
pathway 
0.0001
95108 
0.000
16005 
0.01
252
039 
Wnt Signaling 
Pathway NetPath 
0.0001
3969 
0.000
13350
4 
0.63
168
380
4 
Nucleotide GPCRs 2.50E-
05 
1.84E-
05 
0.19
748
477 
    
Prolactin Signaling 
Pathway 
0.0002
31988 
0.000
22040
7 
0.49
753
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557
3 
Regulation of toll-like 
receptor signaling 
pathway 
0.0001
83211 
0.000
17844 
0.77
445
960
8 
    
SRF and miRs in 
Smooth Muscle 
Differentiation and 
Proliferation 
1.07E-
05 
8.59E-
06 
0.63
338
315
4 
    
TFs Regulate miRNAs 
related to cardiac 
hypertrophy 
2.86E-
05 
2.07E-
05 
0.14
486
143
9 
    
TGF-beta Receptor 
Signaling Pathway 
0.0001
87969 
0.000
17412
2 
0.35
722
186
4 
    
Toll-like receptor 
signaling pathway 
0.0001
83211 
0.000
17844 
0.77
445
960
8 
    
TP53 network 2.38E-
05 
1.48E-
05 
0.04
612
208
7 
    
Trans-sulfuration and 
one carbon metabolism 
1.43E-
05 
1.14E-
06 
5.34
E-
27 
    
Trans-sulfuration 
pathway 
1.19E-
06 
4.30E-
07 
0.81
770
729
5 
    
TSLP Signaling 
Pathway 
0.0001
34434 
0.000
13093
3 
0.81
590
106
9 
    
Type II diabetes 
mellitus 
4.88E-
05 
3.85E-
05 
0.15
196
427 
    
Type III interferon 
signaling 
1.78E-
05 
1.59E-
05 
0.75
278
930
8 
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Supplementary Table 8 The predicted targets of the currently marketed HAT drugs at tpr > 0.9. Note that 
ornithine decarboxylase is correctly predicted for only elfornithine. 
Gene Name 
 
Pentamid
ine 
(-2.75) 
Suram
in (-
14.89) 
Nifurti
mox 
(-1.47) 
Elfornith
ine (-
0.33) 
Melarsop
rol 
Cell-division control 
protein 2 homolog 6, 
putative;Tb11.47.0031 
0 0 0 0 1 
Cell division control 
protein 2 homolog 
2;Tb927.7.7360 
0 0 0 0 1 
Cell division related 
protein kinase 2, 
putative;Tb10.70.2210 
0 0 0 0 1 
Protein kinase, 
putative;Tb10.70.1760 
0 0 0 0 1 
Serine/threonine-protein 
kinase, 
putative;Tb10.70.5890 
0 0 0 0 1 
Serine/threonine protein 
kinase, 
putative;Tb927.3.4560 
0 0 0 0 1 
Protein kinase, 
putative;Tb09.160.0570 
0 0 0 0 1 
Protein kinase, 
putative;Tb11.01.0330 
0 0 0 0 1 
Protein kinase, 
putative;Tb927.7.1900 
0 0 0 0 1 
Pteridine reductase, 
putative;Tb927.8.2210 
0 0 0 0 1 
Protein kinase, 
putative;Tb09.211.2260 
0 0 0 0 1 
Glucose 
transporter;Tb10.6k15.2
030 
1 0 0 0 0 
Glucose transporter, 
putative;Tb927.4.2290 
1 0 0 0 0 
Hexose 
transporter;Tb10.6k15.2
040 
1 0 0 0 0 
Glucose 
transporter;Tb10.6k15.2
020 
1 0 0 0 0 
Ornithine 
decarboxylase;Tb11.01.5
300 
0 0 0 1 0 
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Gene Name 
 
Pentamid
ine 
(-2.75) 
Suram
in (-
14.89) 
Nifurti
mox 
(-1.47) 
Elfornith
ine (-
0.33) 
Melarsop
rol 
Cyclin 3;Tb927.6.1460 0 0 0 0 1 
Cyclin 6;Tb11.01.8460 0 0 0 0 1 
NADPH--cytochrome 
p450 reductase, 
putative;Tb09.211.4110 
0 0 0 0 1 
NADPH--cytochrome 
P450 reductase, 
putative;Tb11.01.0170 
0 0 0 0 1 
NADPH--cytochrome 
p450 reductase, 
putative;Tb11.02.5420 
0 0 0 0 1 
NADPH--cytochrome 
p450 reductase, 
putative;Tb09.211.4110 
1 0 0 0 0 
NADPH--cytochrome 
P450 reductase, 
putative;Tb11.01.0170 
1 0 0 0 0 
NADPH--cytochrome 
p450 reductase, 
putative;Tb11.02.5420 
1 0 0 0 0 
NADPH--cytochrome 
p450 reductase, 
putative;Tb09.211.4110 
0 0 0 1 0 
NADPH--cytochrome 
P450 reductase, 
putative;Tb11.01.0170 
0 0 0 1 0 
NADPH--cytochrome 
p450 reductase, 
putative;Tb11.02.5420 
0 0 0 1 0 
Protein kinase, 
putative;Tb09.211.2260 
0 0 0 0 1 
Protein kinase, 
putative;Tb10.329.0030 
0 0 0 0 1 
Mitogen-activated 
protein 
kinase;Tb927.8.3550 
0 0 0 0 1 
Protein kinase, 
putative;Tb927.7.1900 
0 0 0 0 1 
Protein kinase, 
putative;Tb11.01.4130 
0 0 0 0 1 
Protein 
kinase;Tb11.01.1030 
0 0 0 0 1 
Rac serine-threonine 
kinase, 
putative;Tb927.6.2250 
0 0 0 0 1 
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Gene Name 
 
Pentamid
ine 
(-2.75) 
Suram
in (-
14.89) 
Nifurti
mox 
(-1.47) 
Elfornith
ine (-
0.33) 
Melarsop
rol 
Ubiquitin-conjugating 
enzyme E2, 
putative;Tb09.211.0050 
1 0 0 0 0 
Cyclin 3;Tb927.6.1460 0 0 0 0 1 
Cyclin 6;Tb11.01.8460 0 0 0 0 1 
Protein kinase, 
putative;Tb10.70.1760 
0 0 0 0 1 
Serine/threonine-protein 
kinase, 
putative;Tb10.70.5890 
0 0 0 0 1 
Serine/threonine protein 
kinase, 
putative;Tb927.3.4560 
0 0 0 0 1 
NAD-dependent protein 
deacetylase 
SIR2rp1;SIR2rp1 
1 0 0 0 0 
Protein kinase, 
putative;Tb09.160.0570 
0 0 0 0 1 
Protein kinase, 
putative;Tb11.01.0330 
0 0 0 0 1 
Protein kinase, 
putative;Tb927.7.3210 
0 0 0 0 1 
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Supplementary Table 9 Predicted targets common to 5 known drugs and compounds in SH dataset 
Gene ID Gene Name Biological Process 
Tb11.01.8460 Cyclin 6 cell cycle 
Tb11.01.4130 Protein kinase, putative biosynthetic process;cell cycle;nitrogen 
compound metabolic process;phosphate-
containing compound metabolic 
process;regulation of transcription from RNA 
polymerase II promoter;transcription 
elongation from RNA polymerase II promoter 
Tb927.4.2290 Glucose transporter,  
putative 
Tb10.6k15.2040 Hexose transporter 
Tb11.02.5420 NADPH--cytochrome p450  
reductase, putative 
Tb10.70.1760 Non-specific serine/threonine 
protein kinase 
intracellular signal transduction;phosphate-
containing compound metabolic 
process;regulation of biological 
process;response to stimulus 
Tb09.211.4110 NADPH--cytochrome p450 
 reductase, putative 
Tb10.6k15.2030 Glucose transporter 
Tb927.7.3210 Protein kinase, putative cell cycle 
Tb11.01.1030 Protein kinase  
Tb11.01.0170 NADPH--cytochrome p450  
reductase, putative 
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Gene ID Gene Name Biological Process 
Tb11.01.0330 Protein kinase, putative chromatin 
organization;cytokinesis;cytoskeleton 
organization;phosphate-containing 
compound metabolic process;regulation of 
cell cycle 
Tb927.3.4560 Non-specific serine/threonine 
protein kinase 
intracellular signal transduction;phosphate-
containing compound metabolic 
process;regulation of biological 
process;response to stimulus 
Tb927.7.1900 Protein kinase, putative biosynthetic process;cell cycle;nitrogen 
compound metabolic process;phosphate-
containing compound metabolic 
process;regulation of transcription from RNA 
polymerase II promoter 
Tb10.6k15.2020 Glucose transporter 
Tb10.70.5890 Serine/threonine-protein kinase, 
putative 
intracellular signal transduction;phosphate-
containing compound metabolic 
process;regulation of biological 
process;response to stimulus 
Tb927.6.1460 Cyclin 3 cell cycle 
 
 
 
 
Supplementary Table 10 Bioactivity values extracted from ChEMBL for the NP dataset. 
CMPD_CHE
MBLID 
PCHEMBL_
VALUE 
TARGET_CH
EMBLID 
PROTEIN_ACC
ESSION 
PREF_NAME ORGANISM 
CHEMBL624
6 
5 CHEMBL4331 P68871 Hemoglobin beta chain Homo sapiens 
CHEMBL155
3072 
5 CHEMBL12932
31 
P51450 Nuclear receptor ROR-
gamma 
Mus musculus 
CHEMBL168 5.02 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL168 5.02 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL400
074 
5.02 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.03 CHEMBL3594 Q16790 Carbonic anhydrase IX Homo sapiens 
CHEMBL624
6 
5.03 CHEMBL4362 Q6P6U0 Tyrosine-protein kinase 
FGR 
Rattus norvegicus 
CHEMBL169 5.03 CHEMBL17411
86 
P51449 Nuclear receptor ROR-
gamma 
Homo sapiens 
CHEMBL221
543 
5.03 CHEMBL2581 P07339 Cathepsin D Homo sapiens 
CHEMBL624
6 
5.04 CHEMBL3729 P22748 Carbonic anhydrase IV Homo sapiens 
CHEMBL463
665 
5.04 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.05 CHEMBL3510 Q9ULX7 Carbonic anhydrase 
XIV 
Homo sapiens 
 
 
 
 
237 
 
CMPD_CHE
MBLID 
PCHEMBL_
VALUE 
TARGET_CH
EMBLID 
PROTEIN_ACC
ESSION 
PREF_NAME ORGANISM 
CHEMBL169 5.05 CHEMBL4696 P00489 Glycogen 
phosphorylase, muscle 
form 
Oryctolagus 
cuniculus 
CHEMBL169 5.05 CHEMBL4696 P00489 Glycogen 
phosphorylase, muscle 
form 
Oryctolagus 
cuniculus 
CHEMBL155
3072 
5.05 CHEMBL12932
31 
P51450 Nuclear receptor ROR-
gamma 
Mus musculus 
CHEMBL624
6 
5.06 CHEMBL2326 P43166 Carbonic anhydrase VII Homo sapiens 
CHEMBL865
9 
5.07 CHEMBL2916 O14746 Telomerase reverse 
transcriptase 
Homo sapiens 
CHEMBL169 5.07 CHEMBL4343 P06766 DNA polymerase beta Rattus norvegicus 
CHEMBL624
6 
5.09 CHEMBL3242 O43570 Carbonic anhydrase XII Homo sapiens 
CHEMBL168 5.1 CHEMBL23665
17 
Q9YQ12 Protease Human 
immunodeficiency 
virus 1 
CHEMBL169 5.1 CHEMBL23665
17 
Q9YQ12 Protease Human 
immunodeficiency 
virus 1 
CHEMBL443
146 
5.1 CHEMBL4078 O42275 Acetylcholinesterase Electrophorus 
electricus 
CHEMBL155
5307 
5.1 CHEMBL4372 P15917 Anthrax lethal factor Bacillus anthracis 
CHEMBL624
6 
5.12 CHEMBL4789 P35218 Carbonic anhydrase VA Homo sapiens 
CHEMBL168 5.12 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.13 CHEMBL262 P49841 Glycogen synthase 
kinase-3 beta 
Homo sapiens 
CHEMBL822
93 
5.13 CHEMBL3979 Q03181 Peroxisome 
proliferator-activated 
receptor delta 
Homo sapiens 
CHEMBL168 5.13 CHEMBL4343 P06766 DNA polymerase beta Rattus norvegicus 
CHEMBL169 5.14 CHEMBL4903 P24666 Low molecular weight 
phosphotyrosine protein 
phosphatase 
Homo sapiens 
CHEMBL624
6 
5.15 CHEMBL12932
26 
B2RXH2 Lysine-specific 
demethylase 4D-like 
Homo sapiens 
CHEMBL624
6 
5.15 CHEMBL3025 P23280 Carbonic anhydrase VI Homo sapiens 
CHEMBL463
665 
5.15 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL269
277 
5.19 CHEMBL4343 P06766 DNA polymerase beta Rattus norvegicus 
CHEMBL169 5.19 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.2 CHEMBL2326 P43166 Carbonic anhydrase VII Homo sapiens 
CHEMBL365
375 
5.2 CHEMBL12932
31 
P51450 Nuclear receptor ROR-
gamma 
Mus musculus 
CHEMBL168 5.22 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL168 5.22 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.22 CHEMBL5983 O60218 Aldo-keto reductase 
family 1 member B10 
Homo sapiens 
CHEMBL178
3810 
5.22 CHEMBL23665
17 
Q9YQ12 Protease Human 
immunodeficiency 
virus 1 
CHEMBL168 5.25 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL168 5.26 CHEMBL3807 P17706 T-cell protein-tyrosine 
phosphatase 
Homo sapiens 
CHEMBL865
9 
5.28 CHEMBL3979 Q03181 Peroxisome 
proliferator-activated 
receptor delta 
Homo sapiens 
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CMPD_CHE
MBLID 
PCHEMBL_
VALUE 
TARGET_CH
EMBLID 
PROTEIN_ACC
ESSION 
PREF_NAME ORGANISM 
CHEMBL169 5.28 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.29 CHEMBL23665
05 
Q76353 Integrase Human 
immunodeficiency 
virus 1 
CHEMBL624
6 
5.29 CHEMBL3471 Q7ZJM1 Human 
immunodeficiency virus 
type 1 integrase 
Human 
immunodeficiency 
virus 1 
CHEMBL822
93 
5.3 CHEMBL4163 O60603 Toll-like receptor 2 Homo sapiens 
CHEMBL169 5.32 CHEMBL4343 P06766 DNA polymerase beta Rattus norvegicus 
CHEMBL168 5.35 CHEMBL3807 P17706 T-cell protein-tyrosine 
phosphatase 
Homo sapiens 
CHEMBL624
6 
5.37 CHEMBL3912 Q8N1Q1 Carbonic anhydrase 
XIII 
Homo sapiens 
CHEMBL624
6 
5.37 CHEMBL4364 Q64725 Tyrosine-protein kinase 
SYK 
Rattus norvegicus 
CHEMBL168 5.37 CHEMBL3807 P17706 T-cell protein-tyrosine 
phosphatase 
Homo sapiens 
CHEMBL168 5.38 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL865
9 
5.39 CHEMBL235 P37231 Peroxisome 
proliferator-activated 
receptor gamma 
Homo sapiens 
CHEMBL169 5.39 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.4 CHEMBL12932
34 
O97447 Putative fructose-1,6-
bisphosphate aldolase 
Giardia intestinalis 
CHEMBL168 5.4 CHEMBL5983 O60218 Aldo-keto reductase 
family 1 member B10 
Homo sapiens 
CHEMBL169 5.4 CHEMBL5983 O60218 Aldo-keto reductase 
family 1 member B10 
Homo sapiens 
CHEMBL169 5.4 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL178
3811 
5.4 CHEMBL23665
17 
Q9YQ12 Protease Human 
immunodeficiency 
virus 1 
CHEMBL178
3814 
5.4 CHEMBL23665
17 
Q9YQ12 Protease Human 
immunodeficiency 
virus 1 
CHEMBL178
3815 
5.4 CHEMBL23665
17 
Q9YQ12 Protease Human 
immunodeficiency 
virus 1 
CHEMBL624
6 
5.41 CHEMBL4822 P56817 Beta-secretase 1 Homo sapiens 
CHEMBL168 5.41 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.41 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL202
496 
5.41 CHEMBL5077 Q9N1N9 Butyrylcholinesterase Equus caballus 
CHEMBL168 5.42 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.42 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.42 CHEMBL3521 P10586 Receptor-type tyrosine-
protein phosphatase F 
(LAR) 
Homo sapiens 
CHEMBL168 5.43 CHEMBL4343 P06766 DNA polymerase beta Rattus norvegicus 
CHEMBL169 5.43 CHEMBL5983 O60218 Aldo-keto reductase 
family 1 member B10 
Homo sapiens 
CHEMBL202
496 
5.43 CHEMBL5077 Q9N1N9 Butyrylcholinesterase Equus caballus 
CHEMBL169 5.44 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.44 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
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PROTEIN_ACC
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CHEMBL169 5.44 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.44 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.44 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.44 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.45 CHEMBL1824 P04626 Receptor protein-
tyrosine kinase erbB-2 
Homo sapiens 
CHEMBL169 5.46 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL168 5.47 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.47 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.47 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.48 CHEMBL3024 P53350 Serine/threonine-
protein kinase PLK1 
Homo sapiens 
CHEMBL624
6 
5.48 CHEMBL4282 P31749 Serine/threonine-
protein kinase AKT 
Homo sapiens 
CHEMBL269
277 
5.5 CHEMBL12932
31 
P51450 Nuclear receptor ROR-
gamma 
Mus musculus 
CHEMBL624
6 
5.51 CHEMBL2695 Q05397 Focal adhesion kinase 1 Homo sapiens 
CHEMBL169 5.51 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.51 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.51 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.51 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.51 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL168 5.52 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL168 5.52 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL168 5.52 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL168 5.52 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.53 CHEMBL3788 O00444 Serine/threonine-
protein kinase PLK4 
Homo sapiens 
CHEMBL624
6 
5.53 CHEMBL12932
67 
Q9HC97 G-protein coupled 
receptor 35 
Homo sapiens 
CHEMBL624
6 
5.54 CHEMBL4363 Q07014 Tyrosine-protein kinase 
Lyn 
Rattus norvegicus 
CHEMBL865
9 
5.54 CHEMBL5738 P02692 Fatty acid-binding 
protein, liver 
Rattus norvegicus 
CHEMBL169 5.54 CHEMBL3967 P00599 Phospholipase A2 
isozyme DE-I 
Naja melanoleuca 
CHEMBL169 5.55 CHEMBL5983 O60218 Aldo-keto reductase 
family 1 member B10 
Homo sapiens 
CHEMBL169 5.56 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL365
375 
5.57 CHEMBL12932
28 
P10520 Streptokinase A Streptococcus 
pyogenes serotype 
M1 
CHEMBL822
93 
5.59 CHEMBL3344 P05413 Fatty acid binding 
protein muscle 
Homo sapiens 
CHEMBL168 5.59 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.6 CHEMBL2185 Q96GD4 Serine/threonine-
protein kinase Aurora-B 
Homo sapiens 
CHEMBL624
6 
5.6 CHEMBL12932
26 
B2RXH2 Lysine-specific 
demethylase 4D-like 
Homo sapiens 
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CHEMBL169 5.6 CHEMBL5022 P59264 Phospholipase A2 
isozyme PLA-A 
Trimeresurus 
flavoviridis 
CHEMBL624
6 
5.61 CHEMBL4722 O14965 Serine/threonine-
protein kinase Aurora-A 
Homo sapiens 
CHEMBL169 5.62 CHEMBL3807 P17706 T-cell protein-tyrosine 
phosphatase 
Homo sapiens 
CHEMBL624
6 
5.63 CHEMBL4899 P41279 Mitogen-activated 
protein kinase kinase 
kinase 8 
Homo sapiens 
CHEMBL624
6 
5.64 CHEMBL261 P00915 Carbonic anhydrase I Homo sapiens 
CHEMBL169 5.64 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.64 CHEMBL4195 Q7T3S7 Phospholipase A2 Echis carinatus 
CHEMBL624
6 
5.66 CHEMBL205 P00918 Carbonic anhydrase II Homo sapiens 
CHEMBL169 5.68 CHEMBL5983 O60218 Aldo-keto reductase 
family 1 member B10 
Homo sapiens 
CHEMBL624
6 
5.7 CHEMBL4241 P52020 Squalene 
monooxygenase 
Rattus norvegicus 
CHEMBL624
6 
5.7 CHEMBL12932
34 
O97447 Putative fructose-1,6-
bisphosphate aldolase 
Giardia intestinalis 
CHEMBL624
6 
5.7 CHEMBL12932
37 
P54132 Bloom syndrome 
protein 
Homo sapiens 
CHEMBL269
277 
5.7 CHEMBL5983 O60218 Aldo-keto reductase 
family 1 member B10 
Homo sapiens 
CHEMBL168 5.7 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.7 CHEMBL5983 O60218 Aldo-keto reductase 
family 1 member B10 
Homo sapiens 
CHEMBL168 5.72 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.72 CHEMBL4235 P28845 11-beta-hydroxysteroid 
dehydrogenase 1 
Homo sapiens 
CHEMBL624
6 
5.74 CHEMBL5147 P54760 Ephrin type-B receptor 
4 
Homo sapiens 
CHEMBL624
6 
5.75 CHEMBL5145 P15056 Serine/threonine-
protein kinase B-raf 
Homo sapiens 
CHEMBL169 5.75 CHEMBL12932
28 
P10520 Streptokinase A Streptococcus 
pyogenes serotype 
M1 
CHEMBL822
93 
5.77 CHEMBL4879 P12104 Fatty acid binding 
protein intestinal 
Homo sapiens 
CHEMBL624
6 
5.81 CHEMBL1955 P35916 Vascular endothelial 
growth factor receptor 3 
Homo sapiens 
CHEMBL865
9 
5.82 CHEMBL2083 P15090 Fatty acid binding 
protein adipocyte 
Homo sapiens 
CHEMBL822
93 
5.82 CHEMBL239 Q07869 Peroxisome 
proliferator-activated 
receptor alpha 
Homo sapiens 
CHEMBL624
6 
5.89 CHEMBL1913 P09619 Platelet-derived growth 
factor receptor beta 
Homo sapiens 
CHEMBL161
0940 
5.9 CHEMBL4261 Q16665 Hypoxia-inducible 
factor 1 alpha 
Homo sapiens 
CHEMBL822
93 
5.92 CHEMBL3674 Q01469 Fatty acid binding 
protein epidermal 
Homo sapiens 
CHEMBL168 5.93 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL624
6 
5.95 CHEMBL12932
27 
O75604 Ubiquitin carboxyl-
terminal hydrolase 2 
Homo sapiens 
CHEMBL624
6 
5.95 CHEMBL12932
37 
P54132 Bloom syndrome 
protein 
Homo sapiens 
CHEMBL168 5.96 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 5.98 CHEMBL17411
86 
P51449 Nuclear receptor ROR-
gamma 
Homo sapiens 
CHEMBL168 5.99 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
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CHEMBL168 6 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 6 CHEMBL12932
31 
P51450 Nuclear receptor ROR-
gamma 
Mus musculus 
CHEMBL168 6.01 CHEMBL4804 P30305 Dual specificity 
phosphatase Cdc25B 
Homo sapiens 
CHEMBL822
93 
6.03 CHEMBL2083 P15090 Fatty acid binding 
protein adipocyte 
Homo sapiens 
CHEMBL624
6 
6.05 CHEMBL12932
55 
P15428 15-
hydroxyprostaglandin 
dehydrogenase [NAD+] 
Homo sapiens 
CHEMBL624
6 
6.05 CHEMBL12932
55 
P15428 15-
hydroxyprostaglandin 
dehydrogenase [NAD+] 
Homo sapiens 
CHEMBL624
6 
6.1 CHEMBL267 P12931 Tyrosine-protein kinase 
SRC 
Homo sapiens 
CHEMBL624
6 
6.1 CHEMBL279 P35968 Vascular endothelial 
growth factor receptor 2 
Homo sapiens 
CHEMBL624
6 
6.1 CHEMBL12932
26 
B2RXH2 Lysine-specific 
demethylase 4D-like 
Homo sapiens 
CHEMBL624
6 
6.12 CHEMBL5460 P0DMV8 Heat shock 70 kDa 
protein 1 
Homo sapiens 
CHEMBL168 6.14 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 6.15 CHEMBL12932
31 
P51450 Nuclear receptor ROR-
gamma 
Mus musculus 
CHEMBL624
6 
6.16 CHEMBL203 P00533 Epidermal growth factor 
receptor erbB1 
Homo sapiens 
CHEMBL168 6.16 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL168 6.16 CHEMBL335 P18031 Protein-tyrosine 
phosphatase 1B 
Homo sapiens 
CHEMBL169 6.17 CHEMBL17411
86 
P51449 Nuclear receptor ROR-
gamma 
Homo sapiens 
CHEMBL865
9 
6.22 CHEMBL239 Q07869 Peroxisome 
proliferator-activated 
receptor alpha 
Homo sapiens 
CHEMBL865
9 
6.22 CHEMBL239 Q07869 Peroxisome 
proliferator-activated 
receptor alpha 
Homo sapiens 
CHEMBL624
6 
6.24 CHEMBL3717 P08581 Hepatocyte growth 
factor receptor 
Homo sapiens 
CHEMBL624
6 
6.25 CHEMBL12932
36 
P46063 ATP-dependent DNA 
helicase Q1 
Homo sapiens 
CHEMBL624
6 
6.27 CHEMBL12933
08 
Q5A7N4 Likely tRNA 2'-
phosphotransferase 
Candida albicans 
(strain SC5314 / 
ATCC MYA-2876) 
(Yeast) 
CHEMBL624
6 
6.29 CHEMBL5784 O60285 NUAK family SNF1-
like kinase 1 
Homo sapiens 
CHEMBL169 6.3 CHEMBL12932
31 
P51450 Nuclear receptor ROR-
gamma 
Mus musculus 
CHEMBL155
3072 
6.3 CHEMBL340 P08684 Cytochrome P450 3A4 Homo sapiens 
CHEMBL506
814 
6.39 CHEMBL4822 P56817 Beta-secretase 1 Homo sapiens 
CHEMBL312
2152 
6.4 CHEMBL3344 P05413 Fatty acid binding 
protein muscle 
Homo sapiens 
CHEMBL624
6 
6.47 CHEMBL1981 P06213 Insulin receptor Homo sapiens 
CHEMBL624
6 
6.59 CHEMBL4128 Q02763 Tyrosine-protein kinase 
TIE-2 
Homo sapiens 
CHEMBL624
6 
6.6 CHEMBL1957 P08069 Insulin-like growth 
factor I receptor 
Homo sapiens 
CHEMBL624
6 
6.6 CHEMBL4159 Q99714 Endoplasmic reticulum-
associated amyloid 
beta-peptide-binding 
protein 
Homo sapiens 
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CHEMBL624
6 
6.7 CHEMBL1900 P15121 Aldose reductase Homo sapiens 
CHEMBL865
9 
6.75 CHEMBL5738 P02692 Fatty acid-binding 
protein, liver 
Rattus norvegicus 
CHEMBL624
6 
6.8 CHEMBL2392 P06746 DNA polymerase beta Homo sapiens 
CHEMBL312
2151 
6.8 CHEMBL3344 P05413 Fatty acid binding 
protein muscle 
Homo sapiens 
CHEMBL624
6 
6.85 CHEMBL12932
58 
P84022 Mothers against 
decapentaplegic 
homolog 3 
Homo sapiens 
CHEMBL169 6.89 CHEMBL17411
86 
P51449 Nuclear receptor ROR-
gamma 
Homo sapiens 
CHEMBL624
6 
6.9 CHEMBL12932
55 
P15428 15-
hydroxyprostaglandin 
dehydrogenase [NAD+] 
Homo sapiens 
CHEMBL624
6 
6.9 CHEMBL12932
36 
P46063 ATP-dependent DNA 
helicase Q1 
Homo sapiens 
CHEMBL624
6 
6.96 CHEMBL12932
67 
Q9HC97 G-protein coupled 
receptor 35 
Homo sapiens 
CHEMBL624
6 
7 CHEMBL10751
38 
Q9NUW8 Tyrosyl-DNA 
phosphodiesterase 1 
Homo sapiens 
CHEMBL624
6 
7 CHEMBL12932
67 
Q9HC97 G-protein coupled 
receptor 35 
Homo sapiens 
CHEMBL168 7.05 CHEMBL5983 O60218 Aldo-keto reductase 
family 1 member B10 
Homo sapiens 
CHEMBL312
2153 
7.13 CHEMBL3344 P05413 Fatty acid binding 
protein muscle 
Homo sapiens 
CHEMBL624
6 
7.15 CHEMBL10751
38 
Q9NUW8 Tyrosyl-DNA 
phosphodiesterase 1 
Homo sapiens 
CHEMBL624
6 
7.4 CHEMBL3629 P68400 Casein kinase II alpha Homo sapiens 
CHEMBL624
6 
7.85 CHEMBL5619 P27695 DNA-(apurinic or 
apyrimidinic site) lyase 
Homo sapiens 
 
 
Supplementary Table 11 Enriched targets predicted for the NP dataset 
PROTEIN_ACCESSI
ON 
PREF_NAME ORGANIS
M 
Trypanosoma brucei 
orthologue 
Gene Name 
P43166 Carbonic anhydrase VII Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
O14746 Telomerase reverse 
transcriptase 
Homo 
sapiens 
Tb11.01.1950 Telomerase reverse 
transcriptase, putative 
P22748 Carbonic anhydrase IV Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
Q9ULX7 Carbonic anhydrase XIV Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
Q16790 Carbonic anhydrase IX Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
O43570 Carbonic anhydrase XII Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
Q8N1Q1 Carbonic anhydrase XIII Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
P35218 Carbonic anhydrase VA Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
P23280 Carbonic anhydrase VI Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
P49841 Glycogen synthase kinase-
3 beta 
Homo 
sapiens 
Tb927.10.13780 Glycogen synthase kinase 3 
O60218 Aldo-keto reductase family 
1 member B10 
Homo 
sapiens 
Tb11.02.3040 Aldo/keto reductase, 
putative 
P10586 Receptor-type tyrosine-
protein phosphatase F 
(LAR) 
Homo 
sapiens 
Tb10.70.0070 Tyrosine specific protein 
phosphatase, putative 
P53350 Serine/threonine-protein 
kinase PLK1 
Homo 
sapiens 
Tb927.7.3210 Protein kinase, putative 
 
 
 
 
243 
 
PROTEIN_ACCESSI
ON 
PREF_NAME ORGANIS
M 
Trypanosoma brucei 
orthologue 
Gene Name 
P53350 Serine/threonine-protein 
kinase PLK1 
Homo 
sapiens 
Tb927.6.5100 Serine/threonine-protein 
kinase, putative 
P53350 Serine/threonine-protein 
kinase PLK1 
Homo 
sapiens 
Tb927.7.6310 Serine/threonine-protein 
kinase PLK 
P41279 Mitogen-activated protein 
kinase kinase kinase 8 
Homo 
sapiens 
Tb11.46.0003 Protein kinase, putative 
Q96GD4 Serine/threonine-protein 
kinase Aurora-B 
Homo 
sapiens 
Tb11.01.0330 Protein kinase, putative 
O14965 Serine/threonine-protein 
kinase Aurora-A 
Homo 
sapiens 
Tb11.01.0330 Protein kinase, putative 
P00915 Carbonic anhydrase I Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
P54132 Bloom syndrome protein Homo 
sapiens 
Tb927.8.6690 ATP-dependent DEAD/H 
DNA helicase recQ, 
putative 
P00918 Carbonic anhydrase II Homo 
sapiens 
Tb11.01.0290 Carbonic anhydrase-like 
protein 
P0DMV8 Heat shock 70 kDa protein 
1 
Homo 
sapiens 
Tb09.160.3090 Heat shock protein, putative 
P27695 DNA-(apurinic or 
apyrimidinic site) lyase 
Homo 
sapiens 
Tb927.8.5510 DNA-(apurinic or 
apyrimidinic site) lyase 
P15121 Aldose reductase Homo 
sapiens 
Tb11.02.3040 Aldo/keto reductase, 
putative 
Q9NUW8 Tyrosyl-DNA 
phosphodiesterase 1 
Homo 
sapiens 
Tb927.2.5750 Tyrosyl-DNA 
Phosphodiesterase (Tdp1), 
putative 
P68400 Casein kinase II alpha Homo 
sapiens 
Tb927.2.2430 Casein kinase II, alpha 
chain 
P68400 Casein kinase II alpha Homo 
sapiens 
Tb09.211.4890 Casein kinase II, putative 
P06746 DNA polymerase beta Homo 
sapiens 
Tb927.5.2780 Mitochondrial DNA 
polymerase beta 
P06746 DNA polymerase beta Homo 
sapiens 
Tb927.5.2790 Mitochondrial DNA 
polymerase beta-PAK 
Q6P6U0 Tyrosine-protein kinase 
FGR 
Rattus 
norvegicus 
Tb927.5.2780 Mitochondrial DNA 
polymerase beta 
Q6P6U0 Tyrosine-protein kinase 
FGR 
Rattus 
norvegicus 
Tb927.5.2790 Mitochondrial DNA 
polymerase beta-PAK 
P06766 DNA polymerase beta Rattus 
norvegicus 
Tb927.5.2780 Mitochondrial DNA 
polymerase beta 
P06766 DNA polymerase beta Rattus 
norvegicus 
Tb927.5.2790 Mitochondrial DNA 
polymerase beta-PAK 
Q07014 Tyrosine-protein kinase 
Lyn 
Rattus 
norvegicus 
Tb11.02.0780 Squalene monooxygenase, 
putative 
P52020 Squalene monooxygenase Rattus 
norvegicus 
Tb11.02.0780 Squalene monooxygenase, 
putative 
 
 
 
Supplementary Table 12 Bioactivity values extracted from ChEMBL for the small molecule hits (SH) 
dataset. 
COMPO
UND_KE
Y 
PUBLISHED
_VALUE(uM) 
TARGET_
CHEMBLI
D 
PROTEIN_
ACCESSIO
N 
PREF_NAME ORGANISM 
SID92764
752 
6.657 CHEMBL42
18 
P06492 Alpha trans-inducing protein 
(VP16) 
Herpes simplex 
virus (type 1 / strain 
17) 
SID56463
673 
0.987 CHEMBL17
41207 
Q96LD8 Sentrin-specific protease 8 Homo sapiens 
SID56463
673 
0.935 CHEMBL17
41207 
Q96LD8 Sentrin-specific protease 8 Homo sapiens 
SID87225
754 
0.125 CHEMBL10
75322 
Q9Y2T6 G-protein coupled receptor 55 Homo sapiens 
SID87225
754 
7.66 CHEMBL12
93267 
Q9HC97 G-protein coupled receptor 35 Homo sapiens 
SID17415
722 
2.534457 CHEMBL10
75322 
Q9Y2T6 G-protein coupled receptor 55 Homo sapiens 
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COMPO
UND_KE
Y 
PUBLISHED
_VALUE(uM) 
TARGET_
CHEMBLI
D 
PROTEIN_
ACCESSIO
N 
PREF_NAME ORGANISM 
SID85774
5 
1.3 CHEMBL23
7 
P41145 Kappa opioid receptor Homo sapiens 
SID85693
8 
2.6 CHEMBL18
59 
O95180 Voltage-gated T-type calcium 
channel alpha-1H subunit 
Homo sapiens 
SID49649
053 
6.84 CHEMBL17
41179 
P31941 Probable DNA dC->dU-editing 
enzyme APOBEC-3A 
Homo sapiens 
SID56373
536 
4.82 CHEMBL59
79 
P05186 Alkaline phosphatase, tissue-
nonspecific isozyme 
Homo sapiens 
SID56373
536 
2.16 CHEMBL34
02 
P10696 Alkaline phosphatase placental-
like 
Homo sapiens 
SID42448
92 
3.14 CHEMBL34
02 
P10696 Alkaline phosphatase placental-
like 
Homo sapiens 
SID11532
948 
2.41 CHEMBL17
41208 
Q96P20 NACHT, LRR and PYD 
domains-containing protein 3 
Homo sapiens 
SID56322
618 
2.226 CHEMBL17
41164 
O60240 Perilipin-1 Homo sapiens 
SID17414
218 
2.32 CHEMBL23
7 
P41145 Kappa opioid receptor Homo sapiens 
SID22411
930 
7.62 CHEMBL17
41208 
Q96P20 NACHT, LRR and PYD 
domains-containing protein 3 
Homo sapiens 
SID14737
257 
6.76 CHEMBL23
7 
P41145 Kappa opioid receptor Homo sapiens 
SID49679
708 
3.179 CHEMBL12
93249 
Q13887 Kruppel-like factor 5 Homo sapiens 
SID24781
162 
1.67 CHEMBL41
58 
P49327 Fatty acid synthase Homo sapiens 
SID24781
162 
0.859 CHEMBL41
58 
P49327 Fatty acid synthase Homo sapiens 
SID85802
6 
7.12 CHEMBL23
7 
P41145 Kappa opioid receptor Homo sapiens 
SID85802
6 
6.831 CHEMBL22
7 
P30556 Type-1 angiotensin II receptor Homo sapiens 
SID85802
6 
0.56 CHEMBL50
23 
Q00987 p53-binding protein Mdm-2 Homo sapiens 
SID49645
303 
9.9 CHEMBL17
41213 
Q9BQF6 Sentrin-specific protease 7 Homo sapiens 
SID24822
843 
9.63 CHEMBL55
73 
P09923 Intestinal alkaline phosphatase Homo sapiens 
SID49649
021 
4.86 CHEMBL23
7 
P41145 Kappa opioid receptor Homo sapiens 
SID56373
639 
3.34 CHEMBL59
79 
P05186 Alkaline phosphatase, tissue-
nonspecific isozyme 
Homo sapiens 
SID92764
752 
7.073 CHEMBL43
74 
Q9Y5X4 Photoreceptor-specific nuclear 
receptor 
Homo sapiens 
SID49827
024 
4.529 CHEMBL22
7 
P30556 Type-1 angiotensin II receptor Homo sapiens 
SID49678
979 
2.8 CHEMBL23
7 
P41145 Kappa opioid receptor Homo sapiens 
SID22412
622 
1.864 CHEMBL12
93249 
Q13887 Kruppel-like factor 5 Homo sapiens 
SID85774
5 
2.761 CHEMBL53
13 
P38532 Heat shock factor protein 1 Mus musculus 
SID85693
8 
0.2667 CHEMBL17
41219 
Q9QUQ5 Short transient receptor potential 
channel 4 
Mus musculus 
SID17414
218 
9.825 CHEMBL53
13 
P38532 Heat shock factor protein 1 Mus musculus 
SID17403
305 
3.3493 CHEMBL17
41219 
Q9QUQ5 Short transient receptor potential 
channel 4 
Mus musculus 
SID85765
9 
0.668 CHEMBL17
41219 
Q9QUQ5 Short transient receptor potential 
channel 4 
Mus musculus 
SID14732
424 
5.308 CHEMBL17
41219 
Q9QUQ5 Short transient receptor potential 
channel 4 
Mus musculus 
SID17432
288 
6.6827 CHEMBL17
41219 
Q9QUQ5 Short transient receptor potential 
channel 4 
Mus musculus 
SID24781
162 
3.637 CHEMBL53
13 
P38532 Heat shock factor protein 1 Mus musculus 
SID24809
545 
5.308 CHEMBL17
41219 
Q9QUQ5 Short transient receptor potential 
channel 4 
Mus musculus 
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COMPO
UND_KE
Y 
PUBLISHED
_VALUE(uM) 
TARGET_
CHEMBLI
D 
PROTEIN_
ACCESSIO
N 
PREF_NAME ORGANISM 
SID49649
021 
5.926 CHEMBL53
13 
P38532 Heat shock factor protein 1 Mus musculus 
SID49665
200 
0.8413 CHEMBL17
41219 
Q9QUQ5 Short transient receptor potential 
channel 4 
Mus musculus 
SID24781
888 
10 CHEMBL21
46304 
P35639 DNA damage-inducible transcript 
3 protein 
Mus musculus 
SID24781
162 
4.21 CHEMBL21
46304 
P35639 DNA damage-inducible transcript 
3 protein 
Mus musculus 
SID85774
5 
2.82 CHEMBL55
67 
P08659 Luciferin 4-monooxygenase Photinus pyralis 
SID49667
183 
3.418 CHEMBL55
67 
P08659 Luciferin 4-monooxygenase Photinus pyralis 
SID49728
456 
3.651 CHEMBL55
67 
P08659 Luciferin 4-monooxygenase Photinus pyralis 
SID49668
938 
9.27 CHEMBL17
41194 
P87108 Mitochondrial import inner 
membrane translocase subunit 
TIM10 
Saccharomyces 
cerevisiae S288c 
SID85644
3 
1.98 CHEMBL17
41194 
P87108 Mitochondrial import inner 
membrane translocase subunit 
TIM10 
Saccharomyces 
cerevisiae S288c 
SID85644
3 
8.24 CHEMBL17
41194 
P87108 Mitochondrial import inner 
membrane translocase subunit 
TIM10 
Saccharomyces 
cerevisiae S288c 
SID85644
3 
4.44 CHEMBL17
41180 
P32897 Mitochondrial import inner 
membrane translocase subunit 
TIM23 
Saccharomyces 
cerevisiae S288c 
SID42448
92 
3.71 CHEMBL10
75257 
P03070 Large T antigen Simian virus 40 
SID17401
675 
7.45 CHEMBL21
46295 
P65502 Probable nicotinate-nucleotide 
adenylyltransferase 
Staphylococcus 
aureus (strain 
N315) 
 
 
 
Supplementary Table 13 Enriched targets predicted for the small molecule hits (SH) dataset 
PROTEIN_A
CCESSION 
PREF_NAME ORGANISM Trypanosoma 
brucei orthologue 
Gene Name 
O95180 Voltage-gated T-type calcium 
channel alpha-1H subunit 
Homo sapiens Tb10.70.4750 Calcium channel 
protein, putative 
Q96P20 NACHT, LRR and PYD domains-
containing protein 3 
Homo sapiens TB927.1.4180 Uncharacterized 
protein 
Q96P20 NACHT, LRR and PYD domains-
containing protein 3 
Homo sapiens Tb927.7.1430 Putative 
uncharacterized 
protein 
Q96P20 NACHT, LRR and PYD domains-
containing protein 3 
Homo sapiens Tb11.02.4230 Putative 
uncharacterized 
protein 
P87108 Mitochondrial import inner 
membrane translocase subunit TIM10 
Saccharomyces 
cerevisiae S288c 
Tb927.7.2200 Putative 
uncharacterized 
protein 
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Supplementary Table 14 Compounds from the SH dataset showing compounds that are predicted to readily 
cross the BBB (plogBB >0.3) and the targets they are predicted to bind. 
Compound Target plogBB 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Protein kinase_ putative;Tb09.211.2260 1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Protein kinase_ putative;Tb10.70.1760 1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Serine/threonine-protein kinase_ 
putative;Tb10.70.5890 
1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Serine/threonine protein kinase_ 
putative;Tb927.3.4560 
1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Protein kinase_ putative;Tb927.8.5730 1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Protein kinase_ putative;Tb927.2.2120 1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Protein kinase_ putative;Tb927.7.5220 1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Protein kinase_ putative;Tb927.3.5650 1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Protein kinase_ putative;Tb10.61.2490 1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Protein kinase_ putative;Tb10.61.1520 1.23 
CC1(C)CC(CC(C)(C)N1)N1COC2=C(C1)C=
C(Cl)C1=CC=CN=C21 
Protein kinase_ putative;Tb10.6k15.0770 1.23 
CN[C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl
)=C2)C2=CC=CC=C12 
Protein kinase_ putative;Tb927.2.2120 1.14 
CN[C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl
)=C2)C2=CC=CC=C12 
Protein kinase_ putative;Tb927.7.5220 1.14 
CN[C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl
)=C2)C2=CC=CC=C12 
Protein kinase_ putative;Tb927.3.5650 1.14 
CN[C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl
)=C2)C2=CC=CC=C12 
Protein kinase_ putative;Tb10.61.2490 1.14 
ClC1=CC(Cl)=C(OCCCCCN2CCNCC2)C=
C1 
Glucose transporter;Tb10.6k15.2030 0.93 
ClC1=CC(Cl)=C(OCCCCCN2CCNCC2)C=
C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.93 
ClC1=CC(Cl)=C(OCCCCCN2CCNCC2)C=
C1 
Hexose transporter;Tb10.6k15.2040 0.93 
ClC1=CC(Cl)=C(OCCCCCN2CCNCC2)C=
C1 
Glucose transporter;Tb10.6k15.2020 0.93 
CC1=CC(Cl)=CC(Cl)=C1OCCCCCN1CCN
CC1 
Glucose transporter;Tb10.6k15.2030 0.93 
CC1=CC(Cl)=CC(Cl)=C1OCCCCCN1CCN
CC1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.93 
CC1=CC(Cl)=CC(Cl)=C1OCCCCCN1CCN
CC1 
Hexose transporter;Tb10.6k15.2040 0.93 
CC1=CC(Cl)=CC(Cl)=C1OCCCCCN1CCN
CC1 
Glucose transporter;Tb10.6k15.2020 0.93 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Glucose transporter;Tb10.6k15.2030 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Hexose transporter;Tb10.6k15.2040 0.90 
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CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Glucose transporter;Tb10.6k15.2020 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Flap endonuclease 1;FEN1 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb10.329.0030 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Mitogen-activated protein 
kinase;Tb927.8.3550 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb927.3.1610 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb11.01.4250 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb11.01.4230 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb927.7.1900 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase;Tb11.01.1030 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Rac serine-threonine kinase_ 
putative;Tb927.6.2250 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb09.160.0450 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb927.5.2820 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb10.70.0960 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb10.70.0970 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine-protein kinase_ 
putative;Tb11.01.6650 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine-protein kinase A_ 
putative;Tb927.8.7110 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine protein kinase_ 
putative;Tb09.160.1090 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;TB927.1.3130 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine-protein kinase_ 
putative;Tb927.8.1670 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Putative uncharacterized 
protein;Tb11.01.1050 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine-protein kinase_ 
putative;Tb927.8.1690 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb927.7.3580 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine-protein kinase_ 
putative;Tb10.70.6680 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb11.01.2900 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb927.5.3320 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine-protein kinase A_ 
putative;Tb927.4.5310 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb927.8.5730 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb09.160.0570 0.90 
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CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb11.01.0330 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb10.61.1520 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb10.6k15.0770 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine-protein kinase_ 
putative;Tb927.7.4090 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine-protein kinase_ 
putative;Tb927.5.1650 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Protein kinase_ putative;Tb10.70.1760 0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine-protein kinase_ 
putative;Tb10.70.5890 
0.90 
CN1CCN(CC1)NC1=C2C=C3C=CC=CC3=
CC2=NC=C1 
Serine/threonine protein kinase_ 
putative;Tb927.3.4560 
0.90 
ClC1=CC=C2OC3=CC=CC=C3N=C(N3CC
NCC3)C2=C1 
Protein kinase_ putative;Tb09.211.2260 0.84 
CN1CCN(CC1)C1=CC(C)=CC2=C1NC1=C
2C=CC=C1 
Protein kinase_ putative;Tb09.211.2260 0.83 
CN1CCN(CC2=C(O)C3=NC=CC=C3C(Br)=
C2)CC1 
Glucose transporter;Tb10.6k15.2030 0.82 
CN1CCN(CC2=C(O)C3=NC=CC=C3C(Br)=
C2)CC1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.82 
CN1CCN(CC2=C(O)C3=NC=CC=C3C(Br)=
C2)CC1 
Hexose transporter;Tb10.6k15.2040 0.82 
CN1CCN(CC2=C(O)C3=NC=CC=C3C(Br)=
C2)CC1 
Glucose transporter;Tb10.6k15.2020 0.82 
CC1=CC=CC(CN2CCN(CC3=CNC4=CC=C
C=C34)CC2)=C1 
Protein kinase_ putative;Tb09.211.2260 0.81 
CN1C(N(C)C2=CC=CC=C12)C1=CC=C(O)
C=C1 
Flap endonuclease 1;FEN1 0.80 
CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC
=C12 
Flap endonuclease 1;FEN1 0.75 
BrC1=CC=C(C=C1)C1=NC(N2CCNCC2)=C
2C=CC=CC2=N1 
Glucose transporter;Tb10.6k15.2030 0.73 
BrC1=CC=C(C=C1)C1=NC(N2CCNCC2)=C
2C=CC=CC2=N1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.73 
BrC1=CC=C(C=C1)C1=NC(N2CCNCC2)=C
2C=CC=CC2=N1 
Hexose transporter;Tb10.6k15.2040 0.73 
BrC1=CC=C(C=C1)C1=NC(N2CCNCC2)=C
2C=CC=CC2=N1 
Glucose transporter;Tb10.6k15.2020 0.73 
BrC1=CC=C(C=C1)C1=NC(N2CCNCC2)=C
2C=CC=CC2=N1 
Protein kinase_ putative;Tb927.7.1900 0.73 
BrC1=CC=C(C=C1)C1=NC(N2CCNCC2)=C
2C=CC=CC2=N1 
Protein kinase_ putative;Tb09.211.2260 0.73 
CC1=CC(Br)=C(OCCCCCCN2CCNCC2)C(
C)=C1 
Glucose transporter;Tb10.6k15.2030 0.69 
CC1=CC(Br)=C(OCCCCCCN2CCNCC2)C(
C)=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.69 
CC1=CC(Br)=C(OCCCCCCN2CCNCC2)C(
C)=C1 
Hexose transporter;Tb10.6k15.2040 0.69 
CC1=CC(Br)=C(OCCCCCCN2CCNCC2)C(
C)=C1 
Glucose transporter;Tb10.6k15.2020 0.69 
NC1C(CC2=C(Cl)C=C(Cl)C=C2)CC2=CC=
CC=C12 
NADPH--cytochrome p450 reductase_ 
putative;Tb09.211.4110 
0.67 
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NC1C(CC2=C(Cl)C=C(Cl)C=C2)CC2=CC=
CC=C12 
NADPH--cytochrome P450 reductase_ 
putative;Tb11.01.0170 
0.67 
NC1C(CC2=C(Cl)C=C(Cl)C=C2)CC2=CC=
CC=C12 
NADPH--cytochrome p450 reductase_ 
putative;Tb11.02.5420 
0.67 
CCC1=C(Cl)C=CC(OCCCCCN2CCNCC2)=
C1 
Glucose transporter;Tb10.6k15.2030 0.66 
CCC1=C(Cl)C=CC(OCCCCCN2CCNCC2)=
C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.66 
CCC1=C(Cl)C=CC(OCCCCCN2CCNCC2)=
C1 
Hexose transporter;Tb10.6k15.2040 0.66 
CCC1=C(Cl)C=CC(OCCCCCN2CCNCC2)=
C1 
Glucose transporter;Tb10.6k15.2020 0.66 
ClC1=C(OCCCCNCC=C)C=CC(Br)=C1 Glucose transporter;Tb10.6k15.2030 0.66 
ClC1=C(OCCCCNCC=C)C=CC(Br)=C1 Glucose transporter_ 
putative;Tb927.4.2290 
0.66 
ClC1=C(OCCCCNCC=C)C=CC(Br)=C1 Hexose transporter;Tb10.6k15.2040 0.66 
ClC1=C(OCCCCNCC=C)C=CC(Br)=C1 Glucose transporter;Tb10.6k15.2020 0.66 
CNC(C)(C)CC1=C2CCCC2=CC2=C1CCC2 Glucose transporter;Tb10.6k15.2030 0.65 
CNC(C)(C)CC1=C2CCCC2=CC2=C1CCC2 Glucose transporter_ 
putative;Tb927.4.2290 
0.65 
CNC(C)(C)CC1=C2CCCC2=CC2=C1CCC2 Hexose transporter;Tb10.6k15.2040 0.65 
CNC(C)(C)CC1=C2CCCC2=CC2=C1CCC2 Glucose transporter;Tb10.6k15.2020 0.65 
CC(C)(C)C(N)CCC1=C(Cl)C=C(Cl)C=C1 Glucose transporter;Tb10.6k15.2030 0.62 
CC(C)(C)C(N)CCC1=C(Cl)C=C(Cl)C=C1 Glucose transporter_ 
putative;Tb927.4.2290 
0.62 
CC(C)(C)C(N)CCC1=C(Cl)C=C(Cl)C=C1 Hexose transporter;Tb10.6k15.2040 0.62 
CC(C)(C)C(N)CCC1=C(Cl)C=C(Cl)C=C1 Glucose transporter;Tb10.6k15.2020 0.62 
CN(C)CCCNCCCC1=CC=C(C=C1)C(C)(C)
C 
Glucose transporter;Tb10.6k15.2030 0.59 
CN(C)CCCNCCCC1=CC=C(C=C1)C(C)(C)
C 
Glucose transporter_ 
putative;Tb927.4.2290 
0.59 
CN(C)CCCNCCCC1=CC=C(C=C1)C(C)(C)
C 
Hexose transporter;Tb10.6k15.2040 0.59 
CN(C)CCCNCCCC1=CC=C(C=C1)C(C)(C)
C 
Glucose transporter;Tb10.6k15.2020 0.59 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Glucose transporter;Tb10.6k15.2030 0.57 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.57 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Hexose transporter;Tb10.6k15.2040 0.57 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Glucose transporter;Tb10.6k15.2020 0.57 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Protein kinase_ putative;Tb09.211.2260 0.57 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Protein kinase_ putative;Tb927.8.5730 0.57 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Protein kinase_ putative;Tb10.61.1520 0.57 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Protein kinase_ putative;Tb10.6k15.0770 0.57 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Protein kinase_ putative;Tb10.70.1760 0.57 
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CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Serine/threonine-protein kinase_ 
putative;Tb10.70.5890 
0.57 
CC1=CC=CC2=CC(C3=CC=CC=C3)=C(N=
C12)N1CCNCC1 
Serine/threonine protein kinase_ 
putative;Tb927.3.4560 
0.57 
ClC1=CC(Cl)=C(CCNCC2=CNC3=CC=CC
=C23)C=C1 
Glucose transporter;Tb10.6k15.2030 0.57 
ClC1=CC(Cl)=C(CCNCC2=CNC3=CC=CC
=C23)C=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.57 
ClC1=CC(Cl)=C(CCNCC2=CNC3=CC=CC
=C23)C=C1 
Hexose transporter;Tb10.6k15.2040 0.57 
ClC1=CC(Cl)=C(CCNCC2=CNC3=CC=CC
=C23)C=C1 
Glucose transporter;Tb10.6k15.2020 0.57 
CN1C2=NC3=CC=CC=C3C2=C(C)C=C1Cl Glucose transporter;Tb10.6k15.2030 0.57 
CN1C2=NC3=CC=CC=C3C2=C(C)C=C1Cl Glucose transporter_ 
putative;Tb927.4.2290 
0.57 
CN1C2=NC3=CC=CC=C3C2=C(C)C=C1Cl Hexose transporter;Tb10.6k15.2040 0.57 
CN1C2=NC3=CC=CC=C3C2=C(C)C=C1Cl Glucose transporter;Tb10.6k15.2020 0.57 
CN1C2=NC3=CC=CC=C3C2=C(C)C=C1Cl Flap endonuclease 1;FEN1 0.57 
CN1C2=NC3=CC=CC=C3C2=C(C)C=C1Cl Protein kinase_ putative;Tb10.70.1760 0.57 
CN1C2=NC3=CC=CC=C3C2=C(C)C=C1Cl Serine/threonine-protein kinase_ 
putative;Tb10.70.5890 
0.57 
CN1C2=NC3=CC=CC=C3C2=C(C)C=C1Cl Serine/threonine protein kinase_ 
putative;Tb927.3.4560 
0.57 
CCCCNCC1=CC(Br)=C(OCC2=CC=C(F)C=
C2)C(OC)=C1 
Glucose transporter;Tb10.6k15.2030 0.56 
CCCCNCC1=CC(Br)=C(OCC2=CC=C(F)C=
C2)C(OC)=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.56 
CCCCNCC1=CC(Br)=C(OCC2=CC=C(F)C=
C2)C(OC)=C1 
Hexose transporter;Tb10.6k15.2040 0.56 
CCCCNCC1=CC(Br)=C(OCC2=CC=C(F)C=
C2)C(OC)=C1 
Glucose transporter;Tb10.6k15.2020 0.56 
CNCCCC1SC2=C(C=CC=C2)C(C)C2=C1C
=CC=C2 
Glucose transporter;Tb10.6k15.2030 0.55 
CNCCCC1SC2=C(C=CC=C2)C(C)C2=C1C
=CC=C2 
Glucose transporter_ 
putative;Tb927.4.2290 
0.55 
CNCCCC1SC2=C(C=CC=C2)C(C)C2=C1C
=CC=C2 
Hexose transporter;Tb10.6k15.2040 0.55 
CNCCCC1SC2=C(C=CC=C2)C(C)C2=C1C
=CC=C2 
Glucose transporter;Tb10.6k15.2020 0.55 
CC1=CC(NCCN2CCCCC2)=C2C=CC3=CC
=CC=C3C2=N1 
Glucose transporter;Tb10.6k15.2030 0.53 
CC1=CC(NCCN2CCCCC2)=C2C=CC3=CC
=CC=C3C2=N1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.53 
CC1=CC(NCCN2CCCCC2)=C2C=CC3=CC
=CC=C3C2=N1 
Hexose transporter;Tb10.6k15.2040 0.53 
CC1=CC(NCCN2CCCCC2)=C2C=CC3=CC
=CC=C3C2=N1 
Glucose transporter;Tb10.6k15.2020 0.53 
CC1=CC(NCCN2CCCCC2)=C2C=CC3=CC
=CC=C3C2=N1 
Flap endonuclease 1;FEN1 0.53 
CC(C)C1NC(CC(=N1)C1=CC2=C(OCO2)C
=C1)C1=C(O)C=CC(Cl)=C1 
NADPH--cytochrome p450 reductase_ 
putative;Tb09.211.4110 
0.53 
CC(C)C1NC(CC(=N1)C1=CC2=C(OCO2)C
=C1)C1=C(O)C=CC(Cl)=C1 
NADPH--cytochrome P450 reductase_ 
putative;Tb11.01.0170 
0.53 
CC(C)C1NC(CC(=N1)C1=CC2=C(OCO2)C
=C1)C1=C(O)C=CC(Cl)=C1 
NADPH--cytochrome p450 reductase_ 
putative;Tb11.02.5420 
0.53 
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CC1=CC(NCCN2CCOCC2)=C2C=CC3=CC
=CC=C3C2=N1 
Glucose transporter;Tb10.6k15.2030 0.53 
CC1=CC(NCCN2CCOCC2)=C2C=CC3=CC
=CC=C3C2=N1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.53 
CC1=CC(NCCN2CCOCC2)=C2C=CC3=CC
=CC=C3C2=N1 
Hexose transporter;Tb10.6k15.2040 0.53 
CC1=CC(NCCN2CCOCC2)=C2C=CC3=CC
=CC=C3C2=N1 
Glucose transporter;Tb10.6k15.2020 0.53 
CCOC1=C(OC)C=CC(CNCCC2=CC=CC(Cl
)=C2)=C1 
Glucose transporter;Tb10.6k15.2030 0.53 
CCOC1=C(OC)C=CC(CNCCC2=CC=CC(Cl
)=C2)=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.53 
CCOC1=C(OC)C=CC(CNCCC2=CC=CC(Cl
)=C2)=C1 
Hexose transporter;Tb10.6k15.2040 0.53 
CCOC1=C(OC)C=CC(CNCCC2=CC=CC(Cl
)=C2)=C1 
Glucose transporter;Tb10.6k15.2020 0.53 
CCCCNCC1=C(Cl)C2=CC=CC=C2N1 Glucose transporter;Tb10.6k15.2030 0.52 
CCCCNCC1=C(Cl)C2=CC=CC=C2N1 Glucose transporter_ 
putative;Tb927.4.2290 
0.52 
CCCCNCC1=C(Cl)C2=CC=CC=C2N1 Hexose transporter;Tb10.6k15.2040 0.52 
CCCCNCC1=C(Cl)C2=CC=CC=C2N1 Glucose transporter;Tb10.6k15.2020 0.52 
COC1=CC2=C3CNCC3=C(C)N=C2C(OC)=
C1 
Protein kinase_ putative;Tb10.70.1760 0.51 
COC1=CC2=C3CNCC3=C(C)N=C2C(OC)=
C1 
Serine/threonine-protein kinase_ 
putative;Tb10.70.5890 
0.51 
COC1=CC2=C3CNCC3=C(C)N=C2C(OC)=
C1 
Serine/threonine protein kinase_ 
putative;Tb927.3.4560 
0.51 
NC1CCCC2=C1NC1=CC=C(Cl)C=C21 NADPH--cytochrome p450 reductase_ 
putative;Tb09.211.4110 
0.46 
NC1CCCC2=C1NC1=CC=C(Cl)C=C21 NADPH--cytochrome P450 reductase_ 
putative;Tb11.01.0170 
0.46 
NC1CCCC2=C1NC1=CC=C(Cl)C=C21 NADPH--cytochrome p450 reductase_ 
putative;Tb11.02.5420 
0.46 
CC(C)(C)C1=CC=C(OCCCCCCN2CCNCC2
)C=C1 
Glucose transporter;Tb10.6k15.2030 0.45 
CC(C)(C)C1=CC=C(OCCCCCCN2CCNCC2
)C=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.45 
CC(C)(C)C1=CC=C(OCCCCCCN2CCNCC2
)C=C1 
Hexose transporter;Tb10.6k15.2040 0.45 
CC(C)(C)C1=CC=C(OCCCCCCN2CCNCC2
)C=C1 
Glucose transporter;Tb10.6k15.2020 0.45 
OC1=C2N=CC=CC2=C(CN2CCOCC2)C=C
1Br 
Flap endonuclease 1;FEN1 0.44 
CN1C2=C(C=CC=C2)C2=C1C=C1C=C(C)N
=C(C)C1=C2 
Protein kinase_ putative;Tb927.2.2120 0.44 
CN1C2=C(C=CC=C2)C2=C1C=C1C=C(C)N
=C(C)C1=C2 
Protein kinase_ putative;Tb927.7.5220 0.44 
CN1C2=C(C=CC=C2)C2=C1C=C1C=C(C)N
=C(C)C1=C2 
Protein kinase_ putative;Tb927.3.5650 0.44 
CN1C2=C(C=CC=C2)C2=C1C=C1C=C(C)N
=C(C)C1=C2 
Protein kinase_ putative;Tb10.61.2490 0.44 
CN1C2=C(C=CC=C2)C2=C1C=C1C=C(C)N
=C(C)C1=C2 
Protein kinase_ putative;Tb10.70.1760 0.44 
CN1C2=C(C=CC=C2)C2=C1C=C1C=C(C)N
=C(C)C1=C2 
Serine/threonine-protein kinase_ 
putative;Tb10.70.5890 
0.44 
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CN1C2=C(C=CC=C2)C2=C1C=C1C=C(C)N
=C(C)C1=C2 
Serine/threonine protein kinase_ 
putative;Tb927.3.4560 
0.44 
CN1C2=C(C=CC=C2)C2=C1C=C1C=C(C)N
=C(C)C1=C2 
Protein kinase_ putative;Tb09.211.2260 0.44 
NC1=C(SC=C1)C=CC1=CC=CS1 NADPH--cytochrome p450 reductase_ 
putative;Tb09.211.4110 
0.44 
NC1=C(SC=C1)C=CC1=CC=CS1 NADPH--cytochrome P450 reductase_ 
putative;Tb11.01.0170 
0.44 
NC1=C(SC=C1)C=CC1=CC=CS1 NADPH--cytochrome p450 reductase_ 
putative;Tb11.02.5420 
0.44 
OC1=C2N=CC=CC2=C(CN2CCOCC2)C=C
1Cl 
Flap endonuclease 1;FEN1 0.42 
CCN1CCCC(C1)NC1=C2C=C3C=CC=CC3
=CC2=NC=C1 
Glucose transporter;Tb10.6k15.2030 0.42 
CCN1CCCC(C1)NC1=C2C=C3C=CC=CC3
=CC2=NC=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.42 
CCN1CCCC(C1)NC1=C2C=C3C=CC=CC3
=CC2=NC=C1 
Hexose transporter;Tb10.6k15.2040 0.42 
CCN1CCCC(C1)NC1=C2C=C3C=CC=CC3
=CC2=NC=C1 
Glucose transporter;Tb10.6k15.2020 0.42 
CCN1CCCC(C1)NC1=C2C=C3C=CC=CC3
=CC2=NC=C1 
Protein kinase_ putative;Tb10.329.0030 0.42 
CCN1CCCC(C1)NC1=C2C=C3C=CC=CC3
=CC2=NC=C1 
Mitogen-activated protein 
kinase;Tb927.8.3550 
0.42 
CCN1CCCC(C1)NC1=C2C=C3C=CC=CC3
=CC2=NC=C1 
Protein kinase_ putative;Tb09.160.0570 0.42 
CCN1CCCC(C1)NC1=C2C=C3C=CC=CC3
=CC2=NC=C1 
Protein kinase_ putative;Tb11.01.0330 0.42 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Glucose transporter;Tb10.6k15.2030 0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Hexose transporter;Tb10.6k15.2040 0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Glucose transporter;Tb10.6k15.2020 0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Protein kinase_ putative;Tb927.7.1900 0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Protein kinase_ putative;Tb09.160.0570 0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Protein kinase_ putative;Tb11.01.0330 0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Protein kinase_ putative;Tb10.329.0030 0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Mitogen-activated protein 
kinase;Tb927.8.3550 
0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Cell-division control protein 2 homolog 
6_ putative;Tb11.47.0031 
0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Cell division control protein 2 homolog 
2;Tb927.7.7360 
0.41 
CN1CCN(CC1)C1=NC(NC2=CC=C(F)C=C
2)=NC(NC2=CC=C(F)C=C2)=N1 
Cell division related protein kinase 2_ 
putative;Tb10.70.2210 
0.41 
CC1CCN(CC2=C3C=CC=NC3=C(O)C(Br)=
C2)CC1 
Glucose transporter;Tb10.6k15.2030 0.40 
CC1CCN(CC2=C3C=CC=NC3=C(O)C(Br)=
C2)CC1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.40 
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CC1CCN(CC2=C3C=CC=NC3=C(O)C(Br)=
C2)CC1 
Hexose transporter;Tb10.6k15.2040 0.40 
CC1CCN(CC2=C3C=CC=NC3=C(O)C(Br)=
C2)CC1 
Glucose transporter;Tb10.6k15.2020 0.40 
OC1=C2N=CC=CC2=C(CN2CCCC2)C=C1
Cl 
Glucose transporter;Tb10.6k15.2030 0.40 
OC1=C2N=CC=CC2=C(CN2CCCC2)C=C1
Cl 
Glucose transporter_ 
putative;Tb927.4.2290 
0.40 
OC1=C2N=CC=CC2=C(CN2CCCC2)C=C1
Cl 
Hexose transporter;Tb10.6k15.2040 0.40 
OC1=C2N=CC=CC2=C(CN2CCCC2)C=C1
Cl 
Glucose transporter;Tb10.6k15.2020 0.40 
OC1=C2N=CC=CC2=C(CN2CCCC2)C=C1
Cl 
Flap endonuclease 1;FEN1 0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Glucose transporter;Tb10.6k15.2030 0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Glucose transporter_ 
putative;Tb927.4.2290 
0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Hexose transporter;Tb10.6k15.2040 0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Glucose transporter;Tb10.6k15.2020 0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 NADPH--cytochrome p450 reductase_ 
putative;Tb09.211.4110 
0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 NADPH--cytochrome P450 reductase_ 
putative;Tb11.01.0170 
0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 NADPH--cytochrome p450 reductase_ 
putative;Tb11.02.5420 
0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Flap endonuclease 1;FEN1 0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Protein kinase_ putative;Tb927.2.2120 0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Protein kinase_ putative;Tb927.7.5220 0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Protein kinase_ putative;Tb927.3.5650 0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Protein kinase_ putative;Tb10.61.2490 0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Serine/threonine-protein kinase_ 
putative;Tb927.7.4090 
0.40 
CC1=CC=C2C=CC3=CC=C(C)N=C3C2=N1 Serine/threonine-protein kinase_ 
putative;Tb927.5.1650 
0.40 
CC(NC1=C2C=CC=CC2=NC(=N1)N1CCN
CC1)C1=CC=CC=C1 
Protein kinase_ putative;Tb927.7.1900 0.40 
CC(NC1=C2C=CC=CC2=NC(=N1)N1CCN
CC1)C1=CC=CC=C1 
Protein kinase_ putative;Tb09.211.2260 0.40 
CC(NC1=C2C=CC=CC2=NC(=N1)N1CCN
CC1)C1=CC=CC=C1 
Protein kinase_ putative;Tb10.70.1760 0.40 
CC(NC1=C2C=CC=CC2=NC(=N1)N1CCN
CC1)C1=CC=CC=C1 
Serine/threonine-protein kinase_ 
putative;Tb10.70.5890 
0.40 
CC(NC1=C2C=CC=CC2=NC(=N1)N1CCN
CC1)C1=CC=CC=C1 
Serine/threonine protein kinase_ 
putative;Tb927.3.4560 
0.40 
COC1=C(OCCCCCN2CCNCC2)C=CC(CC=
C)=C1 
Glucose transporter;Tb10.6k15.2030 0.39 
COC1=C(OCCCCCN2CCNCC2)C=CC(CC=
C)=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.39 
COC1=C(OCCCCCN2CCNCC2)C=CC(CC=
C)=C1 
Hexose transporter;Tb10.6k15.2040 0.39 
COC1=C(OCCCCCN2CCNCC2)C=CC(CC=
C)=C1 
Glucose transporter;Tb10.6k15.2020 0.39 
CN(C)CCCNC1=C2C=CC=CC2=NC(=N1)C
1=CC=C(Cl)C=C1 
Glucose transporter;Tb10.6k15.2030 0.38 
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CN(C)CCCNC1=C2C=CC=CC2=NC(=N1)C
1=CC=C(Cl)C=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.38 
CN(C)CCCNC1=C2C=CC=CC2=NC(=N1)C
1=CC=C(Cl)C=C1 
Hexose transporter;Tb10.6k15.2040 0.38 
CN(C)CCCNC1=C2C=CC=CC2=NC(=N1)C
1=CC=C(Cl)C=C1 
Glucose transporter;Tb10.6k15.2020 0.38 
NCCNCCOC(C1=CC=C(Cl)C=C1)C1=CC=
C(Cl)C=C1 
Glucose transporter;Tb10.6k15.2030 0.35 
NCCNCCOC(C1=CC=C(Cl)C=C1)C1=CC=
C(Cl)C=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.35 
NCCNCCOC(C1=CC=C(Cl)C=C1)C1=CC=
C(Cl)C=C1 
Hexose transporter;Tb10.6k15.2040 0.35 
NCCNCCOC(C1=CC=C(Cl)C=C1)C1=CC=
C(Cl)C=C1 
Glucose transporter;Tb10.6k15.2020 0.35 
NCCNCCOC(C1=CC=C(Cl)C=C1)C1=CC=
C(Cl)C=C1 
NADPH--cytochrome p450 reductase_ 
putative;Tb09.211.4110 
0.35 
NCCNCCOC(C1=CC=C(Cl)C=C1)C1=CC=
C(Cl)C=C1 
NADPH--cytochrome P450 reductase_ 
putative;Tb11.01.0170 
0.35 
NCCNCCOC(C1=CC=C(Cl)C=C1)C1=CC=
C(Cl)C=C1 
NADPH--cytochrome p450 reductase_ 
putative;Tb11.02.5420 
0.35 
CC1=CC2=C(NC3=CC4=C(OCCO4)C=C3)
C=C(C)N=C2C(C)=C1 
Glucose transporter;Tb10.6k15.2030 0.34 
CC1=CC2=C(NC3=CC4=C(OCCO4)C=C3)
C=C(C)N=C2C(C)=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.34 
CC1=CC2=C(NC3=CC4=C(OCCO4)C=C3)
C=C(C)N=C2C(C)=C1 
Hexose transporter;Tb10.6k15.2040 0.34 
CC1=CC2=C(NC3=CC4=C(OCCO4)C=C3)
C=C(C)N=C2C(C)=C1 
Glucose transporter;Tb10.6k15.2020 0.34 
COC1=C(C=CC=C1)N1CCN(CC2=C(O)C3
=NC=CC=C3C(Cl)=C2)CC1 
Glucose transporter;Tb10.6k15.2030 0.34 
COC1=C(C=CC=C1)N1CCN(CC2=C(O)C3
=NC=CC=C3C(Cl)=C2)CC1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.34 
COC1=C(C=CC=C1)N1CCN(CC2=C(O)C3
=NC=CC=C3C(Cl)=C2)CC1 
Hexose transporter;Tb10.6k15.2040 0.34 
COC1=C(C=CC=C1)N1CCN(CC2=C(O)C3
=NC=CC=C3C(Cl)=C2)CC1 
Glucose transporter;Tb10.6k15.2020 0.34 
CC1=CC(Cl)=C2C(N)=C(C)C=C(C)C2=N1 Glucose transporter;Tb10.6k15.2030 0.32 
CC1=CC(Cl)=C2C(N)=C(C)C=C(C)C2=N1 Glucose transporter_ 
putative;Tb927.4.2290 
0.32 
CC1=CC(Cl)=C2C(N)=C(C)C=C(C)C2=N1 Hexose transporter;Tb10.6k15.2040 0.32 
CC1=CC(Cl)=C2C(N)=C(C)C=C(C)C2=N1 Glucose transporter;Tb10.6k15.2020 0.32 
CC1=CC(Cl)=C2C(N)=C(C)C=C(C)C2=N1 NADPH--cytochrome p450 reductase_ 
putative;Tb09.211.4110 
0.32 
CC1=CC(Cl)=C2C(N)=C(C)C=C(C)C2=N1 NADPH--cytochrome P450 reductase_ 
putative;Tb11.01.0170 
0.32 
CC1=CC(Cl)=C2C(N)=C(C)C=C(C)C2=N1 NADPH--cytochrome p450 reductase_ 
putative;Tb11.02.5420 
0.32 
CC1=CC(Cl)=C2C(N)=C(C)C=C(C)C2=N1 Flap endonuclease 1;FEN1 0.32 
OC1=C(CN2CCCCC2)C=CC2=CC=CN=C1
2 
Glucose transporter;Tb10.6k15.2030 0.32 
OC1=C(CN2CCCCC2)C=CC2=CC=CN=C1
2 
Glucose transporter_ 
putative;Tb927.4.2290 
0.32 
OC1=C(CN2CCCCC2)C=CC2=CC=CN=C1
2 
Hexose transporter;Tb10.6k15.2040 0.32 
OC1=C(CN2CCCCC2)C=CC2=CC=CN=C1
2 
Glucose transporter;Tb10.6k15.2020 0.32 
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OC1=C(CN2CCCCC2)C=CC2=CC=CN=C1
2 
Protein kinase_ putative;Tb927.7.1900 0.32 
CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2
=NC=C1 
Glucose transporter;Tb10.6k15.2030 0.31 
CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2
=NC=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.31 
CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2
=NC=C1 
Hexose transporter;Tb10.6k15.2040 0.31 
CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2
=NC=C1 
Glucose transporter;Tb10.6k15.2020 0.31 
NCC(O)(C1=CC=C(Cl)C=C1)C1=CC=C(Cl)
C=C1 
Glucose transporter;Tb10.6k15.2030 0.31 
NCC(O)(C1=CC=C(Cl)C=C1)C1=CC=C(Cl)
C=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.31 
NCC(O)(C1=CC=C(Cl)C=C1)C1=CC=C(Cl)
C=C1 
Hexose transporter;Tb10.6k15.2040 0.31 
NCC(O)(C1=CC=C(Cl)C=C1)C1=CC=C(Cl)
C=C1 
Glucose transporter;Tb10.6k15.2020 0.31 
CC1=C(C=CC=C1)N1SC2=CC=CC=C2C1=
O 
Flap endonuclease 1;FEN1 0.31 
NCC(C1=CC=C(Cl)C=C1)C1=CC=C(C=C1)
C1=CC=CC=C1 
Glucose transporter;Tb10.6k15.2030 0.31 
NCC(C1=CC=C(Cl)C=C1)C1=CC=C(C=C1)
C1=CC=CC=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.31 
NCC(C1=CC=C(Cl)C=C1)C1=CC=C(C=C1)
C1=CC=CC=C1 
Hexose transporter;Tb10.6k15.2040 0.31 
NCC(C1=CC=C(Cl)C=C1)C1=CC=C(C=C1)
C1=CC=CC=C1 
Glucose transporter;Tb10.6k15.2020 0.31 
ClC1=CC(Cl)=C(CN2C3=C(CCC3)C(=N)C3
=C2CCCC3)C=C1 
Glucose transporter;Tb10.6k15.2030 0.30 
ClC1=CC(Cl)=C(CN2C3=C(CCC3)C(=N)C3
=C2CCCC3)C=C1 
Glucose transporter_ 
putative;Tb927.4.2290 
0.30 
ClC1=CC(Cl)=C(CN2C3=C(CCC3)C(=N)C3
=C2CCCC3)C=C1 
Hexose transporter;Tb10.6k15.2040 0.30 
ClC1=CC(Cl)=C(CN2C3=C(CCC3)C(=N)C3
=C2CCCC3)C=C1 
Glucose transporter;Tb10.6k15.2020 0.30 
 
 
 
Supplementary Table 15 P-values of GO biological process fold enrichment of small molecule hits that are 
represented in Figure 4:6 
ID Name P-value 
GO:0006468 protein phosphorylation 2.89E-65 
GO:0016310 phosphorylation 7.30E-60 
GO:0036211 protein modification process 1.68E-48 
GO:0006464 cellular protein modification process 1.68E-48 
GO:0043412 macromolecule modification 2.34E-44 
GO:0006796 phosphate-containing compound metabolic process 4.97E-43 
GO:0006793 phosphorus metabolic process 1.11E-42 
GO:0044267 cellular protein metabolic process 3.59E-35 
GO:0019538 protein metabolic process 3.19E-32 
GO:0044260 cellular macromolecule metabolic process 3.46E-31 
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GO:1901564 organonitrogen compound metabolic process 1.95E-28 
GO:0043170 macromolecule metabolic process 8.74E-24 
GO:0006807 nitrogen compound metabolic process 2.47E-20 
GO:0044237 cellular metabolic process 1.24E-19 
GO:0008152 metabolic process 4.01E-19 
GO:0044238 primary metabolic process 5.43E-19 
GO:0071704 organic substance metabolic process 2.91E-18 
GO:0009987 cellular process 1.57E-16 
GO:0008150 biological process 5.26E-14 
GO:0044145 modulation of development of symbiont involved in interaction with host 2.35E-07 
GO:0043900 regulation of multi-organism process 2.35E-07 
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism 2.35E-07 
GO:0050793 regulation of developmental process 5.67E-07 
GO:0051726 regulation of cell cycle 1.60E-06 
GO:0007346 regulation of mitotic cell cycle 5.44E-06 
GO:0000278 mitotic cell cycle 7.31E-06 
GO:0010564 regulation of cell cycle process 1.51E-05 
GO:0015758 glucose transport 6.75E-05 
GO:0052106 quorum sensing involved in interaction with host 9.96E-05 
GO:0052097 interspecies quorum sensing 9.96E-05 
GO:0007049 cell cycle 1.04E-04 
GO:0048874 homeostasis of number of cells in a free-living population 1.14E-04 
GO:0048872 homeostasis of number of cells 1.14E-04 
GO:0009372 quorum sensing 1.14E-04 
GO:0044764 multi-organism cellular process 1.14E-04 
GO:1903047 mitotic cell cycle process 2.83E-04 
GO:0044772 mitotic cell cycle phase transition 4.01E-04 
GO:0044770 cell cycle phase transition 6.65E-04 
GO:0051225 spindle assembly 1.38E-03 
GO:0022402 cell cycle process 1.98E-03 
GO:1902412 regulation of mitotic cytokinesis 2.34E-03 
GO:0071900 regulation of protein serine/threonine kinase activity 2.91E-03 
GO:0043549 regulation of kinase activity 2.91E-03 
GO:0051338 regulation of transferase activity 2.91E-03 
GO:0045859 regulation of protein kinase activity 2.91E-03 
GO:0001932 regulation of protein phosphorylation 3.54E-03 
GO:0031399 regulation of protein modification process 4.23E-03 
GO:0032465 regulation of cytokinesis 4.23E-03 
GO:0051302 regulation of cell division 4.23E-03 
GO:0042325 regulation of phosphorylation 4.23E-03 
GO:0007051 spindle organization 4.97E-03 
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GO:0051174 regulation of phosphorus metabolic process 4.97E-03 
GO:0019220 regulation of phosphate metabolic process 4.97E-03 
GO:0042592 homeostatic process 5.46E-03 
GO:1901988 negative regulation of cell cycle phase transition 8.28E-03 
GO:0042327 positive regulation of phosphorylation 8.28E-03 
GO:0043410 positive regulation of MAPK cascade 8.28E-03 
GO:2000045 regulation of G1/S transition of mitotic cell cycle 8.28E-03 
GO:0000082 G1/S transition of mitotic cell cycle 8.28E-03 
GO:0009967 positive regulation of signal transduction 8.28E-03 
GO:1902806 regulation of cell cycle G1/S phase transition 8.28E-03 
GO:0033674 positive regulation of kinase activity 8.28E-03 
GO:0043406 positive regulation of MAP kinase activity 8.28E-03 
GO:0023056 positive regulation of signaling 8.28E-03 
GO:0071902 positive regulation of protein serine/threonine kinase activity 8.28E-03 
GO:0015749 monosaccharide transmembrane transport 8.28E-03 
GO:0034219 carbohydrate transmembrane transport 8.28E-03 
GO:0044131 negative regulation of development of symbiont in host 8.28E-03 
GO:1902807 negative regulation of cell cycle G1/S phase transition 8.28E-03 
GO:0001934 positive regulation of protein phosphorylation 8.28E-03 
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle 8.28E-03 
GO:0044147 
negative regulation of development of symbiont involved in interaction with 
host 
8.28E-03 
GO:0010647 positive regulation of cell communication 8.28E-03 
GO:1902533 positive regulation of intracellular signal transduction 8.28E-03 
GO:0051093 negative regulation of developmental process 8.28E-03 
GO:0010562 positive regulation of phosphorus metabolic process 8.28E-03 
GO:0045860 positive regulation of protein kinase activity 8.28E-03 
GO:0031401 positive regulation of protein modification process 8.28E-03 
GO:0048584 positive regulation of response to stimulus 8.28E-03 
GO:0044127 regulation of development of symbiont in host 8.28E-03 
GO:0051347 positive regulation of transferase activity 8.28E-03 
GO:0045937 positive regulation of phosphate metabolic process 8.28E-03 
GO:0090307 mitotic spindle assembly 8.28E-03 
GO:0044843 cell cycle G1/S phase transition 8.28E-03 
GO:1901991 negative regulation of mitotic cell cycle phase transition 8.28E-03 
GO:0043405 regulation of MAP kinase activity 8.28E-03 
GO:0043408 regulation of MAPK cascade 8.28E-03 
GO:0045926 negative regulation of growth 8.28E-03 
GO:0043901 negative regulation of multi-organism process 8.28E-03 
GO:0008645 hexose transmembrane transport 8.28E-03 
GO:0000281 mitotic cytokinesis 1.40E-02 
GO:0061640 cytoskeleton-dependent cytokinesis 1.40E-02 
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GO:0043085 positive regulation of catalytic activity 1.65E-02 
GO:1901990 regulation of mitotic cell cycle phase transition 1.65E-02 
GO:0044093 positive regulation of molecular function 1.65E-02 
GO:1901987 regulation of cell cycle phase transition 1.65E-02 
GO:0051821 
dissemination or transmission of organism from other organism involved in 
symbiotic interaction 
1.65E-02 
GO:0044008 dissemination or transmission of symbiont from host by vector 1.65E-02 
GO:0045930 negative regulation of mitotic cell cycle 1.65E-02 
GO:0051822 
dissemination or transmission of organism from other organism by vector 
involved in symbiotic interaction 
1.65E-02 
GO:0044007 dissemination or transmission of symbiont from host 1.65E-02 
GO:0000910 cytokinesis 2.22E-02 
GO:0032268 regulation of cellular protein metabolic process 2.22E-02 
GO:0018105 peptidyl-serine phosphorylation 2.47E-02 
GO:0018209 peptidyl-serine modification 2.47E-02 
GO:0035404 histone-serine phosphorylation 2.47E-02 
GO:0032270 positive regulation of cellular protein metabolic process 2.47E-02 
GO:0043987 histone H3-S10 phosphorylation 2.47E-02 
GO:0051247 positive regulation of protein metabolic process 2.47E-02 
GO:0010948 negative regulation of cell cycle process 2.47E-02 
GO:0044839 cell cycle G2/M phase transition 2.47E-02 
GO:0000086 G2/M transition of mitotic cell cycle 2.47E-02 
GO:0016572 histone phosphorylation 2.47E-02 
GO:0050794 regulation of cellular process 2.48E-02 
GO:0065008 regulation of biological quality 2.52E-02 
GO:0051301 cell division 2.86E-02 
GO:0051246 regulation of protein metabolic process 3.02E-02 
GO:0046777 protein autophosphorylation 3.27E-02 
GO:0050790 regulation of catalytic activity 3.37E-02 
GO:0050789 regulation of biological process 3.50E-02 
GO:0065009 regulation of molecular function 3.55E-02 
GO:0055085 transmembrane transport 3.99E-02 
GO:0040008 regulation of growth 4.08E-02 
GO:0007088 regulation of mitotic nuclear division 4.08E-02 
GO:0045786 negative regulation of cell cycle 4.87E-02 
GO:0051783 regulation of nuclear division 4.87E-02 
 
 
 
Supplementary Table 16 P-values of GO biological process fold enrichment of NPs that are represented in 
Figure 4:6 
ID Name P-value 
GO:0006259 DNA metabolic process 1.32E-16 
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GO:0016310 phosphorylation 1.64E-16 
GO:0009987 cellular process 3.10E-15 
GO:0044238 primary metabolic process 3.74E-15 
GO:0071704 organic substance metabolic process 8.72E-15 
GO:0008152 metabolic process 1.16E-14 
GO:0044260 cellular macromolecule metabolic process 2.64E-14 
GO:0044237 cellular metabolic process 1.25E-13 
GO:0006807 nitrogen compound metabolic process 8.95E-13 
GO:0006796 phosphate-containing compound metabolic process 9.16E-12 
GO:0006793 phosphorus metabolic process 1.47E-11 
GO:0043170 macromolecule metabolic process 1.66E-11 
GO:0036211 protein modification process 6.04E-10 
GO:0006464 cellular protein modification process 6.04E-10 
GO:0006468 protein phosphorylation 6.99E-10 
GO:0033554 cellular response to stress 8.87E-10 
GO:0006281 DNA repair 9.48E-10 
GO:0006974 cellular response to DNA damage stimulus 1.28E-09 
GO:0006950 response to stress 1.35E-09 
GO:1901360 organic cyclic compound metabolic process 4.72E-08 
GO:0008150 biological process 4.73E-08 
GO:0043412 macromolecule modification 4.85E-08 
GO:0006265 DNA topological change 1.10E-07 
GO:0006139 nucleobase-containing compound metabolic process 1.55E-07 
GO:0042866 pyruvate biosynthetic process 2.38E-07 
GO:0009135 purine nucleoside diphosphate metabolic process 2.38E-07 
GO:0006096 glycolytic process 2.38E-07 
GO:0046031 ADP metabolic process 2.38E-07 
GO:0006757 ATP generation from ADP 2.38E-07 
GO:0009185 ribonucleoside diphosphate metabolic process 2.38E-07 
GO:0009179 purine ribonucleoside diphosphate metabolic process 2.38E-07 
GO:0006725 cellular aromatic compound metabolic process 2.40E-07 
GO:0046483 heterocycle metabolic process 2.96E-07 
GO:0009166 nucleotide catabolic process 4.27E-07 
GO:0006090 pyruvate metabolic process 4.27E-07 
GO:0016052 carbohydrate catabolic process 5.60E-07 
GO:1901292 nucleoside phosphate catabolic process 5.60E-07 
GO:1901564 organonitrogen compound metabolic process 8.04E-07 
GO:0006165 nucleoside diphosphate phosphorylation 1.19E-06 
GO:0046939 nucleotide phosphorylation 1.19E-06 
GO:0019363 pyridine nucleotide biosynthetic process 1.50E-06 
GO:0019359 nicotinamide nucleotide biosynthetic process 1.50E-06 
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GO:0072525 pyridine-containing compound biosynthetic process 1.87E-06 
GO:0046434 organophosphate catabolic process 1.87E-06 
GO:0090304 nucleic acid metabolic process 3.47E-06 
GO:0006754 ATP biosynthetic process 3.49E-06 
GO:0009132 nucleoside diphosphate metabolic process 4.24E-06 
GO:0009168 purine ribonucleoside monophosphate biosynthetic process 5.11E-06 
GO:0009127 purine nucleoside monophosphate biosynthetic process 5.11E-06 
GO:0009156 ribonucleoside monophosphate biosynthetic process 6.14E-06 
GO:0009124 nucleoside monophosphate biosynthetic process 7.32E-06 
GO:0006091 generation of precursor metabolites and energy 1.01E-05 
GO:0009145 purine nucleoside triphosphate biosynthetic process 1.03E-05 
GO:0009206 purine ribonucleoside triphosphate biosynthetic process 1.03E-05 
GO:0051716 cellular response to stimulus 1.03E-05 
GO:0019362 pyridine nucleotide metabolic process 1.21E-05 
GO:0046496 nicotinamide nucleotide metabolic process 1.21E-05 
GO:0072524 pyridine-containing compound metabolic process 1.41E-05 
GO:0009150 purine ribonucleotide metabolic process 1.49E-05 
GO:0009201 ribonucleoside triphosphate biosynthetic process 1.65E-05 
GO:0009142 nucleoside triphosphate biosynthetic process 1.65E-05 
GO:0019538 protein metabolic process 1.91E-05 
GO:0072330 monocarboxylic acid biosynthetic process 2.22E-05 
GO:0034655 nucleobase-containing compound catabolic process 2.22E-05 
GO:0009152 purine ribonucleotide biosynthetic process 2.55E-05 
GO:0046034 ATP metabolic process 2.55E-05 
GO:0009259 ribonucleotide metabolic process 2.68E-05 
GO:0006163 purine nucleotide metabolic process 2.68E-05 
GO:0006733 oxidoreduction coenzyme metabolic process 2.93E-05 
GO:0009126 purine nucleoside monophosphate metabolic process 3.36E-05 
GO:0009167 purine ribonucleoside monophosphate metabolic process 3.36E-05 
GO:0044270 cellular nitrogen compound catabolic process 3.84E-05 
GO:0019439 aromatic compound catabolic process 3.84E-05 
GO:0009161 ribonucleoside monophosphate metabolic process 3.84E-05 
GO:0044267 cellular protein metabolic process 4.34E-05 
GO:0046700 heterocycle catabolic process 4.36E-05 
GO:0006164 purine nucleotide biosynthetic process 4.36E-05 
GO:1901361 organic cyclic compound catabolic process 4.36E-05 
GO:0009123 nucleoside monophosphate metabolic process 4.95E-05 
GO:0046390 ribose phosphate biosynthetic process 4.95E-05 
GO:0009260 ribonucleotide biosynthetic process 4.95E-05 
GO:0009144 purine nucleoside triphosphate metabolic process 5.60E-05 
GO:0009205 purine ribonucleoside triphosphate metabolic process 5.60E-05 
 
 
 
 
261 
 
GO:0034404 nucleobase-containing small molecule biosynthetic process 5.60E-05 
GO:0046854 phosphatidylinositol phosphorylation 6.10E-05 
GO:0046834 lipid phosphorylation 6.10E-05 
GO:0019693 ribose phosphate metabolic process 6.84E-05 
GO:0034641 cellular nitrogen compound metabolic process 7.20E-05 
GO:0009199 ribonucleoside triphosphate metabolic process 7.98E-05 
GO:0009141 nucleoside triphosphate metabolic process 7.98E-05 
GO:0006732 coenzyme metabolic process 9.94E-05 
GO:0032787 monocarboxylic acid metabolic process 1.11E-04 
GO:0072521 purine-containing compound metabolic process 1.30E-04 
GO:0005975 carbohydrate metabolic process 1.30E-04 
GO:0009108 coenzyme biosynthetic process 1.52E-04 
GO:0072522 purine-containing compound biosynthetic process 1.86E-04 
GO:0017144 drug metabolic process 1.97E-04 
GO:0046394 carboxylic acid biosynthetic process 2.25E-04 
GO:0051188 cofactor biosynthetic process 2.25E-04 
GO:0016053 organic acid biosynthetic process 2.25E-04 
GO:0006996 organelle organization 2.37E-04 
GO:0016043 cellular component organization 2.53E-04 
GO:0006102 isocitrate metabolic process 3.43E-04 
GO:0051186 cofactor metabolic process 4.16E-04 
GO:0006006 glucose metabolic process 4.85E-04 
GO:0006310 DNA recombination 5.33E-04 
GO:0051276 chromosome organization 7.09E-04 
GO:0071103 DNA conformation change 9.00E-04 
GO:0071840 cellular component organization or biogenesis 9.03E-04 
GO:0030258 lipid modification 9.27E-04 
GO:0032006 regulation of TOR signaling 1.02E-03 
GO:0019752 carboxylic acid metabolic process 1.25E-03 
GO:0006470 protein dephosphorylation 1.38E-03 
GO:0043436 oxoacid metabolic process 1.38E-03 
GO:0044283 small molecule biosynthetic process 1.44E-03 
GO:0006082 organic acid metabolic process 1.45E-03 
GO:0048583 regulation of response to stimulus 1.96E-03 
GO:0006476 protein deacetylation 2.01E-03 
GO:0098732 macromolecule deacylation 2.01E-03 
GO:0035601 protein deacylation 2.01E-03 
GO:0071496 cellular response to external stimulus 2.01E-03 
GO:0031668 cellular response to extracellular stimulus 2.01E-03 
GO:0009991 response to extracellular stimulus 2.01E-03 
GO:0052097 interspecies quorum sensing 2.15E-03 
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GO:0052106 quorum sensing involved in interaction with host 2.15E-03 
GO:0044248 cellular catabolic process 2.30E-03 
GO:0009372 quorum sensing 2.43E-03 
GO:0048874 homeostasis of number of cells in a free-living population 2.43E-03 
GO:0048872 homeostasis of number of cells 2.43E-03 
GO:0044764 multi-organism cellular process 2.43E-03 
GO:1901137 carbohydrate derivative biosynthetic process 2.94E-03 
GO:0044145 modulation of development of symbiont involved in interaction with host 3.07E-03 
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism 3.07E-03 
GO:0043900 regulation of multi-organism process 3.07E-03 
GO:0018342 protein prenylation 3.30E-03 
GO:0097354 prenylation 3.30E-03 
GO:0009056 catabolic process 3.51E-03 
GO:0019318 hexose metabolic process 3.52E-03 
GO:0055114 oxidation-reduction process 4.11E-03 
GO:0006457 protein folding 4.42E-03 
GO:0016126 sterol biosynthetic process 4.89E-03 
GO:0016311 dephosphorylation 4.95E-03 
GO:0050793 regulation of developmental process 5.15E-03 
GO:1901135 carbohydrate derivative metabolic process 5.16E-03 
GO:0005996 monosaccharide metabolic process 6.53E-03 
GO:0016125 sterol metabolic process 6.77E-03 
GO:1901575 organic substance catabolic process 8.69E-03 
GO:1902531 regulation of intracellular signal transduction 8.91E-03 
GO:0072350 tricarboxylic acid metabolic process 1.13E-02 
GO:0010646 regulation of cell communication 1.40E-02 
GO:0009966 regulation of signal transduction 1.40E-02 
GO:0019637 organophosphate metabolic process 1.60E-02 
GO:1901362 organic cyclic compound biosynthetic process 1.64E-02 
GO:0023051 regulation of signaling 1.69E-02 
GO:1903939 regulation of TORC2 signaling 1.86E-02 
GO:0042149 cellular response to glucose starvation 1.86E-02 
GO:0009432 SOS response 1.86E-02 
GO:0007131 reciprocal meiotic recombination 1.86E-02 
GO:0030952 establishment or maintenance of cytoskeleton polarity 1.86E-02 
GO:0035825 homologous recombination 1.86E-02 
GO:1903046 meiotic cell cycle process 1.86E-02 
GO:0030950 establishment or maintenance of actin cytoskeleton polarity 1.86E-02 
GO:0061982 meiosis I cell cycle process 1.86E-02 
GO:0047484 regulation of response to osmotic stress 1.86E-02 
GO:0006278 RNA-dependent DNA biosynthetic process 1.86E-02 
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GO:0010833 telomere maintenance via telomere lengthening 1.86E-02 
GO:0007127 meiosis I 1.86E-02 
GO:0034063 stress granule assembly 1.86E-02 
GO:0140013 meiotic nuclear division 1.86E-02 
GO:0045041 protein import into mitochondrial intermembrane space 1.86E-02 
GO:0007004 telomere maintenance via telomerase 1.86E-02 
GO:0034214 protein hexamerization 1.86E-02 
GO:0009117 nucleotide metabolic process 1.87E-02 
GO:0042592 homeostatic process 2.16E-02 
GO:0055086 nucleobase-containing small molecule metabolic process 2.16E-02 
GO:0006753 nucleoside phosphate metabolic process 2.29E-02 
GO:0006694 steroid biosynthetic process 2.34E-02 
GO:1901293 nucleoside phosphate biosynthetic process 2.36E-02 
GO:0009165 nucleotide biosynthetic process 2.36E-02 
GO:0008202 steroid metabolic process 2.69E-02 
GO:1901617 organic hydroxy compound biosynthetic process 2.69E-02 
GO:0006629 lipid metabolic process 3.09E-02 
GO:0051258 protein polymerization 3.47E-02 
GO:0016569 covalent chromatin modification 3.47E-02 
GO:0034248 regulation of cellular amide metabolic process 3.47E-02 
GO:0006417 regulation of translation 3.47E-02 
GO:0016570 Histone modification 3.47E-02 
GO:0006273 lagging strand elongation 3.68E-02 
GO:1903432 regulation of TORC1 signaling 3.68E-02 
GO:0051321 meiotic cell cycle 3.68E-02 
GO:0009298 GDP-mannose biosynthetic process 3.68E-02 
GO:0034250 positive regulation of cellular amide metabolic process 3.68E-02 
GO:0022616 DNA strand elongation 3.68E-02 
GO:0006271 DNA strand elongation involved in DNA replication 3.68E-02 
GO:0045727 positive regulation of translation 3.68E-02 
GO:0065002 intracellular protein transmembrane transport 3.88E-02 
GO:0044743 protein transmembrane import into intracellular organelle 3.88E-02 
GO:0071806 protein transmembrane transport 3.88E-02 
GO:0065008 regulation of biological quality 3.94E-02 
GO:0007010 cytoskeleton organization 4.07E-02 
GO:0050896 response to stimulus 4.44E-02 
GO:0034654 nucleobase-containing compound biosynthetic process 4.56E-02 
GO:0006626 protein targeting to mitochondrion 4.77E-02 
GO:1990542 mitochondrial transmembrane transport 4.77E-02 
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